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I-1ab«11ed protein (entibody or trensferrinV- 
N*(2-hydroxypropy1)niethacry1anide (HPMA)copolymer conjugates were 
characterised using gel permeation chromatography and the ir average 
molecular weight (Kw) determined (Chapter 3). It  was estimated that 
within a protein-HPMA copolymer conjugate each protein residue was 
probably bound to 10-20 molecules of HPHA copolymer.
The human transferrin  receptor was used as a model target 
antigen/receptor. Pinocytic uptake of HPHA copolymer conjugated to 
monoclonal antibody B3/25 (specific  for the transferrin  receptor) or 
transferrin  (as potential targeting residues) was up to 9 -fold 
higher than the uptake of parent copolymer (Chapter 4). The ab ility  
of these conjugates to bind specifica lly  was confirmed by Scatchard 
analysis of their cell-surface  binding (Chapter 6). Also, using a 
Percoll density gradient (Chapter 5), i t  was shown that 
internalisation of protein-HPHA copolymer conjugates i s  dependent 
upon the ir Nw and that internalised conjugates reach the lysosomal 
compartment.
The transferrin receptor was found to nave limited potential as 
an in vivo model antigen/receptor. H^MA copolymer conjugates 
containing either monoclonal antibody B3/25 or transferrin  were 
detected in a ll rapidly d iv id ing organs/tissues studied (Chapter 7). 
Conjugates containing anti-Thy-1.2 polyclonal antibody (as a 
targeting residue) were shown to localise  preferentially in the 
thymus, spleen, live r, skin and bone marrow. The a b ility  of only <1X 
(administered dose) of conjugate to reach a major target organ, the 
thymus, was consistent with published values (Chapter 8).
Conjugation of HPMA to antibody (IgG) was shown to produce a 
2B0-fo1d reduction in inmunogenicity of the antibody (Chapter 9,
14C
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1.1 IWTROOUCTION
Convtntlonal chentotherapy I s  st111 assoclattd with the 
coapllcetlon of undesirable side-effects, a ris in g  froa a lack of 
specific ity  of drug action. Other major problems include early loss 
of a great deal of administered drug via the kidney, together with 
f ir s t  pass Metabolism by the liv e r.  This often necessitates frequent 
administration of drug, In re la t ive ly  high dose, In order to maintain 
optimal blood level and optimal pharmacokinetic behaviour. The small 
size of conventional drugs together with the ir chemical properties 
have the added disadvantages of fa c ilita tin g  entry Into a ll c e lls  by 
the process of simple d iffusion  and/or active transport across 
membranes, resu lting In ubiquitous rather than specific  d istribution  
of drug In the body. This I s  exemplified In cancer therapy, where 
treatment I s  based on the selective destruction of rapidly dividing 
ce lls. The targets of such therapy are the cancerous ce lls ,  but 
rapidly d iv id ing  ce lls such as those found In the lin in g  of the 
Intestine, h a ir fo ll ic le s  and In bone marrow are equally accessible 
to, and affected by, drug. Conventional chemotherapy can be 
wasteful. Ineffic ient, and unselective.
Conventional chemotherapy is ,  however, on the verge of a radical 
and exciting change. The advent of th is new era of drug delivery has 
been made possib le by the many exciting advances In our fundamental 
knowledge o f ce ll and molecular biology, such as the f ir s t  
description of monoclonal antibodies by H llste in  (reviewed Hllstein, 
1980). Ehrlich, the father of chemotherapy,once stated " corpora non 
aqunt n is i flxato." (agents cannot act unless they are bound); It  Is  
the ambition of sc ientists working In the area of drug delivery not 
simply to have drugs which bind, but bind spec ifica lly  to a 
pre-determlned cell type such as cancer ce lls .  The Increasing number 
of cell-surface  antigens being catalogued, and the ra ising  of
antibodies specific for these antigens (Baldwin & Byers, 1985) may 
offer a p ossib ility  of ce ll-spec ific  targeting of drug as once dreamt 
of by Ehrlich when he talked of "magic bullets". In the following 
study the transferrin receptor will be explored as a model 
cell-surface antigen, to which the soluble, synthetic, polymeric 
drug-carrier poly-N-[2-hydroxypropyl]methacrylamide (HPMA), w ill be 
targeted by conjugation with either transferrin, or monoclonal 
antibody B3/25 (specific for the transferrin receptor).
To achieve selective cell death It  Is  necessary to deliver drug 
specifica lly  and at an optimal concentration to the target cell. I f  
antibodies per se are loaded with drug there Is  the p ossib ility  that 
dénaturation of the antibody may result leading to a loss of antigen 
recognition and binding. Baldwin & Byers (1986) report that 
substitution ratios of three drug residues per antibody molecule may 
result in a loss of antibody specific ity. The use of a drug-carrier, 
which can be optimally loaded with drug and then subsequently bound 
to antibody in a ratio approaching one to one, offers the potential 
of reducing the lim itation of drug-loading when using antibody 
directed conjugates and would therefore allow site-specific  delivery 
of effective concentrations of drug.
1.2 DRUG CARRIERS
Potential drug-carriers may be divided Into two major groups, 
natural and synthetic macromolecules (see Table I. l ) .
Natural macromolecules (Duncan & Kopecek, 1984) have the 
advantage that they may be of discrete size, be non-toxic, and may 
contain the necessary targeting residues within their structure.
Their disadvantages Include the fact that they tend to be iimnunogenlc 
(either in native form or when chemically modified to bind drug), and 
that they are sensitive to dénaturation during binding of drug and 
also when handled experimentally. An example of such in stab ility  was

ob$«rvtd by Trouet, «t ¿1^ (1960) when using ONA es a carrie r 
non*cova1ent1y bound to drug.
Synthetic carrie rs (Duncan & Kopecek, 1984; Kopecek, 1984;
Lloyd, ^  al_^, 1984) have the great advantage that they can be 
tallor-iiade to su it  the requlrenents of any particular drug-delivery 
system. Within the overall structure o f such a carrie r I t  Is  
possib le to provide United  degradation together with an optimal 
number of functional groups for the subsequent binding o f both drug 
and targeting residues (Duncan 8 Lloyd, 1980; Duncan, et a K ,  1963; 
Kopecek, 1984). Synthetic carriers Including HPHA are o f lower 
Imnunogenlclty than natural molecules (see Chapter 8; R1hova,et 
198S), but do become s l ig h t ly  more Immunogenic with the Incorporation 
of amino-acid side chains (Rlhova, et a K ,  1984; R1hova,et a K ,
1985). A disadvantage of synthetic c a rrie rs may be the ir 
po lyd ispersity (Kopecek, 1984).
Synthetic carrie rs fa ll broadly into two main groups, colloidal 
partic le s and polymers (see Table 1.1). Colloidal p a rtic le s (Davis & 
Ilium, 1986} Include liposomes, mlcrospheres, nanoparticles and 
emulsions. A major problem of th is type of synthetic carrie r has 
been i t s  preferential uptake by the reticulo-endothellal (R.E.) 
system. In  particu lar capture by Kupffer c e lls  of the liv e r  following 
Intravenous administration (Duncan & Kopecek, 1984). This uptake by 
the R.E. system has been attributed to the size, shape, charge, 
surface p o la r ity  and r ig id ity  of the carrie rs (Poste & K irsch, 1983; 
Posnansky & Ju11ano,1984; Poste, 1985). Using combinations of 
polyoxamlne and polyoxamer coated mlcrospheres, Davis t  Ilium  (1986) 
have reported that the capture of mlcrospheres by the R.E. system can 
be-reduced by 55X with a redistribution of particles to the bone 
marrow, o r retention within the vascular system. Targeting, however, 
to spec ific  ce ll types remains a major problem with these carriers
(Davis i I11ua. 1986).
Tha carrie r used In th is study I s  a soluble, synthetic polymer 
whose structure has a backbone of N-(2*hydroxypropy1)nethacry1am1de 
(KPMA) (see fig .  1.1). This re la tive ly  Inert structure was 
orig ina lly  developed as a plasma expander (Kopecek,et a K ,  1973). 
Reactive groups have been Incorporated Into  th is  structure by 
copolymérisation of HPHA with N-methacry1oylated oligopeptides 
terminating In p>n1tropheny1 esters (Kopecek, 1984; Fig. 1.2). The 
presence of reactive p-n1tropheny1 (ONp) ester linkages allows 
subsequent binding of drugs and targeting residues which contain an 
aliphatic amino group, by amlnolysis of the ONp ester linkage 
(Kopecek, 1984; Fig. 1.3). The combination of aelno-aclds within the 
oligopeptide s1de>cha1n can be designed to give controlled release of 
terminal group X (where X may be drug, o r targeting-residue) within 
the lysosomal compartment of the ce ll (Duncan & Lloydfl980; Duncan, 
et aK , 1983; Rejmanova,et a K ,  1985). The rate of release of drug 
from such oligopeptide side-chains I s  influenced by the chemical 
nature of the drug Itse lf  (Kopecek. 1984). Incubation of HPHA 
copolymers containing daunomycin or puromycln with lysosomal enzymes 
(Duncan,et 1987) has shown that more than 20% of daunomycin and 
more than 80% of puromycln can be released from HPHA conjugates 
containing a gly-phe-leu-gly oligopeptide side-chain.
HPHA copolymers are taken Into c e l ls  by fluid-phase plnocytosis 
(see Chapter 4). An understanding of the plnocytlc pathway reveals 
that there are a number of ways to Increase both the specific ity  and 
rate of uptake, of the HPHA carrie r (see Section 1.4.2). Using the 
rat visceral yolk sac system, Duncan,et aK., (1984) have demonstrated 
an enhanced rate of uptakq of HPHA re su lt in g  from non-specific 
adsorption after Incorporation of tyrosinamide (10-20%) Into the 
structure of the copolymer. Incorporation of a g ly -g ly  spacer
between [^^^I]-tyro$1na(n1de and the HPHA copolymer backbone resulted 
I2S
In subsequent release of [ I]-tyros1ne within the lysosome.
Polycations also bind strongly to membranes. Shen & Ryser 
(1978; 1979; 1981} showed that covalent attachment of poly*(L*1y$) to 
serum albumin, horseradish peroxidase, or methotrexate resulted In a 
large Increase In their rate of pinocytosis. In particular the 
transport of methotrexate Into ce lls normally drug-resistant was 
achieved (Shen & Ryser, 1978; 1979; 1981). McCormick,^ a K  (1986) 
found that a polycatlonic derivative of HPMA copolymer bound strongly 
to ce lls  both In vivo and In v itro . The polymeric cation adsorbed to 
the cell membrane, or glycocalyx, but did not readily gain access to 
the c e l l’s Interior.
To achieve an Increased uptake by specific cell types It  Is  
possible to use carbohydrates specific for carbohydrate receptors 
(see Table 1.2) or antibodies specific for cell surface antigens. 
Duncan,^ ^  (1985; 1986) have been able to demonstrate uptake of 
modified copolymers v ia  galactose ( live r) and fucose receptors (L1210 
c e lls ).  Increased survival of DBA  ^ mice bearing L1210 cells, 
following treatment with HPHA copolymeric drug carriers containing 
daunomycln and a fucosylamlne targeting residue has been shown 
(Duncan,et ^  1987).
Evaluation of the fe a s ib il ity  of targeting HPKA copolymers by 
Incorporation of antibodies as targeting residues Is  the primary aim 
of th is  study. The fie ld  of Immunotargetlng has expanded rapidly 
over the la s t  decade, since the advent of monoclonal antibodies 
(HcAb; a pure preparation of one c lass of antibody with a single 
defined sp ec ific ity ; M llste in, 1986). A selection of work reported 
by others In th is fie ld  I s  shown In Table 1.3. Immunotargetlng of 
HPMA Is  s t i l l  In It s  Infancy. In v itro  Incubation of HPMA bound to 
non-specific rat IgG (Duncan, et a L ,  1985) was shown to enhance both



Ttblt 1.2
CarbohydrtU receptors and th>1r c t l lu U r d istribu tion
Carbohydratt Ce lls bearing Reference
rK tp to r the receptor
^ la c to se hepatocytes Ashwell & Harford (1982)
hepatoma Schwartz,et aK  (1982)
^ la c to se -p a rt ic le Kupffer Cells Teraclalra,et al^ (1983)
Mannose-N-acety1 RE c e lls Oavis & Ilium  (1986)
glucosamine
Hannose-fucose monocytes Stahl (1983)
Hannose-6-phosphate fib rob lasts Heufeld,et a K  (1975)
liv e r  c e lls U llr1ch,et aK  (1978)
Fucose hepatocytes P rieels,et aK  (1978)
Hannose fib rob lasts Tomlinson (1986)
Glucose Lewis lung Roche,et a K  (1983)
carcinoma

the rete of pinocyttc uptake and rate of exocytosis of HPHA by the 
rat visceral yolk sac systea. Rlhova & Kopecek (1985) and Rlhova et 
a1. (1986) have shown that HPMA conjugated to a cell-surface active 
drug and antl-Thy-1.2 (monoclonal and polyclonal) antibody was 
70-t1aes more cytotoxic against T-1ymphocytes than the sane 
conjugates bound to non-specific IgG. Partial Inactivation of 
antibodies occurred during conjugation to HPHA and a s ligh t  decrease 
in the in v itro  a ct iv ity  of conjugated, as compared to free drug was 
reported. This was thought to be due to possible steric  hindrance of 
the drug by the antibody.
In the following study monoclonal antibody (HcAb) B3/25, 
specific for the transferrin  receptor will be used as the major model 
system. The structure of an antibody molecule and the transferrin 
receptor w ill now be described.
1.3 THE STRUCTURE OF THE ANTIBODY HOLECUIE
To appreciate the potential of antibodies as targeting moieties 
In drug therapy. It  I s  necessary to have an understanding of the 
structure of the antibody molecule, and Its  antigen binding site 
(Fig. 1.4). Appreciation of the function of the various structural 
domains Is  also necessary to enable prediction of the consequences of 
polymer-antibody conjugation.
Antibodies are secreted by B-lymphocytes and are one of the 
major proteins found in the blood, being approximately twenty per 
cent of the total blood protein. A unique feature of these proteins 
Is  that their basic structure can produce almost in fin ite  
variab ility , determining the specific ity of each particular antibody 
(reviews by Nisonoft, 1975; Kabat, et aL., 1976). Each B-lymphocyte 
(B-cell) and it s  clones, is responsible for the secretion of only one 
of the m illions of d ifferent antibodies. The differentiation of 
B-cells Into clones of antibody-secreting plasma ce lls  is stimulated 
by the presence of a foreign substance which Is
Fig.1.4 The different classes of Iwiwnoglobulin and detailed
structure of IgG. (After Alberts, et al^., 1983).
Yheovychoin* othw vycha«  twovychoin, d  twovychain* €  heavychom
IgG
recognised as an antigen of the antibody. I f  the foreign partic le  Is  
U rge  then I t  can contain a number of sites which are capable of 
e lic it in g  the formation of antibody; each of these s ite s 1$ known as 
an antigenic determinant, and Is  capable uf stimulating a different 
B-ce11. At the other extreme there are particles which are too small 
to e l ic i t  a response unless they are attached to a carrier 
macromo1ecu1e. Such small molecules are known as haptens (or 
haptenic determinants when attached to a carrie r). This type of 
B 'Ce ll stimulation I s  Important when the use of an 
antlbody-polymer-drug conjugate Is  being considered.
Antibodies can be divided Into a number of classes depending on 
the fine structure of the molecule (see Fig. 1.4). The simplest 
structure I s  found In  the IgG class, which form the predominant type 
o f antibody found 1n the blood of higher vertebrates, and as such 
have been the most extensively studied. A molecular weight of 160K 
led Porter (1973) to propose that the molecule I s  composed of 
approximately 2.3x10^ atoms. The overall shape of the molecule Is  
that of a Y, with a two*fold axis o f symmetry passing through the 
ta l l of the Y (comprehensively reviewed by Amaze! A Poljak, 1979; 
Davies & Metzer, 1983; Gorevic, et 198S). Chemical manipulation 
of the molecule, using nercaptoethanol, to reduce disulphide bonds, 
and 6H urea to d isrupt non-covalent bonding, resulted In the 
production of two Identical 50K Dalton chains, and two Identical 25wk>^  
Dalton chains, which were designated the heavy chain and the ligh t 
chains respectively. This gave an IgG subunit structure of 
Each ha lf of the molecule Is  composed of one H and one L chain, and 
the whole I s  held together by covalent and non-covalent bonding to 
form a highly ordered molecule. The heavy chain has been shown to 
contain one or more carbohydrate side-chains, the function of which 
are s t i l l  not absolutely clear.
The function of the antibody aiolecule was related to this 
structure by the use of specific enzyme cleavage using papain and 
pepsin (see Fig. 1.5). Porter (1973) showed that papain cleaves the 
heavy chain on the amino-terminal side of the disulphide bond which 
links the heavy and ligh t chains, to produce three fragments of 
approximately equal size. Two of these fragments are Identical being 
derived from the arms of the Y. the remaining fragment I s  formed from 
the ta ll of the Y. The two Identical fragments are able to bind 
antigen and are therefore given the name antigen-binding fragments, 
(Fab). The second fragment-type from various IgGs was found to 
c ry sta llise  readily, that is,  these fragments formed a homogeneous 
population. They were given the name constant, or crystalline, 
fragments (Fc). The Fab fragments are composed of the entire L chain 
plus the amino-half of the H chain, whereas the fc fragments are 
composed of the carboxyl-terminal ends of two H chains. The binding 
of antigen was therefore confined to the arms of the Y. The ta ll of 
the Y has a complementary role In directing various physiological 
events, such as the fixation of complement, and the uptake of an 
opsonised particle  by macrophages.
Pepsin cleavage I s  specific for the region of the IgG molecule 
below the disulphide bridge which holds together the H and L chains, 
to produce an F(aty) 2  fragment and a mixture of Fc sub-fragments. The 
F(ay )2 fragment Is  bivalent and as such can cross-link antigens to 
form precipitates. The efficiency of th is  bivalent linkage 1$ up to 
10^ greater than a univalent linkage, and Is  further enhanced by the 
f le x ib i l ity  of the arms of the Y, which have been shown to vary 
between 113 and 143 degrees (Sllverton.et a K ,  1977). This 
f le x ib i l ity  optimises the formation of antigen-antibody complexes, 
since the angle between the arms can be regulated to correct for the 
distance between specific antigenic determinants.
F1g. 1.5 Enzyme cleavage of IgG using papain and pepsin.
(After Alberts, et al_., 1983).
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Both the lig h t  (L) and heavy chains (H) of the antibody molecule 
can be sub-d1vlded Into d istin ct regions (Wu & Kabat, 1970). A 
variable region of 108 amino acids I s  found at the am1no*teni1nal end 
of both the heavy and ligh t chains. The remaining amino acids form 
the constant domains; 106 amino acids In the case of the ligh t chain, 
330*440 amino acids in the case of the heavy chain, depending on 
c la ss of antibody (see Fig. 1.6). Within the constant region of the 
lig h t  chain, at position 191 there is  an a llotyp ic  s ite  designated 
Kappa (Leu or Val present) or Llamda (Lys or Arg present).
The structure of the antibody molecule I s  composed of several 
d ist in ct  domains, each of which I s  held together by an Intra-chain 
disulphide bridge (Fig. 1.7). The domains are designated 
(which are homologous), and C^ l^ C^2 C^3 and C|^  (which are 
homologous). Each domain Is  thought to contain at least one active 
site , which In the variable region binds antigen, and In the constant 
region Is  Important In effector functions (such as binding 
complement). The structure of each domain 1s based upon the 
Immunoglobulin fold (Fig. 1.8), that Is,  two sheets of ^-strands, 
with the hydrophobic side-arms of the constituent amino acids packed 
very t igh t ly  between the sheets to form a hydrophobic c le ft.
Each domain has dimensions 4x2.5x2.Snm (Davies, 1977; Davies A 
Hetzger, 1983). Carbohydrate plays a central role In the Interaction 
of the domains, for example, C^l and C^2 are prevented from making 
close contact by carbohydrate; the C^2 regions of both chains must 
Interact v ia  carbohydrate.
1.3.1 The cheracterlstlcs of the antloen-binding s ite
The variable regions contain hypervariable (H.V.) regions (4 In 
3 In V^; Capra & Edmundson, 1977). These regions are composed of
re lative ly  constant (Fig. 1.9). It  I s  within these HV regions that
fig. 1.6 Constant and variable regions of IgG.
Ftj. 1.7 The distinct domins o f  IgG . (After Edelnen, 1973).
Fig. 1.8 The lironoglobulln fold. (After Caprj S Edmondson, 1976).

antibody sp ec ific ity  Is  detemined, (Capra I  Edimindson, 1977), with 
the potential of 10^ different combinations of binding site s 
(Kllste in, 1986).
The strength o f antigen binding Is  determined by the cumulative 
effect of Van der Waals Interactions, H*bond1ng and electrostatic 
forces. These weak forces are effective only when antigen I s  in 
close enough proximity to the antigen-binding site  to allow some of 
the antigen atoms to f i t  into complementary recesses on the antibody 
surface (Amazel, et aK., 1974, the binding of vitamin K; Radian ^  
a l . 1976, the binding of phosphorylchollne).
1.3.2 Tho characteristics of an antigen
An antigen (or antigenic determinant, epitope) may be broadly 
defined as that region of a molecule which Interacts with the binding 
s ite  of an antibody molecule. Those properties which determine 
antigenicity, however, are as yet not fu lly  understood. For 
carbohydrates, the antigen can consist of a sequence of up to five 
sugars, (Nlsonoff, et a K ,  1975; Williams & Woollett, 1984). 
Determination of the antigenicity of proteins Is  more complicated; 
the antigen 1$ composed of a sequence of 6-6 amino acids (Worobec H  
a l . . 1985) which have a continuous, or discontinuous primary 
sequence. This sequence of amino acids may be flexible  or rig id . 
Investigation of continuous antigens (reviewed Karx, 1984; Talner et 
a l . . 1984; Westhof, ^  a K ,  1984) has suggested that f le x ib i l it y  of 
these regions I s  an Important property of the antigen. However, 
others have found (Novotny, et a L ,  1986) (using both continuous and 
discontinuous epitopes) a greater correlation between accessib ility  
of an antigen to antibody and antigenicity, than between f le x ib i l ity  
and antigenicity. Novotny, at aK  (1986) support the view that 
"exceptional surface exposure Is  the key to antigenicity", 
f le x ib ility  being a consequence of th is exposure.
There Is  also debate as to whether d iscre te  antigenic 
detenninants ex ist or whether there are a number of mutually 
overlapping antigens (Benjamin,et a K ,  1984). It  I s  even possible 
that the whole surface Is  potentia lly antigenic, those regions which 
e l ic i t  a response being the most accessible to antibody (Novotny,et 
a K . 1986). I f  antibodies are to be used fo r  drug-targeting I t  may 
not be necessary to define antigenicity, but rather to use those 
antibodies which are known to localise  e ffic ie n t ly  at a target ce11.
At the cell surface I t  I s  glycoproteins and g lycollp ids which 
are accessible to the immune system; often carbohydrate w ill form a 
considerable area of possible Interaction (W illiam s,^  a K ,  1985). 
However, In mammals antigenic determinants are often based on 
proteins rather than carbohydrates (Williams & Wool 1ett,1984). 
Antibodies raised against d ifferent species a lso  seem to recognize 
protein rather than carbohydrate. Felzl (1984,1985) has recently 
found, however, that In some tumour c e lls  antigens are carbohydrate 
In nature, possib ly reflecting novel carbohydrate structures on these 
cells.
The existence of Ideal tumour-specific antigens, as defined in 
Table 1.4, Is  at th is  time thought to be un like ly. Many reports of 
tumour-specific antigens (Teh,et a K , 1985) have been shown to 
cross-react with antibodies raised against normal tissue. There Is  
growing support for the view of Greaves (1979) that “tumour antigens 
are normal antigens which have been produced at an Inappropriate 
time, or In an Inappropriate tissue ". An example of th is would be 
the stab ilisa tion, of a normally transient d ifferentiation  antigen, 
on a tumour ce ll. Such antigens are not foreign and would not e lic it  
an Immune response. I f  novel antigens are present, however, the 
tumour has several ways of avoiding destruction (and avoiding binding 
of an antibody-targeted carrier), these are summarised In Fig. 1.10.
flaurt 1.10
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As stated above anti-carbohydrate antibodies have been found to 
react with novel tumour antigens, and there Is  increasing awareness 
of the Importance of carbohydrate chains of glycolIp ids and 
glycoproteins as oncodevelopmental antigens (Felzl, 1985; Tang et 
a l . . 1985). These novel structures may play a role In cell adhesion 
and hence metastasis of tumour cells.
In the following study the transferrin  receptor has been used as 
a model antigen.
1.4 TKAHSFEMUN AND TH£ TKAMSFEmH RECEPTOA
Use of the transferrin receptor as a model antigen has certain 
advantages; (a) It  has been Isolated and well characterised 
(Schneider, 1983} (b) the density of the receptor i s  thought to be 
dependent on cell type and state of growth, being of higher density 
on rapidly proliferating ce lls such as cancer ce lls  (Trowbridge,
1985) (c) the receptor-ligand complex 1$ Internalised after binding 
o f ligand, be that ligand transferrin or antibody (Schneider & 
Williams 1985; Testa 1985). Understanding of the physiological 
receptor-ligand Interactions w ill allow comparison with data 
reported later using novel antibody or transferrin-containing HPHA 
copolymer ligands.
1.4.1 Transferrin
Iron Is  a transition metal essential to a ll liv in g  organisms for 
blocatalysis and oxygen transport (reviewed Alsen, 1980; Alsen & 
Ustowsky, 1980). The metal can exist in one of two oxidation 
states, Fe^  ^ or Fe^^^ Under physiological conditions of pH, Ionic 
strength, and pO^  Fe^^^ Is  the predominant state. It  Is  essential to 
any liv ing  organism that this cation I s  sequestered since Fe*** Is 
h ighly hydrolytic and will form Insoluble polymers at concentrations
greater than at pH7. Normally serum concentration of Fe^^ ^ Is
70pg/d1 (lOpM) and the so lu b ility  problem Is  overcome by tight 
chelation of Fe^^^ by the serum protein transferrin, which under 
physiological conditions Is  only 20-50% saturated (Alsen, 1980; Alsen 
& Mstowsky, 1980.)
Transferrin Is  synthesised and secreted by hepatocytes (Finch & 
Keubers 1982). There are three main types of transferrin, 
ovotransferrin, serum transferrin , and lactoferrin, the latter being 
d istin ctive  In amino-acid sequence and Immunogenlclty (Alsen, 1980; 
Alsen & Listowsky, 1980). The transferrin described here Is  that 
found In the serum; It  I s  acid ic  and has a molecular weight of 
approximately 80K Daltons. The protein Is  composed of a single chain 
of 676 amlno-aclds and two carbohydrate side-chains. The 
carbohydrate Is  6% by weight and Is  composed of two Identical, nearly 
symmetrical heterosaccharide chains. These chains are of the 
b1-antennary structure common to serum glycoproteins. Both chains 
are found at the C-termlnal region of the protein, Joined by (3-1 
glycosid ic  linkages to asp residues 415 and 668. Unlike other 
glycoproteins removal of the terminal s ia lic  acid residue to expose 
galactose does not Increase clearance from the blood (Alsen 1980).
The function of the carbohydrate Is  unknown.
The overall shape of transferrin  Is  that of an ellipsoid, 
containing two lobes at 30° to each other, which each contain a c left 
in the region of the join. The binding equivalent of transferrin for 
Fe^^^ Is  40K, indicating that the carrier Is  two-sited. None 
(apotransferrln), one (monoferrlc), or two (d iferric) Fe*** molecules 
may be bound to transferrin. X-ray crystallography has shown that 
the shape of the carrier changes during Fe^^  ^ binding, the e llip so id  
becoming more spherical and more resistant to dénaturation.
Iron has the coordination geometry of an octahedron, as seen In
haemoglobin and transferrin . Transferrin i s  able to coordinate at 
only f iv e  o f the s ix  s ite s, leaving the absolute requirement of an 
anion, or HCO^  at the sixth  coordination site. Schlabach and 
Bates (197S) have shown, using different anions, that the 
anion-binding s ite  i s  a c le ft  measuring 3x3x6A. The anion i s  thought 
to function as a bridging ligand between metal and protein, locking 
the metal in  place by occupying a coordination site  that would 
otherwise be'occupied by water, and thus stab ilis in g  the 
metal-protein interaction by preventing hydrolysis of the Fe^^^ The 
bond between the anion and protein is  re la tive ly  lab ile , having a 
h a l f - l i f e  o f 200h at pH7 (Aisen, 1980). I t  i s  the nature o f  th is 
bond which i s  thought to provide the mechanism for the removal of 
Fe^^^ from transferrin . I f  the anion i s  removed by protonation, or 
enzymic cleavage, from the sixth  coordination site, then the protein 
w ill spontaneously fa ll from the other f ive  site s releasing Fe(H2 0 )g. 
Strong binding of neither anion nor protein I s  seen in the absence of 
the other. Without anion binding the transfe rrin  cannot compete with 
the hydrolytic  reactions o f Fe^^^
When loaded with Fe^^^ transferrin  shows a characteristic  
absorbance in the v is ib le  spectrum at 465nm (Aasa,et a K ,  1963). I f  
the protein i s  cleaved to produce two one-sited fragments, then it  is 
found that the spectra of each site  is  d ifferent, with the sum of the 
two spectra being equal to that of the intact spectrum (Aisen, I960). 
There has been a large amount of contradictory evidence in  the 
lite ra tu re  pointing to both the equivalence and non-equivalence of 
these two site s. Today i t  i s  generally accepted that there i s  an 
a c id -la b ile  and an acid-stable site. The two sites have d ifferent 
binding constants, which d iffe r  by a factor of 5 at pH7.4 and a 
factor of 33 at pH6.7. At physiological pH, in the presence of 
anion, Fe”  ^ is  e ssen tia lly  locked into e ither site  on the f ir s t
encounter. The significance of the differential susceptib ility of 
these sites to acid aay be Inportant In the delivery of Iron to 
acidic Intracellular compartnents (see Section l.S ).
1.4.2 The transferrin receptor
The tranferrin receptor I s  a protein composed of 760 amino acids 
(Schneider,et a K ,  1984) It  I s  a Group I I  plasma membrane protein 
(Schneider,et aK  1982; 1984; Ser1al,et a K .  1986), that Is,  the 
receptor spans the membrane once and has Its  N-termlnal on the 
cytoplasmic side of membrane. The C-termlnal extracellular domain 
consists of 671 amino acids, the N-termlnal cytoplasmic domain 61, 
and the intramembrane domain 28 amino acids (Schneider, ^  a1.,
1984) . The receptor ex ists as a disulphide-linked dimer of molecular 
weight 180K Daltons, sub-unit weight 90K Daltons (Schneider,et a l . . 
1982). Trypsin releases a 70K Dalton fragment from the membrane 
which retains the a b ility  to bind transferrin (Schneider,et a l . .
1982; Fig. 1.11). Trowbridge & Omary (1981) using the monoclonal 
antibody B3/25 have shown that the receptor Is  a cell-surface antigen 
on a large number of cell types. It  Is  now thought that the receptor 
may be found on most I f  not a ll nucleated ce lls (Table l.S) and as 
such would explain the dependence of cell growth In v itro  on the 
presence of transferrin (Rudland, et aK., 1977). The cell-surface 
density of the receptor has been reported to be dependent upon 
several factors (Schneider & W illiams,1985; Testa, 1985; Trowbridge,
1985) (a) malignancy; certain malignant ce lls possess a higher 
density of transferrin receptor than the corresponding normal ce lls 
(b) state of differentiation; the erythroblast has a high density of 
receptor, the erythrocyte none (c) state of growth; ce lls which are 
In the ir log phase of growth, and ce lls which are Induced to 
proliferate rapidly In v itro  express a higher density of receptor 
than corresponding ce lls In a le ss active phase of growth. The
Fig. l . n  The transferrin receptor (information taken from
Hay and Cuatrecasas, 1985; Schneider, et £1^., 1982).
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association of rocaptor density and growth has been deaonstrated In 
fib roblasts, lymphocytic lines, breast tumour ce ll line s, leukaemic 
ce ll line s, and may be a feature of a ll cell types. There 1$ dispute 
In the literatu re  as to whether the density of the receptor may play 
an important role  In natural k i l le r  (NK) cell recognition (NemMn et 
a l . . 1982; disputed Bridges & Smith 1985), since normal and malignant 
ce lls ,  which are NK-cell targets, express a high density of the 
transferrin  receptor.
The importance of the Interaction between tran sfe rrin  and Its  
receptor in the control of growth has been Implicated In the work of 
Trowbridge I  Lopez (1982) who found that HcAb 42/6 and transferrin 
bind competitively with the ligand b ind ing-site  of the transferrin 
receptor. I t  has been shown that the growth o f c e l ls  was Inhibited 
In the presence o f HcAb 42/6 together with tran sfe rrin , the cells 
remaining In the S-pha$e of their l i f e  cycle. Th is Inhibition could 
not be overcome by supplying the c e lls  with an alternative  source of 
Iron In the form o f ferrous sulphate or fe rric  n itr llo a ce t ic  acid, 
which are both potential donors of Iron to the c e ll.
Each monomer of the receptor I s  capable o f b inding one molecule 
of Iron-saturated transferrin. I t  has been shown by trypsin cleavage 
of the transferrin-binding fragment from the membrane that each site  
binds Independently of the other (Schneider & W illiams 1985). There 
I s  con flicting  evidence In the literature  as to whether the 
receptor-ligand complex becomes clustered In the coated pits 
following binding of transferrin, or I f  It  I s  a resident of the pit 
(Testa, 1985; Oautry-Varsat, 1986; Cheng, 1986).
The complex I s  Internalised by endocytosis (a term which was 
f ir s t  used by de Ouve, 1963). As the process of endocytosis Is  
central to the following study I t  w ill be described In  detail with 
particular reference to transferrin.
l.S  ENOQCYTOSIS
The tern endocytosis i s  very broad, and on the basis o f the size 
of the ingested substrate the process nay be sub-divided into the 
processes of phagocytosis and pinocytosis. Phagocytosis i s  a 
substrate-triggered event resulting in the uptake of re lative ly  large 
particles, such as senescent ce lls, innune coaiplexes, and bacteria, 
by specialised scavenger ce lls, the macrophages. The process of 
phagocytosis M ill not be discussed further here.
1.5.1 Pinocytosis
Pinocytosis describes the process of ce ll drinking, Hith the 
consequent uptake of extracellular f lu id  and the solutes dissolved 
therein. Pinocytosis, unlike phagocytosis, i s  a constitutive 
process, which occurs in most ce ll types; i t  may be further 
sub-divided to d istinguish  between fluid-phase and adsorptive 
pinocytosis.
1.5.1.1 Fluid-phase pinocytosis
Fluid-phase pinocytosis (fpp) describes the uptake of 
extracellular flu id , and solutes in a non-specific manner 
(Besterman & Low, 1983; Steinrnan, et a K ,  1983; Willingham & Pastan, 
1984). The rate of uptake of solute is  dictated by the rate of 
invagination and pinching o ff of the plasma membrane to form 
pinocytic vesicles, and i s  not regulated by the a va ilab ility  of 
substrate. The rate of ffp varies with cell type, for example the 
macrophage ingests SOX of i t s  volume and 180X of it s  surface area per 
hour, as compared with the fibroblast which Ingests S-lOX of its  
volume and SOX of i t s  surface area per hour (Steinman,et a h ,  1983). 
It  has also been shown (Steinman,et a K ,  1983) that over a 3h period 
the surface area of macrophages remained constant suggesting that 
membrane is  constantly recycling to the ce ll surface after pinocytic 
internalisation.
The function of fpp i s  not absolutely c le ir .  O rig ina lly  I t  was 
thought that a najor function was plasou membrane lip id  and protein 
recycling. However, the 54-180% of cell surface Internalised per 
hour far exceeds the 2% per hour turnover of plasma membrane protein. 
It  seems more l ik e ly  that plasma membrane protein turnover i s  a 
consequence of the continuous endocytosis-exocytosis shuttle. 
Bretscher^et a K ,  (1980) explain the re lative ly  low rate of membrane 
constituent turnover by postulating the Involvement of a molecular 
f i l t e r  which prevents the majority of proteins being Internalised.
1.5.1.2 Adsorptive plnocytosls
Although the rate of plnocytosls I s  not usually affected by the 
presence of substrate, substrate selection can occur by means of 
adsorption to the plasma membrane (Besterman & Low, 1983; Lloyd 5 
U1111ams,1984). Substrates which have an a ffin ity  for the plasma 
membrane and are selectively concentrated within the ce ll Include 
catlonised fe rr it in  (Besterman & Low, 1983) and denatured bovine 
serum albumin (BSA) (Lloyd 5 Williams^1984). The degree of 
concentration depends upon (a) substrate concentration In the ambient 
f lu id  (b) a f f in it y  for the plasma membrane and (c) the density of 
binding s ite s  on the membrane to be internalised. Non-specific 
binding has been demonstrated using the rat visceral yo lk sac 
cultured In v it r o . Experiments using BSA, and native bovine Insu lin  
(Lloyd & U1111ams,1984) led to the proposal that the yolk sac 
membrane contains two types of binding site , one for cationic 
ligands, and another for hydrophobic ligands, the two sites 
operating Independently. It  I s  conceivable that the natural turnover 
In vivo of non-adsorptive circu lating proteins involves such binding
site s. Spontaneous dénaturation may reveal previously masked
'S
hydrophobic, or cationic sites, with the consequent rapid and 
e ffic ien t removal of the protein from circulation.
1.5.1.3 Receptor-Mdlated p in x y to s is
In contrast to simple adsorptive pinocytosis, receptor-mediated 
pinocytosis is  highly specific, a particular receptor being 
responsible for the uptake of only one particular ligand type. For 
example, the galactose receptor recognises those glycoproteins with a 
terminal galactose residue (Wall & Hubbard, 1985), whilst the 
transferrin  receptor recognises transfe rrin  (Schneider.et a l.. 1982). 
The former example is  le ss d iscrim inating in that it  has specific ity  
for a range of glycoproteins which may only have in common an exposed 
galactose residue (Wall & Hubbard, 1985) as compared with the la tter 
example, which i s  specific  for only one protein. It  i s  thought that 
some ligands such as transferrin  and «^'"^croglobulln are also able to 
bind non -specifica lly to low a ffin ity  membrane binding-sites 
(Ste1nman«et a l.. 1983).
There are a wide variety of receptors found on the surface of 
animal ce lls .  Characteristically they are in trin sic  membrane 
proteins which are able to move freely in  the plane of the lip id  
bilayer by lateral d iffusion, with a d iffu sion  coefficient sim ilar to 
other membrane proteins (Pastan & Willingham, 1983). Fluorescence 
labelled ligands have shown that most receptors move randomly and 
freely in the plane of the membrane (Pastan & Willingham,1983). At 
37^C each receptor encounters one of the 1000, or more, coated p its 
found on most types of cultured ce ll, once every 3 seconds.
The d istribu tion  of receptors is  not always uniform across the 
whole ce ll surface, for example the asialoglycoprotein (ASGP) 
receptor i s  confined to one side of the hepatocyte by Junctional 
elements (Wall,et a K ,  1980). Other ce ll types such as those 
possessing m icrov illi,  contain a higher density of receptors in 
certain areas of the cell surface, such as the microvillous area, 
without the presence of Junctional complexes (Weller, 1974) giving
indirect evidence for the existence of domains.
The number of receptors on any one cell specific for a 
particular ligand is  not always constant. There Is  some evidence of 
an interchange between cell surface receptors and an in trace llu la r 
pool, for example the asialoglycoprotein receptor (Steinman, et al_., 
1983) and the transferrin  receptor (Hopkins, 1986) are amongst those 
which exhibit down regulation.
1.S.2 In trace llu lar processing
Once ligand is  bound to receptor, for example transferrin  to the 
transferrin  receptor, there i s  c lustering of the receptors into the 
coated p its (Pastan & Willingham, 1983). It  i s  possible that 
receptors such as the transferrin receptor, low density lipoprotein 
receptor (W illingham ! Pastan,1984; Wileman^et a L .  1985) may cluster 
in these p its  in  the absence of ligand. Internalised ligand enters 
the early peripheral endosomal compartment, (Wileman.et a l..  1985). 
The endosomal compartment is  heterogeneous both in it s  ce llu la r 
d istribution  and morphology (Helenius,et a L ,  1983; Willingham & 
Pastan,1983; Wileman,et a K ,  1985). The vesicles which form the 
endosóme range from 0.3-l^m in diameter and are composed of two or 
possibly three d istin ct sub-populations, the early peripheral 
endosomes, which are usually associated with tubular elements, and a 
second population which is  located near the Golgi-lysosome region of 
the ce ll. The la tte r population are larger, sometimes tubular and 
possibly identified  as CURL (Geuze,et a L ,  1983).
The heterogeneous nature of endosomes has made separation of 
these organelles extremely d iff icu lt .  Indirect studies have shown 
that the vacuole has an acidic in te rior (Pastan & Willingham, 1983). 
Galloway,et ^  (1983) have shown acidification  of endosomes in 
v it ro , and postulate that an ATPase/H^ pump (sim ilar to that found in 
the lysosome) i s  responsible. The o rig in  of the proton pump
responsible for a c ld if ic it io n  I s  thought to be the plasma membrane.
The function of th is  pre-lysosomal acidic compartment i s  thought 
to be that of a "c learing house", sorting out membrane from 
intravesicular contents, and d issociating receptors from ligands.
The prime importance o f the endosóme is  as a site  of recycling 
(Besterman, 1981) of both membrane and receptors (Van Renswoude, et 
a1., 1982). The number of ligands taken up by a cell i s  very large, 
for example fib rob lasts internalise  2x10^ «^macroglobulin molecules 
per hour despite with the presence of only a few thousand 
cell-surface receptors (Dickson, 1981). The cell does not have the 
capacity to resynthesise so many receptors quickly enough to replace 
those internalised. There must be re-use of receptors resu lting from 
recycling. Evidence that such recycling occurs v ia  a pre-lysosomal 
compartment is  several fo ld; (a) the re la t ive ly  long h a lf - l ife  of 
plasma membrane proteins, and in particular receptors, implies that 
they are not exposed to lysosomal enzymes (Steinman, ^  a^^, 1976)
(b) the rapid recycling time (le ss than five  minutes) for receptors 
such as transferrin  i s  too quick to have involved the lysosome (Van 
Renswoude, et 1982) (c) receptor-mediated uptake of ligands 
continues at 16-20°C at which temperature there is  l i t t le  movement to 
the lysosome, i f  Indeed any (Wall & Hubbard, 1985). The role  of the 
endosóme in receptor recycling is  probably to act as an acid 
environment in which the ligand-receptor complex d issociates, as seen 
with the Semliki Forest Virus (SFV) (Harsh, et a K ,  1983) and 
transferrin  (Van Renswoude, et a K ,  1982). It  is  within the acidic 
environment of the endosóme that d ife rric  transferrin  is  subject to 
protonation of the anion at the sixth co-ordination s ite  of Fe^^^
This destab ilises the transferrin-metal Interaction and releases iron 
to the cell (Aisen 1980; Octave, et a K ,  1983; Testa»1985; Hay & 
Cuatrecasas, 1985). Iron is  transported to fe rr it in  (mechanism
unknown) and the apotransforrln-receptor complex I s  subsequently 
recycled back to the plasma membrane. The s it e  of recycling has been 
va rious ly  attributed to the endosóme, Golgi, and lysosome (see Table 
1 .6 ). This confusion may resu lt from the lack o f a common pathway In 
a11 ce11 types. In the fie ld  of drug delivery, I t  Is  necessary to 
know the exact Intrace llu lar routing of particu lar drug-conjugates.
The ultimate fate of those receptors which do not recycle (see 
Table 1.7) Is  the lysosome (Besterman & Low, 1983; Steinman, et a l . .
1983) . Lysosomes (Barrett, 1969; Thines-Simpoux, 1984; Dean, 1977) 
are a heterogeneous population of vesicles, whose characteristics are 
suenarlsed In Table 1.8. There are found to e x ist  two broad 
populations of lysosomes (1) primary lysosomes, which are newly 
formed (11) secondary lysosomes, which resu lt from fusion of a 
primary lysosome with a second vesicle. The membrane of the primary 
and secondary lysosome d iffer, In that the la t te r  contains a high 
proportion of choline phosphate and sphingomyelin (Thines-Simpoux,
1984) , which are normally characteristic o f the plasma membrane, thus 
Ind icating some Interchange between the plasma membrane and the 
lysosome.
The function of the lysosome I s  one of degradation. Material 
which I s  no longer of use to the cell I s  degraded to I t s  constituent 
molecules, which may then be subsequently re-used. The structure of 
the lysosome Is  Idea lly suited to th is  function of digestive 
organelle; (1) the vast battery of enzymes, some of which have 
Incomplete substrate specific ity  (Lloyd & Fo rste r,1986) are able to 
degrade a ll Incoming organic material, be that material polypeptide, 
polysaccharide, polynucleotide, or g lyco llp id  (11) the acid pH-opt1ma 
o f  the enzymes ensures that the maximal effect of these enzymes Is  
w ithin  the confines of the lysosome, reducing potential damage by 
leakage of lysosomal enzymes Into the cytosol (pH7.3) (111) the
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™U t1v«1y high impenieibiltty of the lysosonal nenbrine ensure! th it  
only the monomeric units of degreOed meteriel ere ellomed to re-enter 
the cytosol fo r subseguent re-uso, N oteriil »hich cinnot be degreded 
is  retelned » ith in  the lysosome, thus restrict ing  contact »ith tho 
rest of the ce ll.
The basic design of HPMA drug conjugates i s  such that free drug 
i s  released from the carrier » ith in  the lysosomal compartment 
(Duncan, 1986). I t  is  necessary to detormine the intracellu lar 
routing of a ll  potential HPtW drug-carrier conjugates after 
conjugation to the targeting residue, to determine the optimal 
chemistry of binding drug to the inert HPHA backbone. If ,  after 
conjugation to transferrin  the HMiA copolymer conjugate does not 
enter the lysosomal compartment, but rather recycles through the 
endosomal compartment, then i t  is  possib le to incorporate an 
acid-lab ile  linkage into the overall structure of tho carrier to 
fa c ilita te  release of drug within the endosóme. If ,  alternatively, 
the carrie r i s  not readily endocytosed after conjugation then a 
surface active drug may be attached to the carrier.
Those properties considered to be desirable in a drug-carrier 
are suimaarised in  tame 1.9 This study has examined the potential 
of HPHA copolymer-protein conjugates, in particular 
HPHA-copolymer-antIbody conjugates, to f u lf i l  these requirements.
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2.2 KETHODS
2.2.1 C<n Culturt
2.2.1.1 Aseptic technique
A11 ce11 culture techniques were cerried out in a laminar flow 
cabinet (Class I I ) .  Equipment and materials used were always 
ste rile . Those Items not supplied pre>steri1ised were ste r ilised  by 
e ither ( i)  autoc1aving(l20°C, 151b/m^, ISmin): su itable for 
glassware, certain p lastics ( 1 1 ) m icro-filtration  (0 .2u*i); suitable 
for solutions (111) U.V. irrad ia tion  (>10min) used where (1) and (11) 
not possible. The pipetus, suction pump, a ll associated tubing and 
the inside of the cabinet, were wiped down with methylated sp ir its  
(70X) before and after use. The Inside  of the cabinet was Irradiated 
(U.V., lOmins) after each use.
Sterile  solutions were dispensed by means of a pipetus attached 
to a ste rile  pipette (lOml). Solutions were removed from cell 
cultures by suction (suction pump) v ia  a sterile  Pasteur pipette. 
Whilst dispensing and removing solutions great care was taken to 
ensure that neither the pipette, nor solution, touched the neck of 
any container used.
2.2.1.2 Cell lin e s
Human sk in  Fibroblasts (adherent) were routinely grown in 
complete Ham’s FIO medium (that i s  Ham’s FIO medium containing
newborn ca lf serum (20%)) and antib iotic s (Pen ic illin , lOu 1
Streptomycin, lOugml'^) and incubated (37°C, CO^  incubator) in 
culture flasks (p lastic  25, 75, or I75cm^ growth area).
CCRF/CEH (human lymphoblastic leukaemia) were routinely grown in 
RPMI complete medium (that is ,  RPMI medium containing foetal calf 
serum, 10% and antib iotics, as above and incubated (37^C, CO  ^
incubator) in culture tubes (round-bottomed, p la stic  10 ml).
Clone Hep &2 and Alexander c e lls  (used only in Chapter 6 )
were ■ aintelned by A. Hume and L. Scarlett.
B rie fly, Clone were grown In Ham’s FIO medium containing 
horse serum (15%) and foetal bovine serum (2.5%).
Hep 6 2  were grown in Eagle 's (modified) minimum essential medium 
with Earles sa lts, containing foetal bovine serum (10%).
Alexander c e lls  were grown In Eagle’s (modified) minimum 
essential medium with Earle ’s sa lts containing non-essential amino 
acids ( 1 %) and foetal bovine serum ( 1 0 %).
2.2.1.3 Subculturing
2.2.1.3.1 Fibroblasts
The following protocol describes the sub-culturing of 
2
fibroblasts grown In  f la sk s of 25cm growth area.
At confluence (determined by microscopy) ce lls  were washed (PBS 
without calcium and magnesium, pH 7.4, 10ml). For In i t ia l  
experiments th is was followed by trypsin isatlon  according to the 
method of Koolstra & Lloyd (1985). Pre-washed c e l ls  were Incubated 
In trypsin  (0.25% In  PBS, pH 7.4, 2.5m1 ISmln, 37°C) and recovered by 
centrifugation (1000 rpm, lOmln). The resulting pe lle t was 
resuspended 1n Ham’s FIO complete medium (4m1), and equally divided 
Into culture fla sk s (25cm^) containing complete medium (as above,
5m1). The flasks were gassed (5% CO2  95% a ir, 6-12s).
However, th is  method had a number of disadvantages (1) prolonged 
contact of fib rob lasts with trypsin caused the c e lls  to clump ( 1 1 ) 
recovery of ce lls  by centrifugation I s  potentially damaging ( 1 1 1 ) 
gassing of fla sks resulted In a lowering of the pH of the medium to a 
sub-optimal level. To overcome these d iff ic u lt ie s  the above method 
of trypsinisatlon  was modified. The following modification was used 
In the majority of the experiments.
Trypsin was le f t  In contact with pre-washed c e l ls  fo r one 
minute. After Incubation in residual trypsin (37®C, 15m1n), and
subsequent resuspension In Hen's FIO conpletn nedlun (4n1) the
2
fIb ro b U sts were equally divided Into 2 f la sk s  (2Scm } each 
containing conplete nedlun (5n1).
I f  flasks of larger growth area were used then the volumes of 
reagents were scaled up accordingly.
Nedlun was changed on day 4 after subculturing, and the c e lls  
subcuUured on day 7.
2.2.1.3.2 CCRF/CEN
CCRF/CEN were grown to an optimal den sity  (determined by ce11 
v ia b il ity ,  2.2.1.5). The cell pellet was resuspended by Inversion of 
the ce ll culture tube several tines, and sub-divided 1:10 Into 10 
culture tubes each containing RPMI conplete medium (9nls).
2.2.1.4 Freezing and thawing of ce lls
Cells were stored at -60^C (medlun tern, up to 6 months; -196*^C 
(liqu id  nitrogen, long term, more than 6 months).
Fibroblasts were washed and trypsin ised  (2.2.1.3.1). Detached 
c e lls  were then resuspended In Ham's FIO complete medium containing 
dinethylsulphoxide (DHSO, 10% , 2ml) and transferred  to a 
screw-topped ampoule. The ampoule was g radua lly  cooled. For medium 
term storage c e lls  were sequentially cooled at 4^C (Ih), - 2 0 \  (Ih) 
and f in a lly  -80®C. For long term storage the c e lls  were then further 
cooled to -196®C (after 24h at -80®C).
CCRF/CEN were pelleted (lOOOrpm, 5m1n) washed by resuspension In 
P8S (pH7.4, lOnl) and repelleted (lOOOrpm, lOmln). The pellet was 
resuspended In RPHI complete medium containing DNSO (10%) and treated 
as above.
Cells were rapidly thawed by placing the ampoule In a water bath 
(37®C). The cell suspension (In  medium containing ONSO) was then
transferred to a centrifuge tube ( Ita l)  and slowly (drop at a tine) 
complete medium (Smi) was added, followed by a further addition o f 
complete medium (5m1). After gentle washing the ce lls  were recovered 
by centrifugation (lOOOrpm, I0m1n). As the ce lls  are very fra g ile  
after freezing, they were not subjected to further washing at th is  
time. The c e lls  were resuspended In a large excess of complete 
medium (20m1) to d ilute the effect of any remaining DMSO.
Fibroblasts were transferred to a culture fla sk  (75cm^ growth area). 
Viable c e lls  were given time to adhere to the fla sk  (24h). Medium 
and dead c e lls  were removed by suction, and fresh complete medium 
added (20m1, 75cm  ^ f la sk ). In contrast the CCRF/CEM cell suspension 
was added to culture tubes (2, 10ml) le ft  for 2h and then pelleted 
(1000 rpm, lOmln). The pellet was washed (PBS, pH7.4, 10ml) and 
resuspended In complete medium (10ml).
2.2.1.5 Cell v ia b il it y :  Trypan blue exclusion test
Pre-washed fib rob lasts (PBS pH7.4, 10ml) were trypsinised 
(2.2.1.3.1), and resuspended In PBS (pH7.4, 2m1s). Trypan blue 
(200)i1, 0.4%) was added to a sample of ce ll suspension (200pl). The 
ce lls  were allowed to take up the dye (37°C, lOmln), then duplicate 
samples were placed on a haemocytometer slide  and the percentage 
viable c e lls  determined.
CCRF were pelleted (lOOOrpm, lOmln), washed In PBS (pH7.4, 
lOmIs), repelleted (lOOrpm, lOmln) and then resuspended In PBS 
(2m1s). Trypan blue was added and cell v ia b il ity  determined as 
detailed above. The percentage of viable ce lls  was calculated by the 
following equation:
Total ce ll number In  xnils of 
cell suspension
No ce lls  on haemocytometer 
slide  grid (contains
% v ia b il ity -  viable cell nuwber xlOO 
Total cell nunber
A11 cultures used In this study were > 99X viable.
2.2.1.6 Cell growth
A growth curve was detemlned for each cell type used. A set of 
identical fla sk s (adherent ce lls) or tubes (non-adherent ce lls )  were 
set up on day 0. At each tiiee point (t-0, 24h, 48h, over 
approxinately 10 days) cell number and v ia b il it y  were determined as 
above.
2.2.2 Radioiodination
2.2.2.1 The lodogen method
The method used was o rig ina lly  described by Fraker & Speck 
(1978) and later modified by Dean, 198S).
lodogen (Img in 25m1 dlchloromethane) was added (S0p1) to the 
bottom of an Eppendorf tube (SOOpl). Solvent was allowed to 
evaporate in a fume cupboard, leaving a coating of the solid-phase 
lodogen reag^ent on the sides of the Eppendorf tube. Catalyst-coated 
tubes were stored (-20°C, tigh tly  stoppered) until required.
A stock solution of 4.4mg n l '^  was prepared for a ll ligands to 
be iodinated (the same concentration as HcAb B3/2S supplied by Dr. I. 
Trowbridge). For a ll protein-HPHA copolymer conjugates the 
concentration of protein was used as a measure of conjugate 
concentration. (For example conjugate-associated transferrin 4.8mg 
■ r ^  IgG 6.8mg m l*^  HcAb 83/25 emgml*^). To allow standardisation 
of the lodlnation condition used, in terms of a ratio of ^^®I(pCl) to 
protein (mg) the volume of protein-HPMA copolymer conjugate used for 
iodination was determined by the concentration of protein in the 
preparations as supplied.
In general, (25}i1 4.4ingnir^ IlOyg) wis added carefully to the 
botton of the cata1yst*coated tube. Sodium [^^^I]1od1de (O.SmCI,
5u1) was added (ensuring thorough mixing with the substrate 
solution). The lid  of the Eppendorf tube was quickly dosed and the 
reaction allowed to proceed at room teiiq>erature (alOaln). The 
reaction was stopped by addition of phosphate buffer (O.OSM, pH7.2, 
1»1). Diluted sample was eluted through a disposable gel permeation 
chromatography column (Pharmacia P-10, Sephadex G-2S) with phosphate 
buffer (O.OSN, pH7.2). (The column had been pre-washed with BSA, 
SOOpI, lOOrngm!*^, to prevent non-specific adsorption of protein to 
the column). Fractions (8-drop) were collected and rad ioactivity 
assessed (hand monitor). Those tubes containing the f ir s t  peak 
(corresponding to the radlolabelled substrate eluting with the void 
volume) were pooled and dialysed (8/32” v isk ing  tubing) against NaCl 
(51, 1%) to remove traces of free (^^®I]1odlde. Radlolodinated 
preparations were stored at -20°C.
2.2.2.2 Determination of free [^^^I]1od1de using paper
electrophoresis
The middle 20cm of a piece of chromatography paper (Whatman-1, 
5cmx30cm) was divided Into strip s (40, 0.5cm wide). Radiolabelled 
substrate was applied by streaking across the fifth  strip , and 
electrophoresed (30m1n, 400v) In buffer (barbitone O.IH, pH8.6). 
Strips were cut out and assayed for rad ioactivity (LKB Compugamma, 
30s). Under these conditions only free [^^*l]1od1de migrates In  the 
current. Free [^^^I]1od1de was determined as a percentage of the 
total rad ioactivity recovered ( I f  >2% the preparation was re-dlalysed 
against NaCl).
Routinely, before a ll experiments the percentage of free 
[^^^I]1od1de was determined.
[^^^I]1odide has a h a lf- l ife  of 60 days 
. -  • .-Kt
2.2.2.3 DtUnilnatlon of S{>ec1f1c Activity
Where A • activ ity  on the day of the experlnent 
Ajj ■  in it ia l activ ity  
K ■  the constant for 
-  lassxio'^ 
t • tine (days) froa tg
Specific  Activ ity  -  A(pCi)
pg protein
A sumaary of specific  a ct iv it ie s obtained in  th is study are given in 
Chapter 3. Table 3.2.
2,2.3 Chroaatooraphy
2.2.3.1 Gel permeation chromatography
2.2.3.1.1 Sephadex 6-15 (height 17cm, internal diameter 1.4cm, flow 
rate 12m1h~^, molecular weight separation o f proteins approximately
O-lSOOIc Daltons
Sephadex G-15 columns were used to separate low molecular weight 
degradation products ([^^®I]iod1de, [^^®I]1odotyros1ne) released 
during Incubation of ^^^I-labelled HPMA with fibroblasts (Chapter 4).
The column was calibrated with both [^^^]1od1de and 
(^^^lodotyroslne. A sample (lxlO*cpm in 1ml) was added to the top 
of the column and eluted using Tris/HCl buffer (0.2M, pH8, containing 
NaCl, 0.5M). Fractions (3m1n) were collected and assayed for 
rad ioactivity (LKB, Compugamma, 2min).
For detection of low molecular weight degradation products, 
duplicate medium samples (1ml) were eluted through the column using
the conditions detailed as above.
2.2.3.1.2 Sephacryl S-200 (height 78ca. Internal diaiieter 1.7c«, 
flow rate 8«1h~^, «o lKu la r weight separation of proteins 
approxi«ate1y 5k>250lc Daltons).
Sephacryl S-200 columns were used to separate protein-HPHA 
copolymer conjugates from free unconjugated HPMA copolymer (always 
found as a contaminant in the preparations supplied). A sample of 
^^h-1abe11ed conjugate (approximately 500K cpm in 1«1 total vo l.)  
was characterised by elution through a S-200 column (0.2H Tris/HCl 
buffer, pH8, containing O.SHNaCI). Fractions (6min) were assayed for 
rad ioactivity (LK6 Compuganma, 2min).
Unlabelled crude reaction mixture (lm1) was then eluted through 
the column (under the same conditions as above). Those fractions 
corresponding to protein-HPMA copolymer conjugate (Abs 280nm) were 
pooled and then concentrated by u lt ra f ilt ra t io n  (H illipore, CX-10).
2.2.3.1.3 Sephacryl $-300 (height 112cm, Internal diameter 1.7ca, 
flow rate lOmlh*^) and Sepharose 4B/6B (height 65cm, internal 
diameter 1.7cm, flow rate I3m1h’ ^)
Both Sephacryl S-300 and Sepharose 4B/6B columns were used for 
the molecular weight determination of the protein-HPMA copolymer 
conjugates used in this study.
Both columns were calibrated with a range of proteins and HPMA 
copolymers (of a defined Mw and low polydispersity Table 2.1: see 
Chapter 3 and F igs. 3.5a,b).
For both calibration and molecular weight determination, a spike 
of ^^®I-labelled ligand (approximately 5xl0®cpm in 1ml total vo l.) 
was eluted through the column with buffer (0.2MTr1s/HCl, pH8, 
containing O.SHNaCI). Fractions (6min) were assayed for 
radioactivity (LXB Compugatma 2m1n).
Proteins and HPMA copolymers used to calibrate the $-300 and 
4B/6B gel permeation columns.
Protein Log Molecular Weight
Cytochrome C 4.09
Transferrin (both apo and 
d ife rric }
4.90
IgG 5.18
Fe rrit in 5.67
Thyroglobulin 5.84
4.06
HPMA copolymers of 4.32
d iffe rin g  (supplied 4.60
by Kopecek,et al^.) 4.89
5.17
5.74
S«phadtx-prott1n>A (height lOoi, Internal dlaaeter 1.7ai, flow rate
zailh'*
Sephadex>Prote1n-A chromatography was used to separate 
antIbody-HPHA copolymer conjugates on the basis o f the ir ab ility  to 
Interact with Protein-A.
A sample (1ml) of purified antibody-HPHA copolymer conjugate 
(2.2.3.1.2) was eluted through the column with buffer (O.IM TrIs/HCI, 
pH8). Fractions (3min) were collected and Abs. 280nm determined. 
Those fractions containing antibody-HPMA copolymer conjugate (Abs. 
280nm) were pooled.
Antibody-HPMA copolymer conjugate bound to the column was 
removed by changing to a new buffer (IH acetic acid, pH3) and 
reversing the direction of flow through the colum. Fractions (3min) 
were collected and again Abs. 280nm determined. Those fractions 
containing conjugate were pooled and the pH of the solution brought 
up to 7.5 (NaOH. 5M).
The two preparations were concentrated by u ltra filt ra t io n  
(H illipore, CX-10), and characterise by gel permeation chromatography 
(2.2.3.1.3; Chapter 3, Fig 3.2).
2.2.3.2 Affinity chromto^raphy
A ll preparations (before and after purification  and separation) 
i f  not used immediately were stored at -20*^0. Freezing and thawing 
of a ll preparations was minimised to avoid dénaturation.
2.2.4 Preparation of iron-loaded transferrin
The method used was o r ig ina lly  described by van Renswoude 
(1982). Apotransferrin (6mg) was dissolved in buffer (O.IH Tris/HCl, 
pH8). Sodium n itrilotriacetate  (20m1, 100ii#1, containing ferric 
chloride 12mH) was added and the reaction mixture incubated (30min, 
37®C). The solution was then purified  by elution through a column
(Sephadex 6*2S, height IScn, Internal diameter 1.7cm, flow rate 
IZ i lh " ')  »1th buffer (0.2M TrIs/HCl, pH7.4, contiln irg O.lSMNiCI). 
Fractions (SOOyl) were collected and those eluting on the void volume 
pooled.
The criterion  used to assess the Iron-loading of transfe rrin  was 
the ratio  of Abs. 465nm/Abs.280ni. A ra t io  of >0.046 was Judged to 
Indicate Iron saturation of transferrin  as f ir s t  described by Aasa 
(1963). Samples with a ratio  <0.046 were discarded.
2.2.S Total uptake and intem a llsa tlon  o f ^^^M abelled  lloands by 
human sM n  fibroblasts
In a ll experiments, ligand binding and Internalisation were 
distinguished by trypsinisatlon  (2.2.5.1). Low molecular weight 
degradation products were quantified by e ither (1) G-2S 
chromatography; HPHA copolymer only (2.2.3.1 .1 ), or (11) an Increase 
In acid soluble radioactivity detected In  the Incubation medium above 
that of the corresponding control (2 .2.5.2 ).
2.2.5.1 Determination of the e ffic iency of trypsin isatlon  to remove 
cell surface-bound ^^^M abelled  ligands
These experiments were carried out at 37*^ C (when there I s  the 
potential problem of rapid Inte rna lisa tion  of receptor-bound ligand) 
and at 4*^ C (when there Is  the potential problem of s l ig h t  
conformation changes In the receptor w ithin  a more r ig id  plasma 
membrane).
Cell adherence (determined by microscopy) and cell v ia b il it y  
(2.2.1.5) were not reduced by Incubation at 4®C.
The experimental protocols at 4®C and 37®C are su ffic ien tly  
different to require separate description.
2.2.5 .1.1 Trypsinisatlon of surfoct-bound ligand at 37°C.
Pre-washad (PBS, pH7.4, lOnl) confluent c a lls  (6 fla sks, 25cn^
growth area) were allowed to co«e Into contact with radiolabelled 
ligand (concentrations as detailed in Table 2.2; total volume 3nl In 
Hank’ s balanced salt solution (HBSS), approxiutely 10s). Duplicate 
samples of HBSS were assayed for radioactivity (LKB Compugaiima, 30s). 
C e lls  were rapidly washed (x3, PBS pH 7.4, 10ml) and the flasks 
d iv ided into two groups of three. In one group of fla sks 
surface-bound ^^^I-1abelled ligand was removed by trypsinisation  
(0.25M trypsin in PBS pH7.4, 2.5m1, Inin, followed by Incubation at 
37°C, ISmin in residual trypsin). Detached ce lls  were washed (3x, 
PBS, pH7.4, 10ml) and recoverd by centrifugation (lOOOrpm, lOmin).
The c e l l pellet was digested in NaOH (IH, lm1, overnight). With the 
second group of flasks the ce lls  were simply digested in NaOH (IH, 
2.5ml, overnight). Cell d igests were assayed for both rad ioactivity 
(Smin) and protein (Lowry).
2 .2 .5 .1 .2  Nodificatlon required for trypsinisation  at 4'^C.
( I )  Pre-washed confluent ce lls, stock solutions containing 
radiolabelled ligand, and a ll other solutions used were pre-cooled to 
4»C.
( I I )  It  was necessary to increase the time of incubation (4°C) 
In residual trypsin from ISmin (37®C) to 30min.
The percentage of surface-bound ligand removed by trypsin isation  
was determined as follows
F la sks in group 1 have surface-bound ligand removed by trypsinsation
F la sks in group 2 have not undergone trypsinsation
Percentage trypsin -  ligand bound (p« ng '^cell protein) Group 1 x 100 
Insensitive ligand ligand bound (pn mg'^cell prote1n)Group 2 
- AX
Trypsin sensitive rad ioactiv ity  expressed as a percentage of total 
binding
• ilOO-AlX
The efficiency of trypsin isatlon  at reieovlng the cell 
surface-bound ligands used In  th is study Is  given In Table 2.2.
2.2.$.2.1 Detection of low nolecular weight degradation products as 
an Increase In  acid-solub le radioactivity.
For HPKA copolymer only refer to 2.2.3.1.1. For protein and 
proteln-HPMA copolymer conjugates duplicate samples (1ml, medium 72h 
experiments; HBSS, 3h experiments, see Section 2.2.S.3) were taken at 
each time point. It  was necessary at th is stage to add protein 
(lOOpl serum) to samples contained In HBSS to fa c ilita te  
precipitation of acid Insoluble  radioactivity. Trichloracetic acid 
(TCA, 201, SOOpl) was added to each sample with thorough mixing.
Acid Insoluble rad ioactiv ity  and precipitated protein were removed by 
centrifugation (USE 4L, 6.510^ rpn, 30ie1n, 4°C). The supernatant »as 
assayed for rad ioactivity  (LKB Conpuga«, 30s). It  »as necessary to 
correct the acid soluble counts (2.2.5.2.2) because of the altered 
counting geometry of the sample due to (1) an alteration In the 
counting volume of the supernatant as compared to the orig inal sample 
and (11) trapping of acid soluble radioactivity In the protein pellet 
during centrifugation.
Any Increase In acid-soluble radioactivity was related to that 
seen In a corresponding control.
Table 2.2
Percentage of cell surface-bound Hqand sensitive  to trynsinatlon.
Ugand concentration
(nM)
Trypsin sensitive ligand 
expressed as a percentage 
of to ta l cell*assoc1ated 
rad ioactiv ity
4“C 37°C
Transferrin
apo 10 72 82.7
d ife rric 10 99.7 59
Antibody
IgG 5 NO 93.7
McAb B3/25 5 NO 88.2
Conjugates
P-gly-gly-IqG •5* ND 99.2
P-q ly-gly-Transferrin .10* NO 85.8
P • HPMA copolymer 
*  See Chapter 3 
ND ■  Not determined
2.2.5.2.2 Dtt«ninat1on of th« corrtctlon factor for acld-solubit
rad ioactivity.
Tmo sets of 10 tubes were prepared containing either HBSS or 
Han's FIO complete medium (1ml). A spike of ac1d-so1uble 
rad ioactivity  (IxlO^cpm; (^^®I]1od1de or l[*^®I>1odotyros1ne) was 
added. Acid soluble radioactivity was then determined as 2.2.5.2.1
Correction factor -  Acid soluble rad ioactivity cpm In the original sample
Acid soluble rad ioactivity recovered In the 
supernatant
A correction factor of 1.3 was used In th is study (see Table 2.3).
2.2.5.3 Binding, Internalisation and degradation of ^^^I-1abe11ed 
ligands by fibroblasts
Controls were Identical to experimental fla sk s In a ll details 
but contained no ce lls .  No Increase In the degradation of 
^^^I-labelled ligand was found when controls contained medium or HBSS 
which had previously been In contact with c e lls .  To minimise 
non-specific adsorption of ligand to the surface of vessels glass 
containers were used for preparation of stock solutions and for 
controls.
Pre-washed (PBS, pH7.4, lOmls) confluent c e lls  were Incubated 
(37°C) In the presence of ^^^I-labelled Ugand (concentrations 
detailed In Table 2.4) In a total volume of 7ml (Ham’s FIO complete 
medium, 72h experiments) or 3ml (HBSS, 3h experiments). At 
predetermined time points (for example 0, 30m1n, Ih, 3h) duplicate 
sampeles of medlum/HBSS were taken from s ix  experimental fla sks and 
two controls. Samples were assayed for both total radioactivity and 
the presence of low molecular weight degradation products 
( 2 . 2 . 5 . 2 . 1 ) .

Concentrations of radlolabeHtd Ugand ustd for deterwlnation of 
uptake and in subce llu lar fractionation studies.
Radiolabelled ligand concentration (H )
PVP
HPMA copolymer 50nH
Transferrin lOnH
Antibody 5nH
Protein-HPMA copolymer 
conjugates
P-IgG *126pH
P-Tf 53nM
*
P-McAb B3/25 50nH
*such high concentrations needed to detect any cell-associated 
radioactivity
'’’The low molarity of P-IgS is  attributable to It s  very high 
molecular weight
'^Approximate molarity since the average molecular weight 
i s  variable between batches (here taken as 30K Daltons).
F ib rob lasts were washed (3x, PBS, pH7.4, lOiil, ice*cold) to 
remove loose ly bound ligand and a ll traces of medium (Inactivates 
tryp sin ). The flasks were then placed In Ice (to minimise 
Inte rna lisa tion  of any surface bound ligand) and divided into two 
groups fo r  either trypsin isatlon  or d irect d igestion In NaOH 
(2.2.5.1 .1 ). Cell d igests were assayed fo r both rad ioactivity  (5m1n, 
LKB Compugaima) and total protein (Lowry).
2.2.S.4 Calculations
The uptake of radlolabelled ligand was calculated In terms of p1 
worth o f  Incubation medium whose contained substrate was endocytosed 
mg*^ c e l l protein as previously defined by Williams,et al^. (1975) and 
presented In terms of both Total Uptake and Internalisation; and 
these terms are defined precisely In Chapter 4, Section 4.1.2.
Total Uptake (Tu)
(pi mg*^ cell protein
Cell-associated rad ioactivity (cpm) 
Medium rad ioactivity x Total ce ll protein
(cp» 1 1 1 " ' ) (■g)
In te rna lisa tion  (In) > 
(pi mg'^ cell protein)
* a Degradation products 
(mg*^ ce ll protein)
Trypsin Insensit ive  cell-associated 
radioactivity (cpm)
Medium rad ioactivity x Total ce ll protein
(cpm p1•1 (mg)
•f A Degradation products 
(mg'^ cell protein)
In Appendix S e detailed example Is  given together «1th an 
explanation of the correction needed to determine TU and In of 
conjugate S.
2.2.6 Subctllular fractionation using Percoll density gradient.
2.2.6.1 Standardisation of conditions used.
2.2.6.1.1 firadlent starting density and conditions of 
centrifugation.
The shape of a density gradient Is  a product of total force (g) 
X time, and Is  affected by ro to r geometry, s ize  o f tubes, and the 
density of Percoll used.
F irst, gradients produced with a Becicnan type-65 fixed-angle 
(23.5^, r^y 5.7cm) head and using thick walled polycarbonate 
centrifuge tubes with caps, containing 8ml of Percoll gradient were 
characterised. The following solutions were prepared:-
( I)  Standard Iso-osmotlc Percoll (SIP) was prepared by mixing 
stock Percoll (9ml, Pharmacia. l.I28giimr^) with sucrose/EDTA (2.5H 
sucrose, ImH EDTA, 1ml). Further dilutions o f S IP  were made using 
sucrose/EDTA (0.25M sucrose, InN EOTA) to produce gradients of the 
appropriate starting density (expressed In terms of X SIP).
( I I )  Density-marker beads (Pharmacia, 1.037-1.lldgml'^) were 
pre-swollen In water (1ml) and stored (4^C).
The rotor was pre-cooled (4®C). A series o f gradients (20-90% 
SIP, total volume 8m1) were loaded with density marker beads (lOpl, 
each density). After capping the tubes t igh t ly  the gradients were 
subjected to various combinations of centrifugation conditions (20K, 
29K, 39K rpffi, for 15, 30, 40m1n). A 60% SIP gradient (40m1n, 20K 
rpm) was considered to give optimal, even separation of densities 
associated with a ll subcellu lar organelles; the 30% SIP gradient 
(40m1n, 20K rpm) optimal separation of densities associated with 
plasma membrane and lysosomal compartments. For a ll experiments
d«scr1b«d In Chapter 5 e 30X SIP gradient was used.
2.2.6.1.2 Honogenlsatlcm of fibroblasts.
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Fibroblasts grown to confluence (75cin growth area) were washed 
(PBS, pH7.4, 30h1, x3) and harvested by Incubation In  PBS/EDTA (liril 
EOTA, 37*^0, lO iln ). Detached c e lls  were recovered by centrifugation 
(lOOOrpm, lOmlns) and resuspended In sucrose/EDTA (0.25H sucrose, ImH 
EOTA). The cell suspension was subjected to varying degrees of 
homogenisation (10-100 strokes of the big head of a Bounce 
cell-homogenlser) to produce a duplicate series o f cell-homogenates. 
The f i r s t  series only were spun to remove Intact c e l ls .  Both sets of 
homogenates were mixed with SIP PercoH to produce a 30% SIP gradient 
(5.6m1 homogenate, 2.4m1 SIP Percoll) and centrifuged (20K rpn.
40m1n, 4°C). The gradient was sampled from the top (250p1 samples) 
and the su ita b ility  of homogenisation conditions assessed by 
determination of the lysosomal enzyme hexosaminidase (see below 
2.2.1.6). The lysosomes are of prime Importance In  th is  study, too 
many burst lysosomes would make results d if f ic u lt  to Interpret. A 
compromise between ce ll breakage, to release organelles, and 
maintenance of lysosomal Integrity was necessary. Optimal conditions 
were found to require 20 strokes of the Oounce homogeniser, followed 
by a short spin to remove whole ce lls (lOOOrpn lOmlns).
2.2.6.1.3 Enzyme assays used to determine the buoyant densities of 
subcellu lar organelles.
2.2.6.1.3.1 Plasma membrane marker: 5’-nucleot1dase:.
The method of Avruch & Uallach (1971) was used.
5’ -AMP(0.15M), para-nitrophenol (6mH) In buffer (TrIs/HCl, pH 9, 
54mM, containing NgCl2 . 13mH) was prepared immediately before use.
Substrate solution (SOOpl) was mixed thoroughly with 
sub-ce llular fraction (lOOpl) and incubated (37®C, 30m1n). The
rsactlon was stopped by placing the tubes on Ice and adding ZnSO^ 
(0.25M, 200p1). The tubes were vortexed and 6a(OH^ added (0.25H, 
200p1). After thorough vortexing the precipitate was re«oved by 
centrifugation (HSE, 4L, SSOOrpm, 20ni1n). Supernatant (SOOpl) was 
added to sc in t il la t io n  f lu id  (Liquicint, 4.2ir1) and assayed for 
rad ioactivity  (LKB Rack ^-counter, lOnIn). The counting standard 
(representing lOOX hydrolysis) was coaposed of 1:1 substraterH^O. 
Quenching was checked by addition of a spike [^H] (lOOOcpa) to each 
and recounting.
2.2.6.1.3.2 Nuclear Marker: DMA
The method of Erwin, et a K  (1981) was used.
Subcellular fraction (lOpI) was precipitated by Incubation (4*^C, 
>4h) with TCA (lOX, 15p1). The solution was centrifuged (HSE 4L, 
6.5K rpn, 20ni1n, 4^C) and the precipitate resuspended In TCA (5%, 
SOOpI) and hydrolysed by Incubation at (30a1n). The resulting 
solution was cooled (4°C) and centrifuged (to renove solubilised 
aldehydes resulting froia ONA hydrolysis; 6.5k rpa, 20i1n, 4*^C). The 
supernatant was decanted and DABA (lOOpl, 200mgmr^ aqueous solution, 
decolorised by addition of activated charcoal). The solution was 
Incubated (Ih, 60°C) and the reaction stopped by addition of HCl 
(2ml, IN). Fluorescence was read (Extinction (Ex) 420nm, Emission 
(Em) 520nin).
To ensure that Percoll was not a fluorophore at the wavelength 
used In th is  assay a control gradient (Identical to the one used for 
separation of organelles, but containing no homogenate) was 
fractionated and the fluorescence of fractions determined (Ex 420nm, 
Em 520nm). Percoll was found not to act as a fluorophore under these 
conditions. Sim ilar control studies were performed for each of the 
follow ing fluorescence based assays:-
2.2.6.1.3.3 Prottin Assay: F1uortscaaln«
The Method of Uelgele, ct a K  (1972) was used.
Subcelluiar fraction (2S)i1) was Mixed with buffer (borate, 0.2M, 
pK9.2S, 2m). Fluorescamlne (450|ii, 30ing/100ffl1 acetone) was added and 
the solution Mixed. The fluorescence was read after More than Imln 
(Ex 390nM, Em 47SnM)
2.2.8.1.3.4 LysosooMi Marker: hexosaMlnidase
The method of G riffith s, et a K  (1978) was used.
A substrate solution containing
4-Methyl•uMbe111fery1-2*acetaMldo*2-deoxy-0-D-g1ucopyranos1de (2.5aM) 
in citrate buffer (0.2M, pH4.3) containing Triton XlOO (0.1%) was 
prepared Innedlately before use.
Substrate solution (SOpI) was added to subcellular fraction 
(25p1), and the resulting solution Incubated (37^C, lOMln). The 
reaction was stopped by the addition of Na^CO  ^ (ImM, 1.95m 1, pHlO). 
Fluorescence was read (Ex 365nM, Em 450nm).
2.2.6.1.3.5 Mitochondrial Marker: MonosMlne oxidase 
The Method of Sherwin (1980) was used.
A substrate solution containing homovanllllc acid (2.5tngmr^ 
SOpl), peroxidase (0.7Sngmr^, SOpl) tryptamlne (1.3niH, 300p1), 
phosphate buffer (0.26M, pH7.4, 1m1 containing Triton xlOO, 0.1%) was 
prepared lamedlately before use.
Subcellular fraction (lOOpI) and substrate (1.4ml) were 
incubated (37°C, 30m1n) fluorescence was read (Ex 339nm, Em 425nm).
2.2.6.1.3.6 Cytosolic Marker: LOH
The method of Lowry,et aK  (19S7) was used.
A substrate solution containing pyruvate (Llm gial'^) NAOH^  
(T.lmgml*^) In phosphate buffer (O.IM, pH7.5) was prepared 
ImMedlately before use.
Substrate solution (20pl) was added to subcellular fraction
(I0)i1) and incubated (37''C, 30i1n). HCl (0.5M, 20)i1) Mas added to 
the reaction ilx tu re  and le ft  >30s. Na(OH) (7.5H, 200)i1) was added 
and the solution incubated (37*^0, 30e1n). The reaction was stopped 
by addition of water (2ia1} and fluorescence read (£x 364nn Em 465nm}.
2.2.6.2 Subcellular d istribution  of [^^^Il-labe lltd  ligands. 
Pre-washed confluent fibroblasts (75ca^ growth area) were
Incubated (37°C) In the presence of [^^^I]-1abe11ed ttgand (for 
concentrations see Table 2.4) in H6SS (lOml) for predetermined times 
I (2h, 5h, sometimes 24h). At each time point c e lls  were washed (3xPBS 
pH7.4, 30m1s) to remove any loosely bound ligand. The fib rob lasts 
were then harvested and fractionated as detailed above (2.2.6.1.2). 
Each and every fraction was assayed for both hexosaminidase (2Sp1) 
and rad ioactivity (22Sp1).
The shape of the gradient was determined fo r every 
homogenisation by inclusion of a control density gradient, calibrated 
with density marker beads, in the position d ire ctly  opposite a 
density gradient containing homogenate In the rotor head.
2.2.5.3 Calculations
For a ll subcellu lar fractionation experiments the rad ioactivity 
recovered In each fraction was expressed as a percentage of the total 
radioactivity recovered from the gradient.
Total rad ioactivity (cpm) on the gradient was determined by 
addition of the rad ioactivity (cpm) in each fraction as fo llow s:*
Total rad ioactivity • [^jcpm
(cpm)
The percentage rad ioactivity (cpm) in each fraction was then 
expressed as a percentage of the total radioactivity:
Percent rad ioactivity  In 
fraction (n)
ewa In tube n x 100
cp«
2.2,7 DeUrilnatlon of the cell surface density of and the affinity 
of ^^^l-1abelled ligand for the transferrin receptor.
These experiments were carried out at 4^C and required that a11 
materials (ce lls, so lutions) were pre-coo1ed.
C e lls  (see Table 6.4) were grown to confluence or an equivalent 
density. After washing (PBS, pH 7.4, 10ml x 3, Ice-cold) c e l ls  were 
placed on Ice. A se rie s of flasks/tubes were prepared containing a 
spike o f [^^^I)-1abe11ed ligand (for concentrations see Table 2.5) 
and Increasing concentrations of unlabelled ligand (approximately 
0-400pm) in a total volume of 3m1 (HBSS). C e lls  were Incubated (4°C) 
for 45m1n In the presence of ligand (after which time binding was 
shown to have plateaued). Duplicate samples of HBSS were taken and 
assayed for rad ioactivity  (30s, LKB Compugamma). Cells were washed 
(PBS, pH7.4, 10ml, Ice-cold  x3) to remove loose ly  bound ligand and 
then digested by Incubation (37^C, overnight) In NaOH (0.5M, 2.5mls). 
The ce ll digest was assayed for both rad ioactiv ity  (5m1n) and protein 
(Lowry).
2.2.7.1 Calculations
The data were processed In several ways:-
1. To show a plateau of specific binding.
Total binding (pm mg'^cell protein) was plotted against total 
concentration of ligand present (nm m l 'V
2. To show the percentage of non-specific binding.
The binding of [^^^I]-labe lled  ligand was plotted against Increasing 
concentrations of unlabelled ligand.
Table 2.5
Typical concentrations of radiolabelled Ugand used for determination 
of the density of, and a ffin ity  of ligand fo r, the transferrin  receptor.
Ligand concentration (M)
radiolabelled
ligand
unlabelled
ligand
Transferrin lOnM 0-400nH
(aps and d ife rric)
McAb B3/25 5nH 0-200nM
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3. Sotchard analysis to allow determination of the density of the 
transferrin receptor, and the a ffin ity  of ligand for the receptor. 
Data was plotted according to the linear expression of the Scatchard 
equation (Scatchard, 1946):
6 • B 4 Bnax
f S
-  concentration of ligand bound to a cell surface 
receptor/antigen
• concentration of free ligand present In the Incubation medium
- dissociation constant of binding
 ^ • Intercept on x axis and In these data Includes high and low 
a ffin ity  binding.
Experimentally determined values were plotted ind ividually (since 
there were two variables, bound and free). Trip licate results were 
denoted by Joining Individual points with a tie -line .
2.2.6 Determination of the body distribution of ^^^1-labelled 
lleandi after administration (either Intraoerltoneel or Intravenous)
Mice (DBAg, male, up to 20-weeks of age; Chapters 7 and 8) were 
always Injected under mild conditions of anaesthetic (Judged by the 
ab ility  of the mouse to move free ly Immediately after Injection). 
Radiolabelled ligand (usually l-2xI0^cpn in O.lrn! total volume, 
approximately lOpg protein) was administered via either the 
peritoneal cavity (Ip) or the ta ll vein (1v). After injection mice 
were kept In metabolic cages to fac ilita te  collection of urine and
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faeces. At predetermined times (2h, 5h, sometimes 24h) the mice ««ere 
weighed and anaesthetised (from this point I t  was ensured that mice 
were always under anaesthetic). Following Ip Injection of 
radlolabelled ligand the peritoneal cavity was washed (to recover any 
residual radioactivity) by Injection of saline (lY, 37^C, 3m1). The 
abdomen was massaged gently, and the washings removed via a small 
Incision. Following a ll routes of administration the bladder and Its 
contents were removed from the animal before death (to minimise loss 
of ur1ne*assoc1ated radioactivity). Animals were then k illed  by 
opening the thoracic cavity and puncturing the heart. A sample of 
blood (50pl) was taken from the ventricle of the heart and 
Immediately added to NaOH (IH, 1ml; prevents coagulation of blood and 
consequent loss of blood-associated radioactivity within the 
micropipette). Organs/tlssue (Table 2.6) were removed and weighed.
A sample of skin (known weight, uncontaminated with blood), stomach 
and Intestine were digested In NaOH (IN, 37^C, overnight) and the 
femur In HC1 (6H, 37°C. overnight). A ll other organs, plus urine and 
faeces, were frozen overnight (easier to homogenise organs after 
freezing) and subsequently homogenised In as l i t t le  water as possible 
(usually 3ml); the faeces were blended. The total volume of each 
homogenate, the faeces total urine (and peritoneal wash when taken) 
were measured and duplicate samples (1ml) assayed for radioactivity 
(LK6 Compugamma, Smin). Blood counts were corrected to give total 
blood radioactivity using the relationship that a mouse contains 
5.77mls of blood per lOOg body weight (Dreyer and Ray, 1911). Femur 
counts were corrected to give total bone marrow radioactivity using 
the a correction factor of 15.87 (Benner, et aK , 1981).

2.2.6.1 Calculations
Results were expressed In terns of a percentage of the 
administered dose, and sometimes as a percentage of administered does 
recovered per gram of organ.
% (Administered Dose) -  Radioactivity (cpm) present In the organ xlOC 
Radioactivity (cpm) administered
In Appendix 6 a detailed example Is  given together with an 
explanation of the correction needed to determine the body 
distribution of conjugate S.
2.2.6 Determination of the Iwajnoeenlcltv of proteln-HPHA copolymer 
conjugates
This work was carried out In the laboratory of Dr. B. Rlhova, 
Institute of Microbiology, Prague (March 7-28th 1987).
2.2.9.1 Protxol of Imnlsatlon
Ligand was administered using either a combination of complete 
Freund’s adjuvant (CfA) for the f ir s t  Injection, followed by two 
further Injections using alum precipitate or by three Injections In 
solutlon(SOL). Mice (AJ and BIO) were Injected with ligand (lOOpg 
protein per Immunisation per mouse) (Table 2.7) according to the 
p rotxo l shown In Fig. 2.1. On the seventh day after the final 
Injection mice were exsanguinated. Blood of six  mice, which had been 
Immunised Identically, was pooled and allowed to stand overnight 
(4*^C). Serum was separated from the resulting blood clot and spun 
(2000rpm, lOmln) to remove any contaminating erythrocytes and stored 
at -20®C.
Control sera (used to determine I f  there were any naturally 
xcu rr in g  antibodies to the ligands used In this study) was prepared 
from unimmunised mice of the same strain.
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2.2.9.2 $«r1a1 d ilution  of s«ra.
Serial d ilution  of sera was carried out Inmedlately before use.
Sera were se r ia lly  diluted using PBS containing albuain or 
gelatin, (1%). One volume of serum was mixed thoroughly with one 
volume of PBS/albuaIn (usually 150[U lS0p l). Of th is 1:1 dilution 
one volume was taken and mixed thoroughly with one volume of 
PBS/a1bum1n In the next well, and so on. The resulting dilutions of 
sera are given In Chapter 9 (Table 9.2).
2.2.9.9 Estimation of antibody titres ELISA assay.
Ligand (SOpI, SOOmgml'  ^ or 2mgmr^) was bound to microtitre 
plate wells (96 well ELISA plate) overnight (4°C). Unbound ligand 
was removed by suction and the plates thoroughly washed with PBS 
(200pl pH7.2 X 3 ) .  PBS (SOpl containing albumin (1%) and gelatin 
(0.02%) or gelatin (1%: when the ligand It s e lf  contains albumin) was 
added to each well and the plates le ft to stand at room temperature 
(ensures that the plates are evenly coated with some form of 
protein). This solution was removed after Ih and again the plates 
were thoroughly washed with (1) PBS (200jj1) (11) PBS containing 
Tween-20 (0.2%; 200ul) ( i l l )  PBS (200pl). Se ria lly  diluted serum 
(2.2.9.2; SOpl) was added to wells coated with corresponding Uganda, 
starting with the highest d ilution (lowest concentration), to produce 
a series of wells containing the same antigen (ligand) but different 
concentrations of antibody. The plates were now incubated (37®C, 
90min) to allow antibody to interact with antigen. Sera was then 
removed and the plates thoroughly washed as above (PBS, PBS 
containing 0.2% Tween-20 x 3, PBS). Ant1-(murine)IgG conjugated to 
horseradish peroxidase (50pl, diluted 1:500 in PBS/albumin) was now 
added to each well and the plates Incubated again (37°C, Ih). 
Unreacted ant1-(murine)Ig6-horseradish peroxidase conjugate was 
removed from the plates, which were again thoroughly washed (PBS,

Tabi« 2.7
SuBwary of imiiunlsatlon protocol
Ligand
antigen
Dose per 
Ineunlsatlon
Inmunlsatlon Strain of 
House
Hunan Serum 100^g CFA AJ;B10
Albumin lOOug SOL
Human Ganna lOOpg CFA AJ; 810
Globulin (IgG) lOOug SOL
Human Transferrin lOOpg SOL AJ; BIO
(Tf) 100^ SOL
P-g ly-gly-Tf 100^ CFA AJ; BIO
lOOiig SOL
p-qly-gly-IgG lOO^g CFA AJ; BIO
lOOug SOL
P HPMA cODOlymer
CFA complete Freund's adjuvant
SOL solution
PBS/Tween x 3, PBS). OrthophenlenediMine (substrate for horseradish 
peroxidase; SOp1 0.5ng In phosphate buffer O.IH, pH6 containing 
HjO^i 30%) was added to each we11. The reaction was stopped after 
l-Snln (depending on the Intensity of colour) by addition of H^SO  ^
(50p1, 2M). The absorbance 492nn was read (ELISA Titertek 
HuUlscan). The highest antibody d ilution  (HAD) at which a positive 
antibody-antigen reaction could be detected waas noted.
2.2.9.4 Calculations
Each graph was drawn to show the well number of the HAD at which 
a positive antibody-antigen reaction could be detected on the 
ordinate, against strain of mouse, antigen concentration used to coat 
the ELISA place well and form of limnunisatlon (CFA or SOL) on the 
abscissa.

3.1 INTRODUCTION
Both HPMA copolyMr and HPMA copolymer conJu9 ates used in this 
study were synthesized by Kopecek, ^  i K  (reviewed Kopecek, 1964) at 
the In s t itu te  of Macromolecu1 ar Chemistry, Prague. Optimal 
conditions for the synthesis of HPMA copolymer-protein, in particular 
HPMA copolymer-antibody, conjugates are not yet fu lly  understood. 
Using an am inolysis reaction to attach protein to HPMA copolymers 
(see Chapter 1, 1.2) there i s  an inherent problem of copolymer 
characterisation. Reaction involves conjugation of two 
m ultifunctional compounds, with potential for multiple substitutions 
(re su lt in g  in the formation of high molecular weight complexes), and 
also there i s  no control over the orientation of the protein within 
the conjugate. The c r ite r ia  used for binding protein to HPMA 
copolymer have been defined by Kopecek (1984); (1) the conjugate 
should contain a bond between the protein and HPMA copolymer which is 
stable in  v ivo  and in v it ro  (11) the protein should retain it s  
c e l l- sp e c if ic  binding a f f in it y  ( l i i )  high molecular weight complexes 
should be minimised. Using these c rite r ia  HPMA copolymer conjugates 
were supplied  (detailed in  Table 3.1, and Appendices 1 and 2) as 
crude reaction  mixtures, which contained both free polymer and 
conjugate, but no detectable free protein (typical elution profile  
provided Fig. 3.1). No evaluation of molecular weight, 
stoichiometry, or orientation of protein had been made.
In  order to make any meaningful bio logical assessments of these 
conjugates i t  was necessary that as detailed a characterisation as 
possib le  should be attempted. It  was not possib le to obtain 
characterisation  with the accuracy required, but without some form of 
characterisation  the b io logical evaluation of such conjugates would 
be t o t a l ly  worthless. With th is qualification  in mind, an attempt 
was made to determine purity, molecular weight average (Mw), and


sto lch lO M try  of the HPMA copo1y*er-prote1n conjugates. A nuaèer of 
gel peraeatlon chronatography techniques were employed and their 
Interre lationsh ips are shown In  f ig .  3.2. The orientation of 
antibody In iMaunoconJugate 4 was Investigated using prote1n-A 
a ffin ity  chromatography (Fig. 3.3). To fa c ilita te  efficient 
detection of these substrates they were usually radlolabelled 
([^^^I]1od1de, lodogen method of radlolabelling, Fig. 3.4).
A range of analytical columns were used (Fig. 3.2). Sephacryl 
S-200 superfine (Hoi. wt. range suitable for protein separation 
5K-250K Daltons) was used to separate polymer-protein conjugates from 
free unconjugated HPMA copolymer precursor (flw approximately 7K 
Daltons). Sephacryl S-300 superfine (Mol. wt. range suitable for 
protein separation 10K-1.5M Daltons and sepharose 4B/6B (Mol. wt. 
range suitable for protein separation 20K-10M Daltons) were used to 
determine the Hw of purified conjugates. These conjugates were 
composed o f both protein and soluble synthetic polymer, which makes 
molecular weight evaluation very d iff ic u lt .  Gel permeation columns 
can be calibrated using e ither polymers or proteins (Fig. 3.Sa,b). 
However the calibration  relationship between molecular weight and 
elution volume obtained for proteins and polymers I s  not usually 
superimposable. The elution p ro file  derived from a protein-polymer 
conjugate could therefore theoretically correspond to e ither the 
polymer-based, or protein-based, calibration curves, or In fact 
neither of these, but at some position dependent upon an Indefinable 
relationship between the protein and polymer. For experimental 
purposes columns were calibrated with a range of HPMA copolymers of 
defined Mw and low polyd ispersity (f^/Hn-1.2) and a number of protein 
molecules (Fig. 3.5a,b).
Fig. 3.2
Flow chart to show how oroteln’HPWA copolywer conjugates were purified
by qt1 pemeatlon chromatography and their wolecular wtights 
subsequently determirted.


Fig. 3.5a Calibration of a $-300 superfine ge1 permeation column, 
using both protein and HPMA copolymers of defined %  and 
low polydispersity (iC/Mn > 1.2).
Height • 112cn 
Internal Diameter • 1.7cn
Flow Rate • 10ml h"^
Buffer ■  O.IH Tris/Hcl containing
OHPMA of defined Hm; Mw/Mn • 1.2 
*  Protein
Fig. 3.5b Calibration of a 4B/6B Sepharose gel permeation colunm, 
using both protein and HPKft copolymers of defined Mw and 
low polydlsperslty (iw/Mn ■  1.2}
o  HPMA of defined Mw; Mw/Mn -  1.2 
A Protein
3.2 RESULTS AW DISCUSSION 
3.2.1 Radlolodinatlon
Of the wide range of o x id izing  agents available for 
radlolodinatlon of proteins (SaU c Insk I, ^  i l . *  reviewed by
Hather, 1986) the lodogen method, f ir s t  described by Fraker & Speck 
(1978) was chosen to radlolabel the eacromolecules Investigated In 
th is study for a number o f reasons:*
( I)  the solid-phase cata lyst was considered to subject substrates,
In particular monoclonal antibodies, to the mildest denaturing 
conditions. Gel permeation chromatography of radlolodinated HPMA 
copolymer conjugates, HPMA and protein revealed no formation of 
breakdown products, and subsequent binding experiments showed lit t le .  
I f  any, lo ss of a ffin ity  (see Chapters 4,5,6). These data, 
suggesting minimal or no degradation by lodogen are In agreement with 
the findings of Fraker & Speck (1976), Sa1acinsk1,et aK  (1981) and 
Mather (1986).
( I I )  High rad1o1abe111ng effic ienc ie s have been reported In the 
literature using lodogen (Mather, 1986), and lab e lling  efficiencies 
of 60-80X were routinely achieved In th is  study (Table 3.2).
( I I I )  The solid-phase cata ly st  I s  easily  separated from the reaction 
mixture, and therefore ensures that the radlolodinated preparations 
are catalyst free, and do not contain unwanted chemicals (such as 
sodium metabisulphite used In  the Chloramine-T method of 
rad1o*1od1nat1on).
Although Salacinski, et a K  (1981) had reported that proteins 
radlolabelled by lodogen are stable for up to three months when 
stored at either 4®C or -20°C, In this study I t  was shown that 
(*^^l]1od1de was released from both proteins and HPMA 
copolymer-protein conjugates (stored at -20®C) re la t ive ly  rapidly (7% 
over 4 weeks) necessitating the re-d ia ly sis of a ll  preparations
Table 3.2
A sunmry of typical lodinatlon data.
Molecule Mol. wt. binding 
efficiency of 
p25i}iodide 
%
Specific
Activity
pCi/pg
AppMJi number 
of [ '25 i]Iod ide  
molecules per 
molecule of 
substrate
Dlferric 80K 80 3.1 1:9
transferrin
Antibodies
B3/25 150K 80 3.6 1:4
antl-Thy-1.2 150K 5 0.04 1:360
HPMA coooivners 
6 oroteln-HPMA 
cooo1y«er conjugates
1 15K 60 32 1:3
2 "219K 75 2.97 1:3
3 >2M 70 0.05 1:64
4 ■ 331K 80 13.2 2:1
5 •457K 72 0.24 1:24
Lou specific activ ity of '^^ I-lobe llcd  ontl-Thy-1.2 was consistently 
obtained.
Inmediately prior to the ir use in experiments.
In agreement with Nether (1986) i t  was found that the antibodies 
used in th is study labelled with different efficiencies. A sumnary 
of typical iodination data is  given in Table 3.2. It  can be seen 
that substitution ratios of Í^^^I]iodide varied between 1:360 and 2:1 
(^^^I:HPHA copolymer conjugate). To minimise damage to 
radioiodinated substrate substitution ratios were kept as low as 
possible. Conjugate 4 (which was to be used only for in vivo 
experiments; Chapter 8) was radiolabelled more heavily (2:1 
[^^^I|iodide:HPMA copolymer conjugate) to allow subsequent detection 
of radioactivity in the organs of sacrificed mice. It  was considered 
desirable to administer conjugate 4 to mice at a protein equivalent 
dose in the range lOOng-lOpg as discussed previously by Rihova & 
Kopecek (1985) (also  see Chapter 9). Consequently for a ll
t 9C
radiolabelled ligands to be used in vivo the degree of [ IJiodide 
substitution was increased.
Unconjugated polymer radioiodinated in a stable manner (Fig.
3.6) necessitating it s  removal from a ll preparations supplied.
3.2.2 Purification
S-200 gel permeation chromatography was used as a final 
preparative step to remove the excess unconjugated polymer from the 
reaction mixtures as provided. A S*200 column was chosen because I t s  
separation range meant that polymer-conjugate passed quickly through 
the column, e luting on, or close to, the void volume (Vo), therefore 
ensuring minimal d ilution  of the purified copolymer-conjugate. The 
lower molecular weight, unconjugated copolymers eluted later. Fig. 
3.7a,b shows a typical elution p rofile  from S-200. Fractions 
corresponding to copolymer-protein conjugates (fractions 50 to 65) 
were selected according to their absorbance at 280nm and their 
molecular weights calculated (see methods; Fig. 3.2).
RadloactivUy (con)
Fig. 3.7 Typical S-200 profile of HPMA copolymer-protein conjugates
(a) containing free, unconjugated HPMA copolymer
(b) containing only conjugate.
Purlf ic ttlon  of conjugate 5 was particularly d if f ic u lt  due to 
the low sta rting  concentration of Monoclonal antibody In the reaction 
Mixture with HPMA copolyMer precursor (4.4Mg m1*^ as coMpared with 
2SMg of transfe rrin  or IgG). After conjugation the concentration of 
monoclonal antibody was further reduced to 2.7Mg nl*^. $-200 
chroMatography (Fig. 3.6a) showed the presence of a high percentage 
of radlolabelled unconjugated polyMer (60X). An atteMpt at 
purification, using S*200 as above, resulted in degradation of the 
conjugate, as can be seen by comparing the 46/66 elution p rofile s of 
conjugate 5 before and after purification  (Fig. 3.6b,c). In Fig.
3.6b the peaks corresponding to conjugate 5, free unconjugated 
polyMer and the [^^^I]1odide Internal marker are c learly v is ib le . 
After purification  the peak corresponding to conjugate has 
disappeared and protein Is  detectable In that region of the elution 
p rofile  corresponding to low Molecular weight proteins. There was 
also some evidence of aggregation of conjugate to produce excessively 
high molecular weight protein*HPHA copolymer conjugate e luting on the 
Vo. For these reasons I t  was only possib le to use the crude reaction
1 9 c
Mixture of I'1abe11ed copolymer S In  biological experiments, 
subsequently correcting for the presence of unconjugated copolymer. 
The uptake (Chapter 4), subcellular localisation  (Chapter 5), and 
body d istribu tion  (Chapter 7) of unconjugated copolymer were always 
determined In  control experiments, and therefore in each type of 
experiment the component attributable to radiolabelled, unconjugated 
polymer could be accounted for and subtracted (for calculations see 
the relevant chapters).
3.2.3 Holecular Weight Determination
Sephacryl S*300 and Sepharose 46/66 were chosen to determine the 
molecular weights of the protein-copolymer conjugates because of 
their range of separation of proteins (S-300, lOK -1.5M Daltons;
Fij. 3.8 Gil penBitlon p rofile s o f the preperetioo of HPHA
copoly«er-Mdib 83/25 conjujite (a) S-200 before purificetioo 
(b) S-300 before purification  (c) S-300 after purification  
(buffer used and colunm characteristics detailed e a rlie r).
1od1de
4B/6B, 2OK-10H Daltons). Any conjugal« eluting on the Vo of the 
4B/6B column would probably have such a high molecular weight that 
use as a potential drug-carrier would be limited. Duncan, et aK  
(1981), using PVP, and Cartlldge, et a K  (1986) using HPKA copolymers 
of Increasing molecular weight have shown, In rat viscera! yolk sacs 
cultured In v it ro , there 1s a decrease In the rate of the pinocytic 
uptake o f PVP and HPMA copolymers with Increasing size  (>110K 
Daltons).
Preparation of HPMA copolymeric precursors I s  by radical 
precipitation polymerisation (Kopecek, 1984). The products of such a 
reaction contain molecules of many different chain lengths and upon 
elution through a gel permeation column they tend to give asymetrical 
p rofile s (Fig. 3.9). Determination of using a calibration graph 
Is  not possible, but Instead a sta tist ic a l approach must be used.
Such an approach can be represented graphically by a plot of the 
weight fraction w(H) of HPMA copolymer having a given molecular 
weight M against the molecular weight (Fig. 3.9). For molecular 
weight determinations carried out In  th is  Chapter I t  was assumed that 
within any one preparation a ll the molecules were radlolodinated to 
the same degree of substitution of I]1od1de. It  was therefore 
possible to plot the rad ioactivity (cpm) detected In each fraction 
against fraction number. Using the appropriate calibration graphs It  
was then possible to obtain a value for Hw based on the following 
calculations:-
Let • the weight of that portion of the conjugate 
having molecular weight M^
molecular weight Ml
Fig. 3.9 Typic»1 «lutlon p rofile s obtained for polymers e luting 
through a gel permeation column.
(a) Asyrnnetrica! elution profile
fi« f e lution peak volume
need to use a 
s t a t is t ic a l determination 
of Aw
(b) Symmetrical elution profile
Mw s  e lution peak volume 
can determine Aw by 
reference to a 
calib ration  graph.
Fraction number
Definition of average molecular weight, Aw (Batter and Lohse, 1979). 
Sunmation over the participating individual molecular w e i^ t s  o f a 
polymer substrate with respect to the weight to give Aw o f the participating 
macromolecules under consideration.
Then w. • n.H.
> the number average molecular weight
' the weight average molecular weight
' Ü 1 Ü 1 -
For a11 such calculations performed in  th is  chapter the computer 
programme found in Appendix f  was used.
Upon conjugation of the re la t ive ly  low molecular weight 
copolymeric precursor (17K Daltons; Table 3.1) to re lative ly  high 
molecular weight protein (transferrin, 80K Daltons: antibody 150K 
Daltons) the asymmetry of the elution p ro file s tended to disappear 
giving a symetrical profile  from both S-300 and 4B/6B (Fig. 3.10a-g). 
Symmetrical profiles were obtained fo r  conjugates 2, 4, 4a and 4b, 
and allowed direct determination of th e ir  Mw from calibration curves 
(protein and HPNA: Table 3.3). The v a lid it y  of th is approach is  seen 
by the fact that Ñw of conjugate 2 shows l i t t le  difference when 
calculated by either this method, o r s ta t is t ic a lly  (see Appendices 3 
and 4; Table 3.4). A summary of Hw estimated for a ll HPMA copolymers 
and conjugates used is  given in Table 3.4. The Hw determined by 
reference to the HPHA copolymer calib ration  line indicated that the 
protein-HPMA copolymer conjugates were not eluting from the gel 
permeation columns in a manner characte ristic  of polymer since the
(a) HPMA copolymer-transferHfi; 4B/6B
Fig. 3.10(a-g) Gel permeation p rofiles (4B/6B; S-300) of HPMA 
copolywr-protein conjugates used in this study. 
(For profiles referring to polymer-HcAb B3/25 
refer to Fig. 3.3a,b,c).
(b) HPMA copolymer-IgG; S-300
(c) HPMA copolymer-IgG 4B/6B
(d) HPMA copolyier-anti-Thy-1.2i S-300
(e) HPMA copo1ymep-arti-Thy-1.2j 4B/6B
(f) HPKA copolymer-anti-Thy-1.2 (Fc not available); 4B/6B
Iodide
30 100
Fraction number (6min fractions)
Table 3.3
Proteins and HPMA copolymers used to calibrate the S-300 and 
4B/68 gel perweatlon columns.
Protein Log Molecular Weight
Cytochroffle C 4.09
Transferrin (both apo and 
d iferrlc)
4.90
IgG 5.18
Ferritin 5.67
Thyroglobulln 5.84
4.06
HPMA copolymers of 4.32
d iffering ftw (supplied 4.60
by Kopecek et al^.} 4.89
5.17
5.74
resu lting values of Hw were less than those of the known aolecular 
weight of the protein component (Table 3.4). Alternatively, Hw 
determined by reference to the protein calibration  line may be 
equally Invalid since polymer bound to the surface of protein may 
a lter the passage of protein through the gel permeation column. For 
experimental purposes Mw of the proteln-HPHA copolymer conjugates was 
determined by reference to the protein calibration curve. Data In 
Chapters 4 and 5 seems to support this method of Hw determination.
The sim ilarity In Hw of preparations 4a and 4b, and the fact 
that th is  Hw was s l ig h t ly  lower than that of the parent conjugate 4, 
Is  d iff ic u lt  to explain. I t  Is  possible that the more random 
orientation of antibody In the parent conjugate has some Indefinable 
effect on the passage of the conjugate through the gel permeation 
column. Or, the presence of a relatively low percentage of 
aggregated conjugate eluting on Vo (Fig. 3.10f,g) may have resulted 
from interaction of conjugates of high molecular weight, which have 
consequently been removed from the preparation and therefore resulted 
In reducing the Hw of the preparation as a whole. Or more simply, 
th is  difference may be the result of a s l ig h t  difference In flow rate 
during elution through the column, since the difference In Hw Is  the 
resu lt of only a 1-2 tube difference In the elution peak fraction.
The elution profile  of conjugate 3 was asynmetricaI, Indicating 
the presence of a diverse population of conjugated polymer, which was 
of high molecular welght(elut1ng on and close to the Vo). During the 
course of th is study two preparations of conjugate 3 were supplied 
and both conjugates had th is  very high Hw. The limited biological 
application of such large high molecular weight conjugates Is  
discussed in Chapters 4 and 5. As stated earlier. I t  was desirable 
that conjugates should elute within the range of a 4B/6B column. 
However, further purification of HPHA-copolymer conjugate 3, to
F ij .  3.11 Corrtrtlon of the S-300 jel pemeation p rofile  of 
HPW copoly«er-IgG, to f ic l l iu t e  a sta tist ic a l 
detenalnatlon of an approximate Me (also see Appendix 3).
actual gel permeation profile
extrapolation ( fu ll data I s  stored In  Appendix 3)
Table 3.4
A swaary of the wolecular weight averages (Rw) of conjugates used
In this study.
^colimn and molecular weight 
markers used
Statistica l
approach
Conjugate S-300 4B/6B Calculation
polymer protein polymer protein using 4B/6B profile
2 52.5K 219K S2K 229K 240K* *
4 70.8K 331K 70K 302-331K NO
4a ND ND 66K 251K ND
4b ND ND 66K 251K NO
5 ND ND 151K 457K ND
3(i) . —  Asyaarntrlcal — >>2H
(i1) - — Asymmetrical-------- >2H
* see Appendix 3 and 4
*  Ustnj 4B/6B protein celtbratlon line.
ND Not determined
+* Based on a svm etrlca l elution oroflle  (Fig. 3.9}
**  Based on a non-symmetrlcal elution profile  (Fig. 3.9).
produce fractions of a nore discrete Fh< was not considered advisable, 
In the lig h t  of the observed dénaturation of copolyaer 5 (fomatlon 
of aggregates and degradation products) during any further atteapt at 
purification . Conjugate 3 was not therefore purified  further, and 
the crude reaction a lxture was used for Hw deteralnatlon to a ln la lse  
the p o s s ib il it y  of dénaturation, fron Fig. 3.11 I t  can be seen that 
SOM M te r la l elutes at the and that the p o lyM r p ro file  overlaps 
that o f the conjugate. Therefore, to obtain a rough estimate of 
molecular weight, the conjugate profile  was corrected (Fig. 3.11) by 
extrapolation of the IgG-HPHA copolymer peak to the x axis. The 
values used to extrapolate the conjugate peak were calculated as 
follows ( fu ll data I s  stored In Appendix 3):-
(1) The slopes of the extrapolated lin e s were determined.
Slope • ay
where y ■  the radioactivity (cpm) detected In each tube 
x -  the tube number
(2) To determine the radioactivity (cpn) In  each tube due to the 
presence of conjugate 3, where p rofiles of conjugate and free 
polymer, or conjugate and aggregates, overlapped the following 
re lationsh ip  was used:-
y ■  slope x tube number (see Appendix 3.2)
Uhen elution data I s  processed In th is way the calculated Hw for 
conjugate would be le ss than the actual Hw, because the high
molecular weight fractions at the have been ignored. With th is 
lim itation  In mind, the Hw o f conjugate 3 (preparation 2) was found 
to be >2N Daltons. As can be appreciated such a molecular weight Is  
too great, the conjugate probably containing at least 10 antibody 
molecules. The chemistry o f binding of protein to HPHA copolymer 
precursor must be optimised to produce a stoichiometry approximating 
1HPMA:1 protein molecule, that I s  <200K Daltons. The molecular 
weights of prote1n>HPMA copolymer conjugates given In Table 3.4 
(using the calibration line  based on protein standards) Indicate that 
stoich1o«»etr1es of >1:1 are present for a ll prote1n*HPMA copolymer 
conjugates, with possib ly 10 HPMA copolymer molecules:! transferrin  
(conjugate 2), 10 HPMA copolymer molecules:! antl-Thy-1.2 (conjugate 
4) and 20 HPHA copolymer molecules: ! HcAb B3/25 (conjugate 5) (Table 
3.4). The higher substitution  ratio found In conjugate 5 Is  readily 
explained by the re la tive ly  low proportion of HcAb:HPMA copolymer 
used In the reaction mixture (see earlier). These substitution 
ra t io s are In agreement with Rejmanova (1987).
In the future I t  w ill a lso  be Important to modify binding to 
control the orientation of the protein, particularly antibody within 
a proteln-HPMA copolymer conjugates. In th is  study a crude 
separation of Imnuno-conjugate 4 was made using prote1n-A a ffin ity  
chromatography.
3.2.4 froteln-A A ff in ity  Chromatography
Purified Imuno-conjugate 4 was sub-divided into two broad 
groups by use of prote1n-A a ffin ity  chromatography; conjugate 4a was 
the fraction that passed through the column and was considered to 
have the Fc region of the antibody unavailable for Interaction, that 
Is ,  masked (Langone,1982 stated that a ll rabbit IgG binds to protein 
A). Conjugate 4b bound to the prote1n-A column and was considered to 
have the Fc region of the antibody available for Interaction with
either the proteln-A column or, In later In vivo experiments, to 
ce lls  o f the RE system. It  was assumed that conjugates 4a and 4b 
would have equal potential to bind antigen. The body d istribution  of 
these conjugates was Investigated and resu lts are shown In Chapter 8. 
3.3 COHCLUSlOH
The HPMA copolymer preparations were characterised, as far as 
possible. In terms of purity, Nw, stoichiometry, and orientation of 
the antibody in  inmunoconjugate 4. There I s  however considerable 
inaccuracy In  the determination of Hw and stoichiometry particularly 
in the case of conjugate 3. With th is  lim itation In mind, the 
following study of ce llu la r uptake (Chapter 4) and subcellu lar 
processing (Chapter 5) must be considered in some ways qualitative 
rather than quantitative. Protein concentration In each preparation 
was used as a means of standardising experiments, since exact 
molecular weights were not known. Therefore polymer concentration 
used was somewhat variable.
The possib le  stoichiometries of the conjugates show that 10-20 
polymer molecules may be attached to each protein molecule. This nay 
Interfere with interaction of the protein with It s  specific  
cell-ssurface  receptor, or antigen, and subsequent intrace llu la r 
processing. Th is possib ility  has been Investigated (Chapter 4 and 5). 
To optimise binding of protein to polymer, a lternative methods of 
binding are being Investigated at present in th is laboratory. In the 
literature  a number of methods are reported such as the periodate 
method (Arnon & Sela, 1982; Hanabe,et a l.,  1984), derivatlsatlon of 
IgG with the heterobifunctional reagent
N-$uccin1midyl-3,(2-pyr1dyld1th1o)prop1onate (SPOP ; Jung, et aK , 
1981; Forrester, et a K ,  1984) and the use of 
l-ethyl-3-(3-d1methylaminopropyl)carbodi1m1de (ECOI; Kulkarni, et 
a K ,  1981). An exciting advance towards the conjugation of


4.1 IKTROOUCTION
An Ideal drug-carrier (see Chapter 1, Fig. 1.18) should bind 
specifica lly  to cell surfaces and, depending upon the constituent 
drug, e ither renaln at the cell surface or gain access to the c e IV s  
Interior.
HPHA copolymer containing a small amount of tyrosinamide 
residues (<lmo1 X) shows l it t le ,  or no, non-specific binding to cell 
surfaces and a very slow rate of pinocytic uptake by cell types 
studied. For example, rat visceral yolk sacs (Duncan, ^  ^  1984; 
HcCormick.et a1..l986) and hepatocytes (Duncan.et a l..  1965) capture 
such HPMA copolymers at a rate consistent with uptake by fluid-phase 
pinocytosis.
Residues chosen to promote cell surface Interaction, such as 
carbohydrates or proteins, bound via pendant oligopeptide 
side-chains, have shown a potential to enhance specific binding to 
target c e lls  both In v itro  and In vivo (Duncan,et a K ,  1985; Rihova & 
Kopecek, 1985).
In th is  Chapter, experiments have been carried out to 
Investigate Interaction and cellu lar processing of HPMA copolymer 
conjugates containing transferrin, IgC (non-specific), or 
anti-transferrin  receptor monoclonal antibody 83/25 (HcAb 83/25), 
using human fibroblasts as an In vitro  model system. Radiolabe11ed 
substrates were used to study the binding. Internalisation, and 
subsequent Intrace llu lar degradation of these proteln-HPMA copolymer 
conjugates. Results were compared to those obtained with 
unconjugated protein and parent copolymer.
4.1.1 Methods
Cell culture methods used are given in Chapter 2 (2.2.5.3). 
However the nomenclature used in this Chapter Is  somewhat d iff icu lt  
and worthy of precise definition. The following terms are used
throughout:
Total Uptaka (T.U.) was used to define the sun of
12S
trypsin -sensitive  (bound) I-1abe11ed substrate, and 
tryp sin -in sensitive  (Internalised) ligand, Including any Internalised 
ligand subjected to Intrace llu lar degradation resulting in the 
liberation  of low Molecular weight degradation products fro« the 
ce ll.
Total uptake ■  trypsin-sensitive  (bound) substrate 
(T.U.) +
trypsin -in sensitive  (Internalised) substrate 
+
degraded substrate
Interna lisation  ( In .)  was used to define trypsin-insensitive
12S I-labe11ed ligand and any low Molecular weight degradation 
products liberated froM the cell
In. > trypsin-insensitive  substrate
degraded substrate
4.1.2 Calculations
Calculations used In th is Chapter are given In Chapter 2, 
Section 2.2.5.4.
4.2 RESULTS
4.2.1 PrellMlnary exoerlMentt to detemlne the optliUM t l ie  course 
for Measuring Total Uptake of ^^^I«labelled HWI4« protein, and HFHA 
copoljwer-protein conjugates.
The T.U. of HPKA-gly-g1y-ajn1nopropanol measured over 96h was 
very sim ilar to that of PVP (Fig. 4.1). No low molecular weight 
^^^I-labelled degradation products were detected (G-25

chronAtography) In the culture nedluiR during these experiments.
Trypsin -sensitive  (surface bound) rad ioact iv ity  associated with 
apotransferrin reached a plateau after 3h and degradation products 
were detected in the incubation medium and found to increase with 
time (F ig. 4.2). There was l it t le  change in the extent of binding or 
internalisation  of transferrin  after 3h. Therefore further 
experiments were carried out over a 3h time course.
In these further experiments (3h), I-1abe11ed ligands were 
added to Hank’s balanced sa lt  solution, instead o f complete medium 
(Chapter 2, 2.2.5.3). Complete medium had the disadvantage of 
containing transferrin, immunoglobulins and many other unwanted 
proteins o f  unknown concentration, which could compete with 
^^^I-label1ed substrate fo r binding site s on the fibroblast cell 
surface. The well defined balanced sa lt  so lution  contained no 
unwanted protein. To ensure the integrity o f apotransferrin (in  
terms o f iron-loading) no iron was present in  t h is  solution 
(guaranteed by Suppliers, Flow Laboratories).
4 .i. i C<wrtsw i of T.U. in4 In. of !,«■  llcA> nn i
and transferrin.
T.U. and In. of transferrin  was independent of the iron loading 
of tran sfe rrin  and l i t t le  difference was found between the 
cell-associated radioactivity of apotransferrin and d ife rric  
transfe rrin  (Fig. 4.3). The major contribution to both T.U. and In. 
was attributable to the leve ls of degradation products released into 
the extrace llu lar medium (approximately 47pl mg  ^ cell-protein  after 
3h). In  relation to the total ^^®I-labelled ligand processed very 
l i t t le  cell-associated radioactivity was found to be 
trypsin-sensitive.
Because the processing of transferrin  was shown to be 
independent of iron loading no routine attempt was made to determine
g ¿
(u^a)cud [[93 _^6ui [n) uo[)«[30Ssc [[90
Fig. 4.3 Comparison of the Internalisation and Total Uptake of
^^^I-labelled antibody {non-specific, IgG; specific , HcAb 
83/25) and ^^^I-labelled transferrin  (d lfe rr ic  and apo).
•  apo
o  d lferric
Time (h)
• apo
o d ife rr ic
the Iron loading of tr in sfo rrin  In the trinsferrIn-HPMA copolyaer 
conjugetes.
T.U. of IgG was approxlutely lOOX greater than T.U. of 
transferrin. In., however was approxiMately 20% lower than that of 
transferrin. Nore than S0% of the radioactivity was 
trypsin-sensitive  (3h). Radioactivity attributable to degradation 
products of ^^^Mabelled IgG was found to be equivalent to SOpImg'^ 
ce11-prote1n after 3h.
T.U. and In. of NcAb B3/2S were much higher than those of either 
transferrin  or non-specific IgG. T.U. reached a plateau at 295plmg  ^
cell protein after approximately Ih. This value corresponded to 1.66 
pm mg‘ * protein cell-associated radioactivity. In. of McAb B3/25 
Increased with time, with a significant contribution attributable to 
degradation (after 3h lOOplmg*^ cell-protein). Trypsin-sensitive 
surface-bound radioactivity decreased with time, contributing less 
than 50% of cell-associated radioactivity after 3h.
4.2.3 A comparison of T.U. and In. of ^^^l-labelled IqG-HfHA 
copoliwer iconJmate 31 preparations 1 and 2.
As described In Chapter 3 (3.2.3) two preparations of conjugate 
3 were made and both were of very high molecular weight.
Incubation of the f ir s t  preparation (which had the higher mean 
molecular weight: Hw»2M Daltons) with fibroblasts gave rise  to 
l i t t le  cell-associated radioactivity (Fig. 4.4). T.U. was lower than 
that of HPMA copolymer after 3h and In. was negligible, the majority 
of ce11-associated radioactivity being trypsin-sensitive.
In contrast, the second preparation of conjugate 3 (of lower 
mean molecular weight; Hw>2H Daltons) showed a 300% (3h) Increase in 
T.U. when compared to that of HPMA copolymer, together with an 
enhanced In. (500% Increase after 2h). The sharp decline of In. seen 
after 2h may be attributable to an Inab ility  to detect low levels of 
degradation products.

4.2.4 C flw rIso D  of T.U. »nd In. o f HWW copolywr cofijuntw  Î 
fcooU in ing t n n s f t r r ln ) .  3 (contiin lng >M  8 (conU In liw  HcAb
B3/25).
A ll three conjugates, and In particular those specific  for the 
transferrin  receptor, showed a higher T.U. than that of the parent 
HPMA copolymer (Fig. 4.5a,b; conjugate 2, 800% increase; conjugate 3 
preparation 2, 300% increase) coupled with increased In. (conjugate 
2, 350% increase; conjugate 5, 500% Increase; conjugate 3, 100% 
increase). Trypsin-sensitive rad ioactivity varied from approximately 
80% (conjugate 2, 3h) to approximately 10% (conjugate 5, 3h) of the 
total cell-associated radioactivity.
In contrast, there was a dramatic decline in both T.U. and In. 
o f protein a fter conjugation to HPMA copolymer (Fig. 4.6, 4.7, 4.8), 
although in a ll cases the T.U. and In. were s t i l l  higher than those 
of the parent copolymer.
4.3 DISCUSSION
The observed binding, Internalisation and degradation of 
d ife rric  transferrin  was in accordance with published resu lts (Hay & 
Cuatrecasas, 198S; Oautry-Varsat, 1966; Hunt, 1966). I t  has already 
been reported that the majority of receptor-bound transferrin  
recycles. However, the binding and subsequent intracellu lar 
processing of apotransferrin was, su rp ris ing ly , found to be very 
sim ilar to that of d ife rric  transferrin. Parallel experiments, to be 
presented in Chapter 6, Indicated that the apotransferrin used in 
these experiments had not chelated iron, e ither in preparation or 
cell incubation. The iron-independent cell-association  of 
transferrin  was in agreement with the resu lts of Young & Aisen 
(1979), and Ward (1982), but did not agree with the generally 
accepted model of transferrin  recycling (Hay & Cuatrecasas, 1985;
Fig. 4.5a Comparison of the Total Uptake of HPMA copolymer and 
HPMA copolymer conjugates 2 (contains transferrin)
3 (contains IgG) and 5 (contains McAb B3/25). (All 
ligands were ^®I-labelled.)
Time (h)
copolymer conjugates 2 (contains transfe rrin ), 3 (contains 
Ig8) and 5 (contains HcAb 63/25). (AH ligands were
Fig. 4.5b Comparison of Internalisation of HPMA copolymer, HPHA
125 I-1abe11ed.)
Fig. 4.6« Comparison of the Total Uptake of transferrin (apo and
diferric), HPMA copolymer and HPMA copolymer conjugate
2 (containing transferrin). (All ligands were ^^®I-labelled.)
Fig. 4.6b Comurison of tl» Intenu ltuttor of trinsftrrin (opo'
and dUerrIc). HP)« copolymer and HP)« copolyamr 2 (contains
transferrin). (All ligands were ^^®l-labelled.)
Fig. 4.7a Comparison of the Total Uptake of McAb B3/35, HPMA
copolymer and HPHA copolymer conjugate 5 (contains McAb B3/25).
(All ligands were ^^®I-labelled).
Time (h)
copolymer and KPMA copolymer conjugate 5 (contains KcAb B3/2S). 
(All ligands were ^^^I-labelled.)
F1g. 4.7b Comparison of the Internalisation of McAb 83/25, HPMA
Fig. 4.8a Comparison of the Total Uptake of IgG, HPMA copolymer 
and HPHA copolymer conjugate 3 (contains IgG). (All
IgG
HPMA
copolymer
Time (h)
Fig. 4.3b Comparison of the Internalisation of IgG, HPtIA copolymer 
and HPKA copolymer conjugate 3 (contains IgG). (A11 
ligand were ^^®I-labelled.)
Time (h)
Oautry-Varsit, 1966; Hunt, 1966) In  which tha Intaractlon of 
transferrin  and I t s  receptor I s  described as both Iron and 
pH-dependent:* (1) at physiological pH the a ffin ity  of Iron-loaded 
transferrin  I s  two orders of magnitude greater than that of 
apotransferrin (11) after endocytosis Into the acidic environment of 
the endosóme, Iron I s  liberated from transferrin  (Chapter 1, 1.4) to 
yie ld  apotransferrin, which has a high a ffin ity  for the receptor at 
acidic pH (111) the apotransferrin-receptor complex I s  recycled back 
to the plasma membrane where, under conditions of physiological pH, 
apotransferrin d issociate s from the receptor. The In a b ility  o f th is 
model to explain the internalisation  of the transferrin  receptor In 
the absence of bound transferrin  (Watts, 1985; Ajioka 6 Kaplan, 1986; 
Stein t  Sus$man^l986), and the demonstration of two d istin ct  pathways 
of transferrin-receptor recycling (Golgi and non-Go1g1 mediated;
Stein I  Sussman, 1986) Indicate that the recycling of transferrin  Is  
more complicated than th is model Implies.
The binding. Interna lisation  and degradation of HcAb B3/25 was 
In accordance with a transferrin-independent Internalisation of the 
transferrin  receptor. The shape and size  of transferrin  and HcAb 
83/25 are d iss im ila r  (Chapter 1, 1.3; 1.4) and therefore It  would not 
be expected that binding of HcAb 63/25 to the transferrin  receptor, 
at a s ite  removed from the transferrin-binding s ite  (Trowbridge & 
0mary,1961), would trigge r a ligand-dependent Internalisation of 
receptor. Results presented In th is  study Indicated that, unlike a 
transferrin-receptor complex, receptor-bound HcAb B3/2S did not 
recycle, but remained firm ly attached to the transferrin  receptor. 
Trypsin-sensitive rad ioactivity decreased with time, compared to a 
plateau of T.U., Indicating that receptors were being Internalised 
but not replaced at ce ll surface. This down-regulation of the 
transferrin  receptor occurred after approximately 1.68 pm HcAb bound
ng'^ cell protein. This velue corresponded to approxinutely twice 
the c ilcu U te d  number of transferrin  receptors c e l l '^  (Chapter 6), 
and Indicated that there had been some replacement of cell-surface 
receptors from the large intracellu lar pool (AJIoka & Kaplan, 1986). 
Down-regulation had probably occurred to prevent gross accumulation 
of receptor-McAb complex as a result of l i t t le ,  i f  any, recycling, 
together with the re latively slow degradation of antibody 
(approximately 30% of T.D. after 3h) In agreement with Ruud,et al. 
(1986).
As would be expected T.U. and In. of non-specific Ig6 was lower 
than that o f e ither of the specific  ligands (bearing in mind that the 
majority o f cell-associated transferrin  has recycled). After 3h 
approximately 50% of the IgG remained bound to the ce ll surface 
Identifiab le  as trypsin-sensitive  rad ioactivity. These results are 
In accordance with those of Schneider, ^  a K  (1979, 1981), who 
reported that fibroblasts endocytose IgG (radlolabe11ed with acetate) 
very slowly followed by subsequent incomplete degradation within the 
lysosomes.
Conjugation of transferrin , KcAb 83/25, or IgG to HPHA copolymer 
resulted 1n up to a 9-fo1d Increase In T.U. and a 6-fo ld  increase in 
In. when compared to the parent HPHA copolymer. There was, however, 
a disappointing decrease In the cell-surface  Interaction of the 
proteln-HPMA copolymer when compared to unconjugated protein. A 
number o f Important points emerged from th is  study:*
1. The Importance of conjugate size Is  c le a r ly  seen by comparison 
of T.U. and In. of the two preparations of conjugate 3 (Fig. 4.4).
The lim ited cell-interaction  of the f ir s t  preparation was shown by 
it s  poor capacity to bind to the cell surface, together with an 
ina b ility  to gain access to the c e l l’s In te rio r. In fact the very 
high molecular weight of th is  preparation would probably mean that It
I s  better defined as a collo id  rather than a soluble synthetic 
polymer (see Chapter 1, 1.2). Phagocytic uptake by macrophages, as 
indicated by Duncan,et aK  (1981), would probably reduce the a b ility  
of such conjugates to reach any potentia l target tissue.
2. The T.U. and In. o f the sp e c if ic  HPNA copolymer conjugates, 
containing transferrin  or HcAb B3/25, showed up to a 220% increase in 
T.U. and a 300% increase in In. compared with the non-specific 
conjugate containing IgG, and up to  a 900% increase in  T.U. and 600% 
increase in In. when compared to the parent HPHA copolymer. This 
indicated that these conjugates possessed some a b i lity  to bind 
spec ifica lly  at the cell surface, although a much reduced ab ility  
than unconjugated protein. The probable explanation for this 
reduction in specific ity  has been discussed in Chapter 3 (3.2.3) 
where i t  was stated that there may be as many as 10-20 (conjugate 2, 
conjugate S) HPHA copolymer molecules bound to the protein component. 
Such high ratios of polymer to protein  may result in conjugates where 
protein is  surrounded by HPHA, in  a sim ilar way to the shell of 
polyethylene glycol formed around albumin (Abuchowski,et 1979). 
The resu lt of such a stoichiometry would mean that the protein cannot 
interact e ffic iently  with it s  target antigen, or receptor. This 
would explain the dramatic decrease in T.U. and In. o f protein after 
conjugation to HPHA copolymer. I t  i s  possible that the polymer shell 
is  so effective at masking the protein component that the major 
contribution to the observed increase in T.U. and In ., when compared 
to parent HPHA copolymer, was sim ply a result of an increased a b ility  
of a protein-polymer complex to interact non-specifica lly at the cell 
surface. Obviously i t  is  c r it ic a l that the targeting residue of an 
HPHA copolymer drug-carrier maintains it s  ab ility  to interact 
specifica lly  at the cell surface. The type of cell-surface  
interaction available to these particu lar conjugates, in terms of
specific  o r non>spec1f1c binding, wis further Investigated In  Chapter 6.
3. A coaiparlson of T.U. of transferrin  before and after conjugation 
to HPMA copolymer (Fig. 4.6a) Indicates that conjugate 2 (contains 
transfe rrin ) has escaped fu tile  recycling. The re lative ly  high 
degree of sp ec if ic ity  retained by the conjugated-protein (apparently 
40% of unconjugated protein) Is  readily explained by the fa ct that 
most of the unconjugated protein has recycled and Is  not included In 
th is  data, In  comparison to the conjugate, which has not recycled and 
I s  therefore tota lly  accounted for. This alteration of in trace llu la r 
routing I s  Investigated further In Chapter 5. I f  t ran sfe rrin  1$ to 
be considered as a targeting-residue of a HPMA copolymer drug-carrier 
such a change In intracellu lar routing would be very Important, since 
I t  would be a disadvantage for the majority of the drug c a r r ie r  to be 
regurgitated before transfer Into the secondary lysosomes.
These data describe the Interaction of proteins, HPHA copolymer, 
and proteln-HPHA copolymer conjugates In general terms o f T.U. and 
In. In the following chapters the Intrace llu lar routing, and the 
a b ility  o f these conjugates to bind specifica lly  to the c e l l surface 
Is  discussed.

S . l IHTROOUCTIOW
An Inportant consideration reU t Ing  to the design of HPMA 
copolyners for use as drug-carriers I s  the pendant oligopeptide 
side-chain used to bind drug. These side-chains are used to 
fa c ilita te  controlled release of drug (Duncan, et 1983).
Glycyl-phenyl-1eucy1-glycine has been proposed as a useful 
biodegradable oligopeptide sequence allowing release of drug (for 
example, daunomycln) within the lysosomal compartment (Duncan,et a L ,  
1987) and I t  I s  not cleaved In extrace llular flu ids.
In Chapter 4 It  was shown that binding of HPMA copolymer 
conjugates (containing antibody (IgG or HcAb 83/25), or transferrin ) 
to the fibroblast surface was less e ffic ien t  than binding of 
unconjugated protein. These conjugates were also Interna lised  (and 
degraded) le ss effectively.
The following study has examined the subcellular lo ca lisation  of 
these conjugates after Incubation with fibroblasts. Tulkens, et aK 
(1974) showed that I t  Is  possible to homogenise fib rob lasts and 
successfully separate Intrace llu lar organelles on a sucrose density 
gradient. In the following study Percoll was used, rather than 
sucrose, as a separation medium. It  has several advantages over 
sucrose; (1) s t e r il it y  (11) low v isco s ity  and therefore formed 
gradients rap idly (111) Impermeant to cells.
The presence of subcellular organelles on the gradient was 
Identified by the presence of characteristic marker enzymes (Table 
5.1). As yet there Is  no enzyme which has been Identified  as unique 
to the ”endosome*. This I s  probably attributable to the complex 
nature of th is  Intrace llu lar compartment, which has been Identified 
as a network of tubules and/or vesicles (Geuze, et a K  1983; Hopkins, 
1983; Hard ing,^ a K ,  1985). In recent publications the endosóme has 
been described as multivesicular (3 compartments demonstrated by Wal1&
Hubbard, 198S and multiple compartments described by Gorman & Poretz, 
1987). Confusion concerning exact characterisation of the 'endosóme' 
may resu lt from the suggestion that the "endosóme” Is  not Identical 
In a11 ce ll types (Stahl & Schwartz, 1986). In th is  study no attempt 
was made to Identify the endosomal compartment specifica lly .
5.1.1 Methods
In th is  study fib rob lasts which had been continuously Incubated 
(2h, 5h, sometimes 24h) with ^^^M abelled  antibody (IgG or McAb 
83/25), transferrin . HPMA copolymer, or HPHA copolymer conjugates 
were homogenised and subsequently fractionated on a PercoU density 
gradient.
The data presented are representative of 3 separate, 
reproducible experiments (for each ligand for each time course). It  
was not possib le  to combine experimental results because of errors 
Inherent In  the method used to co llect fractions (Chapter 2,
2.2.6.1.2). The number of fractions (250jil) collected varied between 
30 and 32.
5.1.2 Calculations
Calculations used In th is  Chapter are given in Chapter 2,
Section 2.2.6.3.
I t  I s  Important to note that rad ioactivity detected In the 
lysosomal compartment I s  underestimated for a ll ligands. I t  was 
consistently found that Incubation of fibroblasts, with any 
radlolabelled ligand, increased the f ra g il it y  of the lysosomes during 
homogenisation. Hexosaminidase released during homogenisation of 
fib rob lasts was not confined to fractions characteristic of the 
lysosomal compartment (fractions 21*30). but Instead was detected 
throughout the density gradient. Burst lysosomes were calculated to 
account for 30% of the total hexosaminidase activ ity  (th is compared 
with <10% when fibroblasts had been Incubated In medium alone). It
Tabi» 5.1
Characteristic subcellular localisation  of enzymes/proteins.
Subcellular localisation enzyme
Plasma membrane 5 '* ^ ’uc1eot1dase
Endosomes ?
Lysosomes hexosaminidase
Hitochondria monoam1ne*ox1dase
Nucleus ONA
Cytosol lactate-dehydrogenase
was therefore considered necessary to assay a1 1  fractions, in every 
separation, for the lysosoaal enzyne hexosaiinidase. (The other 
marker enzymes, Table 5.1, were assayed only three times since their 
buoyant densities were found to be consistent and reproducible).
Heasurement of lysosomal enzymes in each fraction of every 
gradient allowed exact quantification o f the extent o f lysosomal 
breakage and the percentage of total hexosaminidase a ct iv ity  detected 
In fractions other than 21-30. To correct the rad ioactivity profiles 
measured on the gradient, rad ioactivity detected in fractions 21-30 
was related to the percentage of intact lysosomes (fo r  example there 
may be 1000 cpm recovered in 70% lysosomes). This re lationship  was 
then used to correct the rad ioactivity detected in fractions other 
than 21-30, by subtraction of rad ioactivity  which was attributable to 
burst lysosomes (as measured by hexosaminidase release; see Fig.
5.1).
Lysosomal-associated rad ioactivity was not increased in parallel 
(since it  was not possib le  to extrapolate the exact o rig ina l density 
of these burst lysosomes).
5.2 RESULTS
5.2.1 Preliminary experiments to determine optimel conditions for 
homogenisation and lubcellular fractionation of fibroblasts.
The number of strokes of a Oounce ce ll homogeniser were varied, 
and lysosomal integrity, together with the number o f intact cells, 
were measured. These parameters were used as an indication of the 
appropriateness of the conditions used. It  was found that 20 
downward strokes of the big head of the homogeniser resulted in least 
damage to lysosomes (< 1 0% burst) coupled with maximal cell breakage. 
It  was surp rising to find that the same conditions used to homogenise 
fibroblasts after incubation with radiolabelled ligand resulted in a
Fig. 5.1a Hexosaminidase p rofile  on the Percoll gradient after 
subcellular fractionation of fib rob lasts previously 
incubated with ^^®I-1 abelled ligand.
M ch higher percentage of burst lysosoaes (approxlaately 30%). 
Intact ce lls  were subsequently reieoved by centrifugation and the 
supernatant produced placed on the Percoll density gradient.
A range of Percoll gradients (5%-95% standard 1so>osiaot1c 
Percoll SIP; Chapter 2, 2.2.6 .1.1) were calibrated with density 
marter beads, under different centrifugation conditions (19-50g, 
10-60w1n). A 30% SIP gradient, spun 40n1n x 19000g gave optimal 
separation between fractions containing plasma membrane and lysosomal 
enzyme markers, whilst maintaining a linear change In density over 
the majority of the gradient (F ig . 5.2). The shape o f gradient was 
reproducible (n>30), and was calibrated using a number of 
fluorlmetric enzyme assays:- 5’ nucleotldase (plasma/membrane), 
monoamine oxidase (mitochondria), ONA (nucleus), lactate 
dehydrogenase (cytosol), and protein. It  was not considered possible 
to identify the endosóme because of the lack of a de fin it ive  marker 
enzyme (see Section 5.1). The horseradish
peroxidase-diamlnobenzldlne density sh ift reaction (Courtoy, et a K ,  
1984) has been used to locate the endosóme, but use of th is  technique 
here was not possible with the small volume of gradient (6n 1 ) and the 
small size of each fraction (250u l). Merlon, et a K  (1983) have 
reported densities of 1.04 and 1.051g ml'^ as characteristic  o f ligh t 
and heavy endosomes and throughout th is section reference w ill be 
made to a pre-lysosomal, or 'endosomal* region corresponding to 
densities o f approximately 1.04-1.065g ml*^.
Occasionally, after homogenisation of fib rob lasts which had been 
Incubated In the presence of ^^^M abelled  ligands rad ioactiv ity  was 
detected at a density lower than that of plasma membrane (that is ,  at 
the top of gradient). This rad ioactivity  was considered to be most 
probably associated with ligand which had su ffic ien t a f f in it y  for the
Fig. 5.2 P rofll* of marker enzymes after subce llu lar fractionation of 
fibroblasts on a 30S SIP Perco11 density gradient.
cell surface not to be removed during the washing procedure, but 
subsequently dissociated from the cell surface during homogenisation. 
It  Is  also possible that th is  a ct iv ity  may have been associated with 
low molecular weight degradation products within the cytosol (LDH 
activ ity  was also detected at very low densities) or, alternatively, 
burst endosomes (no characteristic  enzyme marker to check th is 
possib ility ).
8.2.2 Subcellular lo ca lisa t ion  of ^^^Mabelled HPHA copolymer
After 2h ^^h-labe lled  HPMA copolymer was detected throughout
the gradient (Fig. 5.3, Table 5.2) at densities corresponding to 
plasma membrane (5'*nuc1eot1dase), the pre-1ysosoma1 region of the 
gradient, and the density o f the lysosomal compartment (31X). There 
was no difference In the percentage of HPHA copolymer detected In the 
lysosomes after 5h, although there was more radioactivity detected, 
with Increasing fraction density, In the pre-lysosomal region of the 
gradient (see Fig. 5.3, Table 5.2).
5.2.3 Subcellular lo ca lisa t io n  of ^^^Mabelled HcAb 13/25 and 
^^^1-labtlled HPHA copolwer 5 (contains HcAb 13/251
After 2h there was a high percentage of HcAb B3/25*assoc1ated 
radioactivity recovered at a density equivalent to that of plasma 
membrane (55%) together with some radioactivity detected In fractions 
of higher density In the pre-lysosomal region of the gradient (37%) 
(Fig. 5.4, Table 5.2). After 5h the percentage of plasma 
membrane-associated rad ioactiv ity  was proportionately lower as more 
NcAb-assoclated rad ioactivity was detected at densities of the 
pre-lysosoma1 and lysosomal compartments.
The subcellular lo ca lisa t ion  of conjugate 5 (containing NcAb 
B3/25) was d if f ic u lt  to Interpret because of the high percentage of 
unconjugated HPHA present In th is  preparation. Due to the low 
amounts of rad ioactivity present In each fraction It  was not
Fig. 5.3 Profile  of radioactivity receoverd a fte r subcellular 
fractionation of fibroblasts previously incubated for 
2h or 5h in  the presence of '" l - la b e l l e d  HPMA.
(b) 5h Incubitioo «(th
Fig. 5.4 Profile  of radioactivity recoverd after subcellular fractionation 
of fibroblasts previously incubated for 2h or 5h in the presence of 
^^^I-labelled McAb B3/25 or HPHA copolytter conjugate 5 {contains 
McAb B3/25).
■ ison of the percent of recovered Hgand-assodated radioactivity
detected at the density of the lysosomal enzyme hexosaminidase.
'^^ I-labe lled  substrate Percent of recovered radioactivity 
detected at the density of 
hexosaminidase^
2h 5h 24h
Tf 29 31 -
*IgG 51 55 -
HcAb B3/Z5 13 41 -
HPHC copolymer 31 31 -
P-transferrin 37 59 -
P-IgG (prep. 1) 0 N.D. 6
P-IgG (prep. 2) 42 30 -
P-HcAb B3/25 46 39 -
A These values take no account of either recycling via the 
endosóme or degradation with subsequent exocytosis of 
degradation products.
*  Including rad ioactivity detected at the density of mitochondria 
and nucleus
P » HPMA copolymer
considered to be acceptable to correct for the presence of 
HPNA-associated radioactivity. I t  I s  probable that the gradient 
profile  I s  la rge ly  attributable to the subce1 1 u1 ar processing of 
HPHA, however, there does appear to be a better loca lisation  of 
conjugate within the lysosome than found with parent HPHA (Table S.2) 
(no degradation products were detected for e ither conjugate 5 or HPHA 
after Incubation with fibroblasts 3h, Chapter 4).
12S5.2.4 Subcellular Ixa lisa tlen  of 
125,
M abelled loG and 
¡»labelled HPHA copolymer conjugate 3 (contains Igfi).
After 2h and 5h IgG-assoclated rad ioactiv ity  was detected In a ll 
regions of the gradient (Fig. 5.5). Peaks of rad ioactivity  were 
located at the density of plasma membrane (2h, 23%; 5h, 20%) and, 
su rp ris ing ly , at very high density (mitochondria and nucleus: 2 h,
14%; 5h, 13%). Fig. 5.51 Indicated that th is  peak of rad ioactivity 
at very high density I s  probably associated with the lysosomal 
compartment, since the hexosaminidase also gave an atypical 
d istribu tion  o f activ ity.
Conjugation of HPHA copolymer to IgG altered the gradient 
p rofile  of IgG (Fig. 5.5.2, 5.5.3). After 2h the majority of 
rad ioactivity associated with the f ir s t  preparation of conjugate 3 
{%n »  2x10^ Daltons; Chapter 3) was detected at the density of 
plasma membrane. Even after 24h there was s t i l l  approximately 55% of 
conjugate-associated radioactivity at the density of plasma membrane, 
together with 30% detected at the density of the pre-lysosomal 
compartment (1.04; 1.055; 1.06g ml*^). It  can be seen (Fig. 5.5.2) 
that after both 2h and 5h conjugate-associated rad ioactivity  was 
detected at a density lower than that of plasma membrane (2h, 14%;
5h, 14%).
This pattern of subcellular localisation  contrasted with the 
second preparation of conjugate 3 (Fig. 5.5.3) which, although s t i l l
Fig. 5.5.1 Profile  of both hexosaminidase activ ity  and rad ioactivity 
recovered after subcellu lar fractionation of fib rob lasts 
previously Incubated for 2h or 5h In the presence of
125M ab e lled  IgG

o f high Nw, was of lower ft« than the f ir s t  preparation (ft« > 2x1 0 ^ 
Daltons). After only 2h conjugate-associated rad ioactivity was 
detected at the density of ly so soM s (42%, Table 5.2). After 5h only 
30X of conjugate-associated radioactivity was detected at this 
density, together with an Increased percentage o f conjugate located 
In the pre-1ysosoflia1 region of the gradient (2h, 30%; 5h, 43%). It  
can be seen (Fig. 5.5.3) that there I s  a small percentage of 
rad ioactivity (9%) detected at a density ligh te r than that of plasma 
membrane.
5,2.5 Subcellular localisation of ^^^I«labe11ed transferrin and 
^^^l-labe11ed HPHA copolyer 2(conta1ns transferrin)
After 2h and 5h, transferrin-associated rad ioactiv ity  was spread 
throughout the gradient with 20-26% ( 2h,$h) detected at the density 
o f plasma membrane and 29-31% at the density of lysosomes fig. 5.6; 
Table 5.2.
Conjugation of HPHA copolymer to transferrin  altered this 
gradient profile  (Fig. 5.6). After 2h 20% of conjugate-associated 
rad ioactivity was detected at a density lower than that of plasma 
membrane.
After 5h 59% of recovered radioactivity was detected at the 
density of lysosomes (Table 5.2) with approximately 15% s t i l l  present 
at the density of plasma membrane.
5.3 DISCUSSIOH
The main aim of these studies, using subce llu lar fractionation 
as a tool, was to show that proteln-HPHA copolymer conjugates, were 
able to reach the lysosomal compartment of the c e l l.  This was 
demonstrated to be true for a ll conjugates (Table 5.2), despite the 
fact that the lysosomally-assoclated rad ioactivity given here cannot 
take Into account the total amount of ligand which has reached the 
lysosome for a number of reasons. These Include (1) as detailed
Fig. 5.6 Profile  of rad ioactivity recovered after subcellular fractionation 
of fib rob lasts previously incubated for 2h or 5h in the presence 
of ^^^I-labelled d ife rric  transferrin  or HP!1A copolymer conjugate
earlier (5.1.3) the lysosomal radioactivity I s  underestimated because 
of Increased membrane fra g il ity  after Incubation with rad1o1abe11ed 
ligands ( 1 1 ) no account of degradation and subsequent exocytosis of 
degradation products was made, therefore the values given In Table
5.2 only reflect the ligand-associated rad ioactivity present within 
the lysosome at one Instant In time. This would not dramatically 
alter the values given here for HPMA copolymer and HPHA copolymer 
conjugates, since no degradation products were detected after 
Incubation of these ligands with fibroblasts (Chapter 4). However, 
there I s  a gross underestimation of lysosomal trafficking of a ll the 
proteins, which were shown to experience substantial degradation, 
followed by exocytosis of degradation products (Chapter 4).
The design of these subcellular fractionation experiments 
resulted In a number of Inherent problems. F irst ly , visualisation of 
the subcellular routing of ^^^I-1 abe1 1 ed substrates was d iff icu lt  and 
could be Improved by use of a pulse-chase Incubation. Secondly, the 
problem of increased lysosomal frag ility , resu lting In approximately 
30% lysosomal breakage, was not easily resolved. Less severe 
conditions of homogenisation resulted In a higher percentage of 
Intact ce lls ,  which necessarily had to be removed from the homogenate 
prior to application to the gradient. The experimental conditions 
used here represent the best compromise which could be found. It  was 
not considered acceptable to add radioactivity attributable to burst 
lysosomes to the radioactivity detected In fractions 21-30 (lysosomal 
density) since the original density of the burst lysosomes was not 
known. It  was possible that the observed Increase In membrane 
fra g il ity  was a result of loading the lysosomes with ligand, which 
was then only slowly degraded. This assumption Is  supported by the 
fact that < 1 0 % of the lysosomes of control fibroblasts (which had not
been Incubated with ligand) burst. However, It  cannot explain why 
Increased lysosonal f ra g il it y  was evident In experlaents where l i t t l e  
substrate was located within the lysosome. This I s  d if f ic u lt  to 
explain, but nay resu lt fron the presence of a radlolabelled 
substrate within the lysosone affecting, In some unknown nanner, the 
ly so sm a l nenbrane.
With these lim itations In wind a number of Interesting findings 
emerged:
(1) Conjugation of protein, In particular transferrin, to HPHA 
copolymer altered the sub-cel1 u1 ar processing of the constituent 
protein. The subcellu lar localisation  of unconjugated transferrin  
has been studied at length elsewhere, and data presented here are In 
accordance with these published resu lts (Harding, et a K , 1984; 
Forsbeck, et a K ,  1966; Gorman I  Poretz, 1967). This Is  true even 
though the composition, shape and starting density of the gradients 
used here were not Identical to those used previously. There was 
l i t t l e  difference In  the subcellu lar localisation  of transferrin  
after 2h or 5h. This was In accordance with the accepted model of 
transferrin-receptor Interaction (Chapter 4, 4.1), where I t  Is  
proposed that the majority of transferrin  recycles (thus at any one 
time very l i t t le  I s  resident Inside the ce ll) with the remainder 
entering the lysosomes (Neutra, et a K ,  1985; Hunt, et a K ,  1986; 
Gorman & Poretz, 1987; Stoorvogel, et aK  1967). Lack of any 
accumulation of transferrin  In the lysosomes agreed with the resu lts 
presented In Chapter 4 (Fig. 4.5) where degradation coupled with 
exocytosis of the degradation products of most of the transferrin  
which had entered the lysosome was shown.
After conjugation of transferrin  to HPMA copolymer It s  
subce llu lar localisation  was altered. The presence of 
conjugate-associated rad ioactivity at a density lower than that of
plasat aembrane was thought to b« due to dissociated ligand. It  Is  
possib le that the stoichiometry of protein to polymer (Chapter 3, 
Tf(HPMA}jQ) i s  hindering the tigh t union of the HPHA-conJugated 
transferrin  with It s  receptor, resu lting In a le ss stable 
receptor-transferrin complex than I s  possible for unconjugated 
transferrin . This could resu lt In  removal of conjugate from the cell 
surface by the shearing action of homogenisation. Also, EDTA (InM)
was used In a ll solutions (to prevent dumping of organelles). This 
2+
would remove Ca , which could possib ly Influence the binding of 
transferrin  and conjugate 2  d iffe ren tia lly .
After Internalisation  I t  appeared that conjugate 2 was directed 
to the lysosome rather than regurgitated. In previous experiments 
(Chapter 4) no degradation products had been detected after a 3h 
Incubation of fibroblasts with transferrIn-HPMA copolymer. In 
accordance with these data a build  up of conjugate at the density of 
the lysosomal compartment was detected between 2h and Sh.
(2) The Importance of molecular weight on the subcellu lar 
loca lisation  of an antIbody-HPMA copolymer conjugate was c learly seen 
by a comparison of the d istribu tion  of rad ioactivity on the gradient 
after subcellu lar fractionation of the two preparations of IgG-HPHA 
copolymer conjugate. The f i r s t  preparation of conjugate 3 (Rw»2xl0^ 
Daltons; Chapter 3) was shown to have limited a b ility  to gain access 
to the Inte rio r of the ce ll.  After 24h only 6% of the total 
conjugate-associated rad ioactivity  was found at the density equating 
with that of the lysosomal enzyme marker (Table 5.2). This 
contrasted with the second preparation (fiw>2xl0^ Daltons; Chapter 3) 
In which between 30% and 42% (Sh, 2h; Table 5.2) of 
conjugate-associated rad ioactivity  was detected at the density of the 
lysosomal enzyme marker. The observed decrease In the proportion of 
rad ioactivity detected In the lysosomal region of the gradient
between 2h and 5h nay be due to some degradation of conjugate, 
coupled with release of degradation products, or It  may simply 
reflect the build up of a higher proportion of radioactivity In  the 
pre-1 ysosoma1 region of the gradient.
(3) The density of the lysosomal compartment was affected by the 
presence of certain ^^^I-1abe11ed substrates. In experiments 
Investigating the subcellular localisation of IgG, a U rge  percentage 
of radioactivity (13%, 5h) was detected at a density higher than that 
of the lysosomes, that 1$, at the bottom of the tube. This Is  
d iff ic u lt  to explain, but could be due to lysosomes heavily loaded 
with IgG, since a profile  of hexosaminidase In these fractions was 
sim ilar (Fig. 5.S). This explanation I s  In accordance with the 
results of Schneider,et a1_. (1981), who found that after 24h 
fibroblasts accumulate F(ab)2 *type fragments In the lysosome due to 
Incomplete degradation of IgG.
(4) The Influence of a target antlgen/receptor on Intrace llu lar 
routing was Indicated by the different gradient profile  of McAb B3/25 
determined here, and that of ant1 *plasma membrane antibody described 
by Schneider, et aK  (1979). Whereas here 41% of HcAb 83/25 was 
detected at densities corresponding to the lysosomal compartment 
after 5h, Schneider,et aK  (1979) detected l i t t le  internalisation of 
bound anti-plasma membrane antibody after 36h. Such a contrast In 
the behaviour of antibodies, specific for cell-surface antigens, 
exemplifies the Importance of choosing an antigen which offers a 
■ gateway" to the c e l l’s Interior.
The subcellular localisation  of conjugate 5 (containing HcAb 
83/25) could not be easily resolved, due to the high percentage of 
unconjugated HPMA copolymer (as discussed previously Chapter 3; 3.2). 
In Chapter 4 I t  was shown that no degradation products could be 
detected for HPMA copolymer or conjugate 5 (containing HcAb 83/25)
after Incubation with fibroblasts. This allows a comparison of the 
percentage lysosomal-associated rad ioactivity of these ligands to be 
made using Table 5.2, where I t  can be seen that proportionally more 
of the conjugate I s  localised within the lysosome than parent HPHA 
copolymer.
The re su lts presented here show that a ll the HPKA copolymer 
conjugates, with a ll their inherent problems, such as Inappropriate 
flw, stoichiometry, and undefined orientation of the protein residue 
(see Chapter 3), are Internalised by fib rob lasts and eventually 
localise  within the lysosome. This was true even for the very heavy 
conjugate containing Igfi. This route of Intrace llu lar processing Is  
central to the design of any lysosomotropic drug-carrier.

6.1 IWTRODUCTION
The transferrin  receptor Is  not a tumour-specific antigen,
Indeed a number of ce11 types express the receptor (Tables 6.2 and 
6.3). It  Is ,  however, a tumour-associated antigen (Gatter, ^  a1.. 
1983; Trowbridge, 1985). Recent evidence has shown that the 
transferrin  receptor may be composed of a family of ant1 genica1 1 y 
sim ilar molecules and that the density o f  the receptor I s  related to 
the rate of cell growth, or d ifferentiation  of tumour c e lls  (Gatter, 
et 1987). Indeed Trowbridge, et a K  (1981) have reported 
selective Inh ibition  of human melanoma growth In nude mice using 
anti-transferrin  receptor antibody.
There have been conflicting reports In  the literature  concerning 
the d ifferential a b ility  of transferrin. In  I t s  Iron loaded and 
unloaded forms, to bind to the transferrin  receptor. Hamilton, et 
a l . (1979), Ward, et aK  (1982) and Hopkins 4 Trowbridge (1983) have 
reported that the degree of Iron saturation did not affect the 
binding of transferrin  to it s  receptor. This conflicted with a 
reported lack of a ffin ity  of apotransferrin for the receptor at 
physiological pH (reviewed Hunt, 1986). The work presented in 
Chapter 4 Indicated that there was l i t t l e  difference In the uptake 
and degradation of transferrin In Its  Iron loaded and unloaded forms. 
Scatchard analysis of transferrin binding allowed the nature o f th is  
Interaction to be determined in terms of non-specific and spec ific  
binding.
In the area of targeted drug-delivery choice of a potential 
targeting residue, be i t  monoclonal antibody or a protein specific  
for a receptor, w ill be Influenced by the a ffin ity  of the target 
residue for It s  target antigen/receptor. In th is Chapter a 
comparative study has been made of the number of binding site s 
available to, and the a ffin ity  of McAb 83/25 and transferrin  for
these site s. Since I t  hes been reported (Trowbridge & Ornery, 1981; 
Getter, et e K ,  1983) thet the density of the trensferrin receptor Is  
dependent upon both ce ll type end stete of differentletlon, e number 
of cell lin e s were used, end else CCRF/CD1 subcuUured et two 
different frequencies.
In Chepter 4 I t  wes shown thet upteke of HPMA wes Increesed 
following conjugetlon to HcAb B3/2S, IgG, or trensferrin. In the 
work which follows, the neture of the Interectlon between HPHA 
copolymer-protein conjugetes end fibroblests wes determined In terns 
of sp e c if ic ity  end e ffin ity  of binding. Unfortunetely, beceuse of 
the d if f ic u lt y  In purlficetlon  of conjugete 5 (Chepter 3), It  wes not 
possible to cherecterlse the cell surfece Interectlon of HPHA 
copolymer conjugeted to HcAb 63/25.
6.1.1 Methods
A description of the cell lines used I s  given In Teble 6.1.
Grephicel representetlon of the dete I s  given only for the 
Interectlon of trensferrin, HcAb 83/25 end proteln-HPHA copoymer 
conjugetes with fibroblests, otherwise results ere summerlsed In 
Tebles 6.2, 6.3, 6.4.
In th is  study "spec ific  binding" wes used to define cell 
surfece-bound ^^^I*1 ebe1 1 ed llgend which could not be removed by e 
U rge  excess (usue11y 1000-fold) of unlebelled llgend end which wes 
shown (Scetcherd enelysis) to heve e high e ffin ity  for It s  terget 
entigen/receptor.
"Kon-specific/low e ffin ity  binding" wes used to define cell 
surfece bound ^^^I-lebelled llgend which wes rcedlly removed by en 
excess of unlebelled llgend and which wes shown (Scetcherd anelysis) 
to heve e low a ffin ity  for It s  binding site.
D tt il ls  o f cell lines.
Name of ce ll line Characteristics
*  » 1
Cells mg protein
Human sk in  
fibroblasts
normal 2 .2  X 10®
CCRf/CEM human T^cell leukaemia, 
transformed at pre-T 
cell stage 2 .2  X 10®
Hep 6 3 human hepatoma 2 .1 4  X 10®
Alexander human hepatoma 2 .1 4  X 10®
Clone murine melanoma 2 .1 4  X 10®
determined by relating cell counts (haemocytometer) to protein 
content (Lowry)
Calculations used In th is  Chapter are given In Chapter 2» 
Section 2.2.7.1.
6.2 RESULTS
6.2.1 Density of the transferrin rKeotor on the cell surface of 
fibroblasts deterwined by ^^^1-labelled transferrin or HcAb M/25.
(1) Diferric transferrin
g.1.2 C t leolations
At low concentrations (0-50pn ml*^) a plateau of
specific-binding was seen (Fig. 6.1a) at O.Spm ligand bound ng'^ cell 
protein. Above SOp« T f(fe )2 * r ^  an additional 
1o«-aff1n1ty/non-spec1f1c Interaction was seen, which I t s e lf  
plateaued at l.ASpm of ligand bound per mg cell protein (Fig. 6.1b).
Competitive binding of ^^^I-labelled Tf(fe ) 2  with Tf(Fe ) 2  showed 
that In the concentration range of ligand subseguently used for 
Scatchard ana lysis, Iow-aff1n1ty/non-spec1f1c binding accounted for 
only 8% of the total binding (Fig. 6.1c).
Scatchard ana ly sis  of binding (Fig. 6 . Id) gave a 
Tf(Fa)2 -receptor Interaction which was 92X specific, with a 
if 2.26:
c ilcu lite d  i f f in l t y  o f 8 .18x 1o' m‘ *.
(11) Apotransferrin
At low concentrations (0-50pm ml*^) a specific component of 
binding was seen (F ig. 6.2a) which plateaued at approximately 0.9pm 
apotransferrin bound mg'^ cell protein. At higher concentrations 
th is  specific-b ind ing was masked by an excess of 
low -affin ity/non-specific binding (Fig. 6.2b) which reached a plateau 
at approximately 8pm apotransferrin bound mg*  ^ cell protein. 
Competitive binding o f ^^^I-labelled apotransferrin with unlabelled 
apotransferrin (graph not shown) showed that th is 
low -affln lty/non-speclflc component contributed 50% of the total
(u^3)0Jd uao ßui lud) punoq
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binding In concentration range subsequently used for the Scatchard 
analysis.
Scatchard analysis of binding gave an apotransferr1n*receptor 
Interaction which was 50% specific  (Fig. 6.3c), with a calculated
(111) Monoclonal antibody B3/25
At low concentrations (0-20pm ml*^) a plateau of specific 
binding was seen (Fig. 6.3a) at 0.75p« HcAb B3/35 bound ng'^ cell 
protein. At higher concentrations binding seened to level slig h t ly  
at approxinately l.ZSpn antibody bound mg c e l l‘ d protein (possibly Fc 
Interaction) followed by a non-saturated non-specific binding (Fig. 
6.3b).
Competitive binding of labelled  and unlabelled HcAb B3/25 (graph 
not shown) showed a 0.68% non-specific component of binding In the 
concentration range of antibody to be used In the Scatchard analysis.
Scatchard analysis of binding (Fig. 6.3c) gave a NcAb 
63/25-transferr1n receptor Interaction which was >99% specific with a
3.9xlO®H’’ .
A comparison of binding of transfe rrin  and McAb B3/25 Is  given 
In Table 6.2. I t  can be seen that the calculated receptor density 
was Independent of the ligand used. Also, the a ffin ity  of HcAb 83/25 
for the receptor was highest with apotransferrin having the least 
a ffin ity.
6.2.2 Density of the transferrin rKOPtor on the cell surface of 
COF/CP cells sub»cultured at two different frequencies
Scatchard analysis of CCRF/CEH subcultured every 5 days gave a 
calculated receptor density of 1.71x10^ cell  ^ with a Ka 1.37xlO®H  ^
(binding of McAb B3/25) and 1 .87x lo ' receptor c e l l " ' »ith  Ka 3.09x10^
■ )£ I
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rig. 6.3 contri..
(c) Scatchard analysis of binding
A sunwary of transferrin  receptor density and Hgand a f f in it y .
Table 6.2
Ligand Density transferrin  
receptor c e l l " '
Ka (M"')
(a) Human skin fibroblast 
cells
Tf(Fe¡2 2.26 X 10® 8.18 X 10^
Tf(apo) 2.47 X 10® 2.78 X 10^
B3/25 2.44 X 10® 3.9 X 10®
(b) CCRF/CEM) ( i)  subcultured every 5 days
Tf(Fe)2 1.86 X 10^ 3.09 X lo F
83/25 1.71 X 10^ 1.37 X 10®
( i i )  subcultured every 8 days
Tf(Fe ) 2 1.54 X 10® 2.45 X 10®
(binding of T f(fe )2 ) (Table 6.2). This compared with 1.54x10” 
receptors c e l l‘ d with a Ka of 2.45xlO^H'^ determined (binding of 
T f ife lj)  using CCRF/CEM subcuUured every 8 days. Competitive 
binding of labelled with nonOabelled ligand (data not shown) showed 
that in addition to th is  specific  component of binding there was a 
28X low -affinity/non-specific contribution to T f(fe ) 2  binding and
0.7% to McAb B3/25 binding.
6.2.3 Density of the transferrin rKeptor on the cell surface of a 
veriety of different cell lines
All cell lines (Table 6.1) were grown to confluence or 
equivalent.
Receptor densities and a f fin it ie s  are sunnarised in Table 6.3.
By comparing Tables 6.2 and 6.3 I t  can be seen that the a ffin ity  of 
HcAb B3/25 for the transferrin  receptor I s  usually higher than that 
of Tf(Fe)2 * Also, i f  a comparison Is  made between the different cell 
line s it  appears that an Inverse relationship ex ists between the 
density of the transferrin  receptor and the a ffin ity  o f Tf(Fe) 2  for 
It s  receptor. That is,  the a ffin ity  of T f(fe ) 2  for i t s  receptor is  
lower (done 4.97x10^ fib rob lasts 8.16x10^) when c e lls  have a 
higher density of receptor (for example Clone M2 . 5.4x10^ compared 
fibroblasts, 2 . 4 x lo V  '^^is relationship was also seen when CCRF 
were subcuUured at d ifferent frequencies. However, such a 
pronounced relationship between receptor number and a ffin ity  is  not 
seen with the binding of HcAb B3/25 (Table 6.3; compare Hep G2 , 
receptor density 7,17xlo ' c e l l '* ,  Ka 3.91x10®; CCBF, receptor density 
1.71x10* ce ll, Ka 1.37x10®).
0.2,4 Til, dwslty of fibroblast cell surface binding-sites 
available to HPWA cooolwer con.iu.ate 2 (contain, transferrin) and 
conjuoate 3 (contains lc«l. and the affinity of bindina of conjugates 
for these sites.
Table 6.3
Transferrin receptor density and Ugand a ffin ity  on a number of cell lin e s.
ce11 type Ligand Transferrin receptor 
density ce ll’ '
Ka ( H '')
Hep &2 HcAb 7.17 X lo ’ 2.91 X 10®
B3/25
Alexander T f(fe ) 2 8.30 X 10* 1.41 X 10®
done Tf(fe)j 5.40 X 10* 4.97 X lo '
HPMA copolymer conjugated to IgG (preparation 1} showed United  
a b ility  to bind to the cell surface of fibroblasts (Chapter 4). 
However, Scatchard analysis showed that a large percentage of th is 
binding was specific  (Fig. 6.4a,b) as defined by the high binding 
a ffin ity  of conjugate for the fib rob last ce11 surface (Table 6.4). 
Unfortunately, due to the United  supply of conjugate I t  was not 
possible to perform the competitive binding experiments necessary to 
quantitate the percentage of non-specific binding. However, with 
th is  lim itation In mind there was found to be maximum binding of
mole of conjugate bound to one mole of binding site s),  or 5.94x10 
binding sites c e l l’ ^. Su rprising ly the a ffin ity  of binding was very 
high, 4.76x10^^ but th is Is  probably due to avid ity rather than 
a ffin ity  (see Discussion 6.3).
In Chapter 4 I t  was shown that the uptake of transferrin  was 
Independent of Iron-loading. Here I t  was shown that both 
apotransferrin and d ife rric  transfe rrin  are able to bind specifica lly  
to the transferrin  receptor. For these reasons no attempt was made 
to determine the degree of Iron loading of conjugated transferrin.
Transferrin bound to HPMA copolymer retained I t s  a b ility  to bind 
spec ifica lly  to the cell surface (Fig. 6.5a,b) with maximum binding 
o f 2.08x10’ '
ce ll (assuming 1 mole conjugate bound to I mole of binding sites). 
Again It  was not possible to assess the non-specific contribution to 
th is  figure, although the Scatchard plot (Fig. 6.6b) Indicates that 
I t  w ill not be very large. The a ffin ity  of the HPHA 
copolymer-transferrin conjugate was found to be 1.25x10® M which 
was 22-t1mes lower than that of apotransferrin (Table 6.4).
moles mg*  ^ cell protein, or 5.96x10® binding site s per
i» i )  P 'J'iog


6.3 Discussion
The dost Important conclusion to be drawn from th is study 
relates to the a b ility  of the HPMA copolymer-protein conjugates to 
bind to the fibroblast ce ll surface. It  cannot be said with 
certainty that the transferrIn-HPHA copolymer conjugate I s  s t i l l  
recognising the transferrin  receptor, particularly I f  a comparison Is  
made between the calculated number of transferrin  receptors (2.4x10^ 
c e ir^ )  and the number of binding s ite s recognised by th is  conjuate 
(59.6x10^). I t  was very encouraging, however, to find that the 
conjugate had an a ffin ity  fo r the cell surface, which was only 
22-t1mes less than that of the unconjugated protein. Given that this 
conjugate probably has a stoichiometry of Tfj{HPMA)^g (Chapter 3, 
3.2.3) I t  was not expected that such a high a ffin ity  (1.25x10^ M'^) 
would be seen. With future Improvements In the preparation of this 
conjugate (see General Discussion) It  w ill be possible to Increase 
dramatically the sp e c ific ity  of HPKA-copolymer bound transferrin  for 
I t s  target receptor.
The large IgG-HPHA copolymer conjugate (Chapter 3; Mw»2H 
Daltons) seemed to bind sp e c ifica lly  to a large number of binding 
sites (5.94x10^). This degree of specific binding had not been 
expected for a conjugate which was so removed from an Ideal molecular 
weight and stoichiometry. Interestingly, the calculated a ffin ity  of 
th is  conjugate was very high (4.76x10^^ M ^). Given that th is 
conjugate probably contained at least 10 antibody molecules (Chapter 
3, 3.2.3), and with the resu lt ing  possib ility  o f more than one 
antibody molecule having the a b ility  to recognise the cell surface at 
any one time, It  Is  possib le  that the calculated a ffin ity  constant Is  
a measure of avid ity rather than affin ity. That Is,  the binding of 
th is conjugate to the fib rob last cell surface is  a multivalent 
phenomenon, whereas a f f in it y  I s  used to define a monovalent
Interaction between antibody and antigen. As a re su lt  the calculated 
Ka i s  In fact attributable to the sunMtion of the a f fin it ie s  of 
these aonovalent interactions (see Thompson & Jackson,1984) and as a 
consequence, the calculated number of binding s ite s  w ill be 
underestimated since there was not a 1:1 binding ratio  of conjugate 
to binding site . A consideration of avid ity rather than a ffin ity  
w ill be important in  the future development of antibody*targeted 
drug-carriers, particularly i f  consideration i s  made of the 
p o ss ib il ity  of using combinations of F(at> ) 2  fragments of different 
specific ity  attached to HPHA copolymer as potential targeting 
residues (see General Discussion).
The a ffin ity  and specific ity of a targeting residue for its  
target antigen/receptor is  of obvious importance in  targeted 
drug-delivery. In th is  Chapter i t  was shown that although 
apotransferrin was able to bind to the same number of receptors as 
d ife rric  transfe rrin , there was an additional large  (50%) component 
of non-specific binding Inappropriate to targeted drug-delivery.
This view, however, may be too naive since in v ivo  the drug-carrier 
w ill experience a far more complicated environment, where there are 
many factors, such as transferrin recycling in the absence of bound 
ligand (AJioka S Kaplan, 1966; Stein & Sussman, 1986), local fa lls  in 
pH (apotransferrin i s  reported to have a higher a f f in it y  for the 
transferrin  receptor a low pH; reviewed Oautry-Varsat, 1986) which 
could give apotransferrin some advantage as a targeting residue.
The a ffin ity  of McAb 83/25 for the transfe rrin  receptor was 
consistently higher than that of transferrin, and importantly this 
a ffin ity  was not Inversely related to transferrin  receptor density 
(as was found for transferrin). This observation together with the 
calculated >99% sp ec ific ity  of binding of HcAb 83/25 Indicates that 
HcAb 83/25 is  a more appropriate targeting residue for HPMA copolymer
conjugates directed to the transferrin  receptor than transferrin  ger 
se. Unfortunately I t  was not possible to detenalne the effect of 
conjugation of McAb B3/2S to HP11A copolymer on binding to the 
fibroblast ce ll surface. Results presented previously (Chapter 4) 
Indicate that there Is  Interference with ce ll surface Interaction of 
the antibody following conjugation to HPMA (Chapter 3, stoichiometry 
probably AbiHPHAj^g).
I f  the transferrin  receptor I s  to be used as a potential 
targeting site , It  would be an advantage I f  the target ce lls  
expressed a higher density of receptor. Oudermans,et a K  (1986) have 
shown that the transferrin  receptor density on B*lymphoma Is  
Increased when c e lls  are encouraged to proliferate  (Concanavalln A), 
Testa,et a K  (1986) have found that the erythroleukaemlc cell lines 
(K562 I  HEL) synthesize transferrin  at an enhanced rate after 
subculture, at low density, Into fresh medium. In agreement with 
these published resu lts transferrin  receptor density was found here 
to be higher on CCRF/CEH which had been encouraged to proliferate 
rapidly. Also, a positive  relationship between transferrin  receptor 
density and malignancy was Indicated by the 5-fold higher density of 
receptor on CCRF/CEM (subcultured every 8 days) than fibroblasts 
(subcultured every 7 days). However, the data presented In th is 
Chapter and also the published work of Oudermans (1986), and Testa 
(1986) Indicated that a d irect comparison of the transferrin  receptor 
density between different ce ll lines, grown In different 
laboratories, under different conditions, may be d iff icu lt .  Table
6.2 shows that simply varying the frequency of subculturing made a 
dramatic difference to the density of receptor measured on CCRF/CEM.
Rapidly proliferating cancer ce lls  w1.ll be targets for HPMA 
copolymer-antibody conjugates. A problem when using the transferrin  
receptor as the target antigen/receptor is  the amount of these

A senary  of published values for the transfgrrin  receptor density
Cell type density of 
transferrin 
receptor ceH*‘
(M->)
Reference
Be Mo; choriocarcinoM 3.7x10* 4.2 2.1x10® H M llto r.e t  i l .  1979
K562; erythroleukaemic 1.2x10®
2.65-5.9x10®
2x10®
1.5x10® 
1.1x10® 
1x109
Besancon.et a l, 1985 
Lazarus, eT'aTT 1985 
van Renswou^.et al^. 1982
HeLa; cervical carcinoma 1.8-3.7x10® 2.7x10® H a rd ,e t^ ,  1982
Daudi; Burkitt lymphoma 7.5x10® 2.5x10® Besancon,et al_, 1985
A431; human carcinoma 5x10® N.D. Hopkins & 
Trolibridge, 1983
PMC-22B; melanoma 6.9x10® 1.4x10® Musgrove,et al^ , 1984
Rat liver
Rat brain
Rat hepatocytes
Rat embryo fibroblasts
Hep 6e (Table 6.1)
CCRF (Table 6.1)
2.7x10®
NO
4-6x10*
6-lOxig*
5.1x10*
1.9x10®
5.2x10®
KOxlO*
N.D.
l. lx lO '
N.O.
1.20x10*
l4organ,et a l, 1986 
H ill,e t“a l 'T  1985 
BomfoH Tiiunro, 1985 
Octave,et a l, 1981 
Mu & Wu,^1986 
Husgrove,et al^ , 1984
(Details of f i r s t  isolation of these cell lines can be found in the 
"F Iok catalogue").

The a b ility  of MPHA-copolymer conjugates, containing NcAb B3/25 
or transferrin, to bind to cell-surface  transfe rrin  receptors and 
undergo subsequent internalisation , has been described in Chapters 4 
and S. However, the in v it r o  evaluation o f these conjugates gives 
only a basic indication o f the ir potential fo r use in targeted drug 
delivery. Therefore, i t  was considered necessary to exanine the 
d istribution  of these conjugates in the more complicated in  vivo 
milieu. HPMA copolymer conjugates used in t h is  study contained human 
transferrin, or anti-human transferrin-receptor antibody. The 
fe a s ib il ity  of using these conjugates to determine body d istribu tion  
in mice was supported by the a b ility  of transfe rrin  to bind 
interspecies (Chapter 6; Tsavaler, et 1986), together with the 
large percentage of homology between the mouse and human transferrin  
receptor (Schneider 4 U il lia n s ,  1985).
The transferrin  receptor is  present on most, i f  not a ll,  
nucleated ce lls ,  in particu lar ce lls  which are rapidly d iv id ing  (see 
Chapter 1, 1.4.1; reviewed by Hay and Cuatrecasas, 1965). This 
indicates that, like  the Thy-1 antigen, (Chapter 6) the transferrin  
receptor may be far from ideal as an antigen for use in targeted 
drug-delivery (see Chapter 1, 1.3.3). However, Omary, et ^  (1980) 
have shown that the tran sfe rrin  receptor i s  an important 
imnunodoninant surface-antigen on cultured human tumour ce lls ,  and 
th is  observation, together with data from Getter, ^  al_  ^ (1983) who 
showed that transferrin  receptors have a restricted  d istribu tion  In 
vivo Indicate that th is  receptor may indeed be useful in  promoting 
targeted drug-delivery. The efficiency o f targeting in v ivo , 
however, remains unclear. 6atter,et aK  (1983) have shown that in 
normal ce lls  the transfe rrin  receptor is  localised  mainly in the 
basal epidermis (skin, tongue, tonsil, oesophagus, cervix), the
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•ndocrine pancreas, liv e r  (hepatocytes and Kupffer c e l ls ) ,  testes, 
kidney, stomach and the pitu itary. In contrast, a wide distribution 
of the receptor was found In carcinous and sarcomas. Antibodies 
against the transferrin receptor (which were known to  block receptor 
function, that Is, unlike B3/2S) have been shown to Inh ib it  growth of 
transplanted syngeneic AKR/J SL-2 leukaemic ce lls  In  AKR/J nale mice 
(Sauvage, et a1^, 1987).
Experiments carried out in th is Chapter set out to determine the 
body d istribu tion  of transferrin, anti-transferrin  receptor antibody 
(McAb 63/2S) and polymer conjugates containing these proteins, to 
assess the possib ility  o f using these conjugates to accomplish an 
altered body distribution of drug. The body d istribu t ion  of 
^^^I-labelled HPHA copolymer, HcAb B3/25, d ife rric  transferrin , and 
HPHA copolymer bound to either B3/2S (conjugate S) o r transferrin 
(conjugate 2) was determined 5h after 1v administration to OBA^  male 
mice (approximate age 16 weeks). No attempt was made to determine 
the Iron saturation of the transferrin since the receptor-binding of 
apotransferrin and d ife rric  transferrin have been shown to be very 
s im ila r (Chapter 4 and 6).
7.1,1 Calculations
Calculations used In th is Chapter are as given In  Chapter 2 
Section 2.2.8.1.
7.2 RESULTS
The body distributions of ^^^I-1abel1ed proteins, (HcAb B3/2S
of these proteins (Including the data extrapolated fo r  conjugate 5) 
are summarised In Table 7.1.
The body distribution of ^^^I-labelled HPMA copolymer was gulte 
different from that observed for both the proteins (McAb B3/25 and 
T f(fe )2 ). There was obviously much more rad ioactivity In the urine
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after adalnlstratlon of HPMA copo1y«er (that Is,  49.4% for polyier;
S .5-15.2% for proteins). Second, there was a such higher percentage 
(adninistered dose) of protein-associated rad ioactivity In the blood 
(that Is ,  12.7-36.3% proteins; 2.5% polymer). The level of 
rad ioactivity detected In the bloodstream (5h) after administration 
of antibody was 3-t1mes higher than that observed with transferrin.
Conjugation of HPMA copolymer to e ither transferrin, or McAb 
B3/25, resulted In a marked alteration In  body d istribution. The 
d istribu tion  of conjugates was c loser to that seen previously for the 
radlolabelled-protelns than that of rad1olabe11ed*HPMA copolymer.
The HPMA-copolymer conjugates were retained In the bloodstream (2.5%, 
HPHA; 57.5% conjugate 2; 54.8% conjugate 5) and showed a parallel 
decrease In the rad ioactivity detected In  the urine (49.4%, HPMA;
6.5% conjugate 2; 0% extrapolated for conjugate 5). In most organs 
(heart, live r, kidney, thymus, submaxlllary glands plus attached 
lymph nodes, bone marrow) the percentage (administered dose) 
localisation  of conjugate was comparable to that measured for 
unconjugated protein, but was approximately 10-t1mes higher than that 
seen for HPMA copolymer.
After administration of radlolabelled proteins, and both the 
HPMA copolymer-protein conjugates, rad ioactiv ity  was principa lly 
found In the live r, stomach. Intestine, sk in  and bone marrow. Uptake 
of protein by the liv e r  was s l ig h t ly  reduced after conjugation of the 
protein to HPHA copolymer.
It  Is  Interesting to note that >95% o f the administered dose of 
conjugates 2 and 5 was recovered from the organs selected for 
analysis. In comparison th is  fe ll to between 56-74% when using 
T f(fe ) 2  or McAb.
The body d istribu tions of unconjugated protein (anti-human 
transferrin  receptor HcAb B3/25, human transferrin ) and the HPHA 
copolymer conjugates 2 (containing transferrin ) and 5 (containing 
McAb B3/25), described In th is  Chapter were consistent with binding 
of these ligands to the mouse transferrin  receptor, and with 
accumulation by rapidly d iv id ing c e lls  known to be the natural target 
for transferrin . Body d istribu tions for OBA  ^ mice are consistent 
with the findings of Sauvage,et ^  (1987) who administered HcAb R17 
207 and REH 17.2 (which are both specific  for, and block the function 
of, the transferrin  receptor) Intraperltoneally to 6-8 week old AKRJ 
mice. The experiments described In th is  Chapter, however, followed 
the d istribu tion  of administered ligand over a 5h period (In  contrast 
with the 24h used by Sauvage,^ |Xl (198T)) to allow direct 
comparison of the resu lts with those of HPHA conjugated to the 
antl-Thy 1.2 antibody (Chapter 8). Also, the proteins and conjugates 
were a11 administered Intravenously, which was considered to have 
more relevance to a c lin ica l situation. For th is  reason larger, 
16-week old mice were used rather than 6-8 week old mice used by 
Sauvage.
The 56-74% recovery (of administered dose) of T f(fe ) 2  and HcAb 
B3/25 Implied that these proteins were also present In t issues other 
than those chosen for study in th is chapter, perhaps the brain. This 
would be consistent with the known existence of transferrin  
receptors, with a high a ffin ity  for transferrin . In rat brain (H ill 
et a K ,  1985). Recovery of both HPHA copolymer conjugates was much 
higher (>95%). The high molecular weights (Chapter 3, 3.2.3) of 
these conjugates would probably Interfere with extravasation. This 
assumption was In accordance with the high percentage of conjugate 
remaining In the bloodstream after 5h. Also, a comparison of
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urine-associated rad ioactivity resulting from low molecular weight 
degradation products (Table 7.1) indicated that the conjugates were 
not able to reach target tissues, and undergo subsequent 
intracellu lar processing as e ffic ien tly  as the unconjugated proteins.
In general, i t  was found that the body d istribu tion  of the HPHA 
copolymer conjugates was independent of the protein targeting-residue 
used (transferrin, HcAb B3/25, or anti-Thy 1.2, see following Chapter 
8). These results suggested that e ither the sp e c ific ity  of the 
protein was being masked by conjugated HPMA copolymer (Chapter 3, 
3.2.3; Chapter 4, 4.3), or that the three conjugates were targeting 
to the same tissues, but not necessarily the same ce lls. The latter 
explanation is  in accordance with the sim ilar body d istributions of 
unconjugated antibodies B3/25 (Table 7.1) and anti-Thy-1.2 (Chapter 
8, Table 8.4) 5h after l.v. administration to mice aged approximately 
16 weeks.
It  has been repeatedly cited in the literature  that the density 
of the transferrin receptor is  higher on tumour c e lls  than normal 
c e l ls  (reviewed Hay & Cuatrecasas, 1985; Trowbridge, 1985). There is 
already evidence that the apparent tumour-associated d istribu tion  of 
the transferrin receptor may be of diagnostic value (Gatter, ^  a l . , 
1983; see Section 7.1). In fact, i t  has been proposed that selective 
tumour cell death, brought about by the natural k i l le r  (NK) ce lls ,  is 
related to a high density of the transferrin  receptor on the target 
c e lls  (Herberman & Holden, 1978; Herberman, 1980; 6orysiewicz,et a l . . 
1966). This relationship, however, has not been proven, and has been 
disputed by Bridges & Smith (1985) and Reiber, ^  aK  (1986). It  
would be interesting to see i f  there was a preferential tumour 
localisation  of either HPMA copolymer conjugate 2 or 5 after 
administration to mice bearing tumours, in comparison to the OBA  ^
mice used in th is chapter. It  has been reported that after
conjugation of antl^transferrln  receptor antibody to r Ic In -A  chain 
(Trowbridge t  Domingo, 1981} selective ce11 death of H21 c e lls  In 
nude mice was achieved. This suggested that there was Indeed 
preferential localisation  of antibody at a target tumour. In 
contrast, however, I t  has been reported (Trowbridge, 1985) that In 
some ce ll lines with equal a b ility  to bind the anti-transferrin  
receptor antibody, there were differences In response of the c e lls  to 
the antibody. Such resistance to antibody alone would not be a 
problem when using HPHA copolymer conjugates specific  for the 
transfe rrin  receptor, since the antibody, or transferrin , would 
simply be used to fa c ilita te  binding of HPMA copolymer conjugate to 
the ce ll surface. Cell death would be achieved by the Incorporation 
of drug Into the carrier.
The natural targets fo r transferrin  are a ll rapidly d ividing 
ce lls .  However, these are also the non-specific targets of many 
chemotherapeutic agents used at present In patients (see Chapter 1, 
1.1). Although Sauvage,^ aK  (1987) have reported no evidence of 
acute tox ic ity  In normal tissues after administration of 
anti-transfe rrin  receptor antibody, there could be problems after 
administration of HPMA copolymer conjugates 2 or 5 containing drug. 
R1hova,et a K  (1985; 1986) have reported pharmacological effects 
after administration of HPHA copolymer containing both drug (DNH) and 
targeting residue (antl-Thy-1.2). The data presented In Chapter 8, 
8.3) Indicated that these pharmacological effects were attributable 
to loca lisation  of a low percentage (<1% administered dose) of 
conjugate at the target-organ. The resu lts presented In Chapter 8 
and those presented here suggest that the localisation  of HPHA 
copolymer conjugates, "targeted* to the transferrin  receptor, present 
on normal tissues may be su ffic ien tly  high to deliver a cytotoxic 
quantity of drug to those rapidly d ividing ce lls  that are already the
non-specific target of drug.
Although the transfe rrin  receptor was considered an ideal in 
v it r o  model antigen fo r reasons detailed in Chapter 1 (1.4.1) the 
c lin ic a l relevance of th is  antigen may be more lim ited. The 
transfe rrin  receptor i s  not a tumour-specific antigen, but it  is  
certa in ly  considered to be a tumour-associated antigen (Trowbridge, 
1985). Due to the presence of the receptor on normal c e lls  I t  may be 
necessary to use anti-transfe rrin  receptor HcAb in combination with 
other HcAbs. Sauvage, et aK  (1987) used a combination of the 
ant1-Thy-l antibody (19E12) and the anti-transfe rrin  receptor 
antibody (R17 208) against Sc-2 leukaemia. An increased survival 
time of mice receiving combination therapy was shown when compared to 
mice receiving e ither antibody alone. The p o ss ib il ity  that the 
anti-transfe rrin  receptor antibody and anti-Thy 1.2 are lo ca lis in g  in 
the same tissues has already been mentioned in relation to the HPMA 
copolymer conjugates. The relevance of combination therapy to the 
HPHA copolymer conjugates w ill be discussed in the General 
D iscussion.

8.1 INTRODUCTION
Thy-1 Is  a cell-surface glycoprotein present on mouse thymocytes 
(Williams & Gagnon, 1962). Molecular weights of 17,800, 18,700 
(Williams & Gagnon, 1982) and 25,000 Daltons (Kroczek et aK  1986) 
have been reported for this glycoprotein. The antigen exist In two 
allotypic forms. Thy 1.1 and Thy 1.2. The la tte r form Is  used as a 
target antigen In this study.
The structure of Thy-1 Is  not typical of plasma membrane 
proteins. Low & Kincade (1985) have shown that the glycoprotein Is  
anchored in the plasma membrane via the lip id , phosphatidylinositol. 
This observation was supported by Ishihara et i K  (1987) who found 
that the Thy-1 antigen exhibits a lateral d iffu sion  coefficient In 
the plasma membrane which Is  sim ilar to that of lip id s  embedded 
within the same membrane, but more than 10-t1mes greater than 
membrane proteins.
The function of the Thy-1 glycoprotein Is  thought to be that of 
a "signal transduction molecule". Krozcek et ^  (1986) showed that
crosslinking of Thy-1, using monoclonal antibodies, resulted In a
2+
rapid rise  In the level of cytoplasmic free Ca The Thy-1 
glycoprotein i s  not readily Internalised (Hopkins, 1966), but 
crosslinking of Thy-1 by divalent antibodies In h ib it s  lateral flow of 
the glycoprotein resulting In membrane patching and then capping, 
eventually followed by Internalization (Hopkins, 1986). The 
subsequent Intracellular routing of Thy-1 ligand complexes has not 
been studied, but w ill probably Involve the lysosomal compartment of 
the cell. Understanding of such intracellu lar routing Is  Important 
I f  this antigen Is  considered as a target antigen for antIbody-HPMA 
copolymer drug-carriers.
The Thy-1 antigen has been used as a model target antigen for 
antIbody-HPHA copolymer conjugates (Rlhova & Kopecek, 1985; Rlhova et
i l . . 1986). HPMA copolyaer was conjugated to antl-Thy-1.2 (both 
polyclonal and nonoclonal) and phanucologically active groups 
(dauno«ycin (DNH), or quaternary aemonluB groups). Conjugates 
containing t>oth ant1*Thy*1.2 and a cytotoxic group resulted In a 
sign ificant Increase In  T-ly«phocyte k i l l in g  (both In v itro  and In 
v ivo ) than was observed using s l i l la r  HPHA copolymer conjugates 
containing a non-specific antibody. ^  v itro  evaluation was carried 
out by Incubating spleen cells» Isolated from 12-week old female A/«l 
■ Ice, with appropriate conjugates. To d isc riilna te  between 
cytotoxicity due to the pharmacologically active group and that due 
to the antibody alone, tests were carried out either In the presence, 
or absence, o f complement. Rlhova, et a K  (1986) found that HPHA 
copolymer conjugated to antl-Thy-1.2 was up to 70-t1mes more toxic 
against target T-lymphocytes than a sim ilar HPMA copolymer-conjugate 
containing non-specific antibody.
In vivo evaluation of the activ ity  of such conjugates Involved 
enumeration o f antibody (IgG and IgH) secreting c e lls  (plaque forming 
ce lls ,  PFC) present In the spleen of 8-week old, A/J female mice 
previously Injected Intraperltoneally ( l.p .)  with the HPHA copolymer 
bound to both antl-Thy-1.2 and ONH, on day 4, 3, 2 and 1 before 
stimulation with sheep red blood ce lls  (SRBC; l.p. IxIO^ c e l ls ).  On 
day 5 after Immunisation with SRBC the spleen was removed and PFC 
could then be counted. Rlhova, et aK  (1986) reported that a 97.9% 
reduction In the number of PFC was seen after pre-immunisation of 
mice with HPHA copolymer conjugated to antl-Thy 1.2 and DNH, compared 
to a 67% reduction using sim ilar conjugates containing no drug.
The published ce llu la r  d istribution of Thy-1 In different 
species, is  given In Table 8.1. It  can be seen that T-lymphocytes 
are not unique In displaying the antl-Thy-1.2 antigen, therefore, 
cytotoxic HPMA copolymer-drug conjugates, targeted to the Thy-1
Tab1< 6.1
Cellu lar d istribu tion  of Thy-1 glycoprotein in  different spades
Species Connon
Name
Distribution References
Han Thy-1 neurones
thymocytes (few %)
Kroczek, e t.a l. (1966) 
Williams 1 Gagnon (1982)
Rat Thy-1 neurones 
thymocytes 
peripheral T-ce11s
Williams & Gagnon (1982)
House Thy-1 mouse thymocytes 
peripheral T -ce lls 
neurones 
fibroblasts
Kroczek, ^  aK  (1966)
antigen, w111 probably exhibit a more widespread effect than the 
reduction In PFC reported. In the following study the body 
d istribution  of ^^®I-labelled ant1body-HPMA copolymer conjugates has 
been determined using Thy-1 as a model antigen. In particular the 
following factors were Investigated:-
1. The body d istribution  of HPHA copolymer, unconjugated 
antl-Thy-1.2 antibody, and ant1body*HPMA copolymer conjugates.
2. The body d istribution  of antl-Thy-1.2 antIbody-HPMA copolymer 
conjugates conjugates In which the antibody Is  (a) Fc not available 
or (b) Fc available for Interaction with the cell surface (Chapter 3, 
3.2.4).
3. The effect of route of administration on body d istribution.
4. The effect of age on the body d istribution  of unconjugated 
antl-Thy-1.2, and HPMA conjugated to antl-Thy-1.2.
8.1.1 Calculations
Calculations used In th is  Chapter are as detailed In Chapter 2, 
Section 2.2.S.I.
6.2 RESULTS
Haterlals used In th is study were described In Chapter 3 (Table 
3.1) and Appendices (1 & 2).
8.2.1 Effect of time after administration on the body distribution 
of ^^^1-labelled antl-Thy-1.2 antibody-HPHA copolymer conjugates.
A ll mice were 16-20 weeks of age unless otherwise stated.
This preliminary experiment was designed to determine the 
optimal time course for monitoring the body d istribu tion  of 
HPHA-copolymer antibody conjugates. A ll conjugates were administered 
Intraperltoneally (see Chapter 2, 2.9) and the rad ioactivity 
recovered In each organ expressed as a percentage of the total 
rad ioactivity recovered from the animal. This method of data 
analysis was not used In subsequent experiments because It  was found
that the total rad ioactivity recovered, as a percentage of 
administered dose, was unacceptably low (50%) and the radioactivity 
unaccounted for could perhaps bias the data.
Over a 24h period most of the rad ioactivity recovered was 
located in one, or more, of the following tissues/compartments: 
peritoneal cavity, blood, urine and live r. Fig. 8.1 shows the 
rad ioactivity (% recovered dose) at 1, 5 and 24h.
From Fig. 8.1 i t  can be seen that more than 90% of the recovered 
rad ioactivity associated with the conjugate had le ft  the peritoneal 
cavity after 5h. In paralle l, the rad ioactivity recovered in the 
blood and liv e r  reach a maximum after 5h (within the lim its of the 
time points chosen). There was a steady Increase with time of 
rad ioactivity detected in the urine to a maximum of approximately 50% 
recovered rad ioactivity after 24h.
In subsequent experiments i t  was considered desirable to use a 
time course over which there was maximal transfer of conjugate out of 
the peritoneal cavity to give the greatest p o s s ib il it y  for 
ce ll-sp ec ific  ’targeting”, coupled with a minimal amount of conjugate 
degradation, avoiding the complicating factor of low molecular weight
125I-labe11ed degradation products. A time course of 5h was chosen
for further experiments.
8.2.2 The body distribution of ^^^Mabelled HPHA copolymer, 
anti-Thy-1.2 polyclonal antibody, and antibody-HPHA conjugates 
(containing either non-specific IgC. or antl-Thy-1.2) after i.p.
administration.
All experiments were carried out over 5h. As described in the 
methods (Chapter 2, 2.9), fifteen body compartments were routinely 
assayed for rad ioactivity. These organs constitute approximately 42% 
of the total body weight of a mouse (Appendix 7). The radioactivity 
recovered in these compartments was found to be dependent on the
Fig. 8.1 Body distribution of '^^ I-labe lled  ant1-Thy-1.2-HPMA
copolymer conjugate 1h, 5h and 24h after Intraperitoneal 
administration to D6 A2  male mice (approximate age 16 weeks).
Time (h)
individual conjugates used, varying between 53'70X (Table 8.2).
The body dlstrtbutlon of '^^ I-labe lled  HPHA and ant(body-HPt« 
copolymer conjugates (% administered dose and % administered dose 
gm'^ organ) are shown in Table 8.3. I t  can be seen that HPMA 
copolymer conjugated to antibody (conjugate 3 containing non-specific 
IgG; conjugate 4 containing anti-Thy-1.2) le ft the peritoneal cavity 
more slowly than either the parent HPMA copolymer or unconjugated 
anti-Thy-1.2. In addition there was a much higher recovery of 
rad ioactivity in the blood (approximately 28X antibody-HPNA copolymer 
conjugates; 5% HPMA copolymer) together with a lower recovery of 
rad ioactivity in the urine (4-7% antibody-HPHA copolymer conjugates; 
49% HPMA). As expected, uptake of HPMA copolymer by the live r  was 
increased up to 3-fold after conjugation to antibody.
In general, radioactivity detected in the organs was higher 
after conjugation of HPMA copolymer to anti-Thy-1.2 than to 
non-specific IgG and, with the exception of the intestine, always 
higher than that of the parent HPMA copolymer. In particular, 
loca lisation  in the thymus of conjugate 4 (containing anti-Thy-1.2) 
was 3-5 times greater than either anti-Thy-1.2 unconjugated antibody, 
or conjugate 3 (containing IgG), and 2-3 times greater than HPMA 
copolymer alone (fig . 8.2). In the sk in  a 1.4-fold increase in the 
loca lisation  of conjugate 4 over conjugate 3 was seen (Table 8.3).
When the results were expressed in  terms of the percentage of 
administered dose recovered gm'^ organ (Table 8.3 and Fig. 8.2) it  
seemed that no additional information was obtained. Further results 
were presented only in terms of percentage administered dose.
6.2.3 The body distribution, after i.p. administration, of 
^^^I-labelled HPMA copolymer-antl-Thy-1.2 antibody conjugates in 
which the antibody was la) Fc not available or (b) Fc available.
The mean molecular weights of HPMA copolymer conjugates 4a and
Fig. 8.2 The percent (a^ in lste red  dose) of HPMA (1) polyclonal 
antl-Thy 1.2 antibody, and HPMA copolymer conjugates 3 
(contain IgG) and 4 (contain ant1-Thy-1.2) In the thymus 
5h afte r l.p . administration to OBA2  male nice (approximate 
age 16 weeks).
(A ll Hgatids w re  ’^® I-labe ll« l.)
Ligand
T»b1t 8.2
Tht PTcentaqt of id iln lste red  dose re c o v rtd  i f t T  >d»1n1str<t1on of
I2S I-1ibe11ed HPHA. unconJuq»ttd anti Thy 1.2 >nd antibody-HPMA
copo lyc r conJuq»tt$
‘“ l-lab€lted
substrate
Code
number
X of administered dose recovered
l.p. administration l.v. administration
1 64.6 1 2.6 N.D.
antl-Thy-1,2 70.1 ± 4.4 81.1 t  1.2
4PHA-IgG 3 52.6 1 1.4 N.D.
4PMA-ant1-Thy’ 1.2 4 67.7 t  5.5 66.2 t  1.3
4a 58.9 ± 10 78.2 t  6.4
4b 69.5 t  3.6 81.4 ± 5
’ see Appendix 7
Body wel9 ht recovered > 40-43X o f total mouse weight
r
Body weight recovered • 23X of to ta l mouse weight
M y  dlitrlbution (parctnUgt Of « M n liU rfd  dost) of '^’ I'Ubollod HMt coootywr. uncenjuoottd uit1*Thyl.2 
intibody ond HPM copolyaor-iAtlbody conjugotos. In 16 «ook old NAj m Io • k i  Sh oftor l.p. idalntitrotlon.
Orgon ^^M ibo llcd  fubitriti 
c m  MMCR
1 Antl'THyl.2 3 4
Hoirt A 0.13 to.02 0.42 *0.04 0.31 0.09 0.43 *  0.09
1 O.t 0 0.1 2.76 *0.21 1.07 0.36 2.0 *0 .3
Livor 1.3 *0.3 3.72 *0.37 2.0 *0.39 3.02 *0 .9
0.9 *0.32 2.00 *0 .3 1.07 *0.27 2.9 *0 .3
Lunt 0.19 *  0.04 0.S9 *0.03 0.37 *0.07 0.69 t 0.06
1.4 *0.13 3.06 *0.16 2.29 *0.4 4.10 t 0.4
Mdnoy 0.90 *  0.09 1.34 *0.11 1.11 *0.2 1.41 tO.3
1.04 *0.12 3.00 *0.22 1.99 *0.49 2.6 t 0.69
Sploon 0.21 *0.07 0.37 *0.04 0.44 *0.19 0.34 tO.oe
I.M  *0.S 4.10 *0.$7 9.07 * 2.6 3.23 *  0.7
Thyaui 0.06 * 0.007 0.04 *  0.000 0.04 *0 0.14 t 0.09
1.S4 *0.17 1.30 *0.19 0.99 *0.2 3.49 1 1.3
SgfeMxllUry 0.1S * 0.010 0.43 *0.6 0.3 fl.OO 0.30 *0.09
0.6S *  0.07 2.07 *0.2 1.27 *0.17 1.96 *0 .2
StOMCH 0.49 *  0.04 2.43 *0.16 1.29 *0.17 1.69 *0.94
0.61 *  0.06 9.10 *0.12 1.0 *0.92 2.1 *0 .6
Intostlno 4.0 *0.6 9.63 *0.44 2.90 *0.4 3.29 * 0.72
1.06 *0.27 2.40 *0.07 2.71 *1.9 1.01 * 0.2
Skin 0/0 9.29 *0.4 4.19 *0.73 6.1 t 1.24
2.99 *1.02 0.90 *0.2 1.63 *0 .3
Sono N/0 9.10 *0.42 6.39 *2.71 7.1 *0 .0
9.73 *0.39 3.71 *0.17 4.19 *  0.1
Urino 40.0 2.7 7.3 *2.96 4.70 * 1.3 4.32 * 0.0
Ftccot 0.32 t 0.2 0.14 * 0.02 -
Hood s *  o.ss 29.93 * 1.13 20.2 * 4.96 29.0 *  2.4
forltonool aotti , 2.0 * 1.2 2.00 *  0.46 9.1 *0.20 9.72 *  1
HPHA-loG
HPMA*ontl>Thr1.2
A ■  porcinUfo of iM nlitorod  deto ^S.C. (n* }-9 alco] 
t • oorcintift Of odalnlitorod doto oryin 
N/0 > Hot dottnlntd
4b tftrc shown to bo approx iM ttly equal, but slig h t ly  lower than that 
of parent conjugate 4 (Chapter 3; 251K Daltons, conjugates 4a, 4b: 
301K Daltons, parent conjugate 4). Purification  of conjugate 4 and 
subsequent separation by prote1n*A a f f in it y  chromatography Into 
conjugates 4a and 4b, did not resu lt In the detection of degradation 
products (a problee experienced In the purification  of conjugates 3 
and 5).
The rate of clearance of conjugates 4a, and In particular 4b, 
from the peritoneal cavity was faster than that of parent conjugate 4 
(Fig. 8.3a). This difference In behaviour of the three related 
preparations was again evident In the amount of blood*assoc1ated 
rad ioactivity (X administered dose) (Fig. 8.3b) where both conjugates 
4a and 4b were present to a lesser extent than parent conjugate 4, 
and In the urine (Fig. 8.3c) where more than twice as much 
urine-associated rad ioactivity was detected after administration of 
conjugate 4a than either conjugates 4, 4b, or, In fact, unconjugated 
antl-Thy-1.2 (Table 8.4).
In general organ-associated rad ioactiv ity  was lower after 
administration of conjugates 4a and 4b when cohered to the parent 
copolymer (Table 8.4). Surprising ly, t h is  reduction In 
tissue-loca lisation  was seen In the spleen, thymus, and bone marrow 
(Fig. 8.4), but not In the skin, where up to a 2-fo1d Increase In the 
loca lisation  of 4b, when compared to conjugates 4 or 4a, was seen. 
L it t le  difference was seen between the le ve ls of liver-associated 
rad ioactivity after administration of e ithe r conjugates 4, 4a, or 4b 
(Fig. 8.5). There were however, d ifferences seen In 
faecal-associated rad ioactivity (Fig. 8 .5 ), (OX, conjugate 4;
0.3-0.45X, 4b, 4a).
. a
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TabU 6.4
Body distribution (parcantaot of adiinistarad do$a) of anti-Thv-1.2 
antIbody-HPHA copolyar conJugatas * *. 4a and 4b. in 16 w a k  old aila 
DBA, ■ica, Sh aftar 1,p. adairtlstrition.
Organ 4
conjugate
4a 4b
Heart 0.43 ± 0.05 0.35 ± 0.08 0.24 ± 0.05
Liver 3.82 ± 0.5 3.26 ± 0.3 3.28 ± 1.1
Lung 0.65 ± 0.06 0.41 i  0.06 0.42 t  0.1
Kidney 1.41 t  0.3 1.4 1 0.14 1.23 1 0.4
Spleen 0.34 ± 0.08 0.28 ± 0.03 0.29 t  0.09
Thymus 0.14 t  0.05 0.08 1 0.03 0.07 t  0.02
SubnaxHIary
* *
gland
0.38 t  0.05 0.39 t  0.06 0.39 t 0.04
Stomach 1.69 ± 0.54 1.63 ± 0.43 2.74 t  0.85
Intestine 3.29 ± 0.12 2.98 i  0.73 2.7 ± 0.5
Skin 6.1 ± 1.24 4.25 ± 0.5 9.67 ± 0.9
Bone 7.1 t  0.8 4.43 t 0.8 5.83 i  0.9
Urine 4.32 1 0.8 20.4 ± 1.96 8.6 t  3.6
Faeces 0.44 i  0.2 0.3 1 0.07
Blood 29 ± 2.4 18.4 ± 1.54 17.5 ± 3.9
Peritoneal wash 5.74 ± 1 3.95 t  0.42 1.8 ± 0.9
* - approxinata age
** • plus attached ]ymph nodes 
4 ■ parent HPMA copolymer-antl-Thy-1.2 
4a - Fc region of antibody not available 
4b > Fc available
1.2.4 Tht body d litr lbu t lo n  of intIbwIy-HWW
cooo liftr conJuattit ccaptrtd a fttr «Itlw r Intriptriton»«! or 
in t r iv n o u s «d iln istrtt lo n .
The percentage o f adalnistered dose recovered after Intravenous 
( l. v . )  Injection was generally higher (66-84%} than after l.p. 
administration (68-70%) (Table 8.2).
A comparison of Tables 8.4 and 8.5 shows that the pattern of 
tissue/organ d istribu tion  was dependent upon the route of 
administration. Administration d irectly  into the bloodstream 
resulted In a higher recovery of rad ioactivity In the blood, than 
seen following l.p. administration, for a11 substrates Investigated 
(Table 8.5; Fig. 8.6). Also rad ioactivity recovered In  the urine for 
conjugates 4, 4a and 4b, but not for unconjugated antl-Thy-1.2, was 
higher after l.v . administration (Fig. 8.6). Both unconjugated 
antl-Thy-1.2 and HPHA copolymer conjugate 4b (Fc presenting) showed 
an Increase In liver-associated rad ioactivity (Fig. 8.7a) together 
with considerable rad ioactivity recovered In the faeces (Table 8.5; 
Fig. 8.71) and Increased localisation  In the spleen and Intestine.
This differed from the body d istribution  of conjugate 4a (Fc masked), 
which showed greater association (than after l.p . administration) 
with lungs, stomach. Intestine, and sign if ican tly  higher leve ls of 
rad ioactivity In the bone marrow.
8.2.5 The effect o f mouie aot (3 week or 16 weeks of age) on the
body d istribution  of ^^^l-label1ed antl-Thy-1.2 and antl-Thy-1.2 
antlbody-HWA copo lye r conjugates.
Unconjugated ^^^I-labelled antl-Thy-1.2 antibody was
route and the body d istribu tion  of radioactivity compared with that 
described earlie r fo r 16 week old mice. The data obtained are shown 
In Fig. 8.8a,b and Table 8.6.
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H]. 8.8a Comparison of the body d istribu tion  of anti-Thy-1.2 antibody 5h 
after i.p . administration to e ither 3-week or 16-week (Q )  
old male OBA  ^ male mice. (A ll ligands were ^^^I-labelled.)
I.On
Fig. 8.8b Cnnparison of the body d istribution  of enti-Thy-1.2
entibody 5h efter i.v . administration to e ithe r 3-wek (H I 
or 16-week O  old DShg male mice. (A ll ligands were 
’^® I-labelled.)


In general, the body d istribu tion  seen was sim ilar after e ither 
route of administration. However, there did seem to be a difference 
In body d istribu tion  related to the age of the animals used (Fig. 
6.8a,b). An Increased localisation  of antl-Thy-1.2 unconjugated 
antibody In the skin (31% l.p .; 44% l.v . ) ,  bone marrow (25% l.v . 
only) and thymus (20% l.p .; 29% l.v .)  of 3-week old OBA  ^ mice was 
seen when compared to the d istribu tion  seen In  16-week old mice 
(compare Tables 8.3 and 8.6; Fig. 8.8a,b). Also, a decrease In  the 
radioactivity detected In blood, live r  and spleen was seen following
l.p. and l.v . administration to 3-week old mice when compared to the 
16-week old mice.
In a second series of experiments, to determine the body 
d istribution  of conjugates 4a and 4b In 3-week old DBA  ^ male mice. It  
was Impossible to carry out l.v . Injections due to the small size  
(approximately 6g) of the animals supplied (guaranteed as 3-weeks of 
age). Therefore, these animals could only be used to examine the 
body d istribu tion  of ^^^I-labelled HPMA copolymer conjugates after
l.p. administration. I t  was shown (Fig. 8.9a,b) that the body 
d istribution  of conjugates 4a and 4b was dependent upon the age of 
the mice used. In contrast to the data obtained using ant1-Thy-I.2 
unconjugated antibody there was shown to be a decreased localisation  
of both conjugates 4a and 4b In the thymus (4a, 63% decrease; 4b, 86% 
decrease), sk in  (4a, 45%; 4b, 70.5%) and an Increased localisation  In 
the bone marrow (4a, 33% Increase; 4b, 81% Increase) of 3-week old 
■ Ice when compared to 16-week old mice.
The body d istribu tion  of HPMA copolymer conjugates 4a and 4b In 
3-week old mice are compared In Fig. 8.10, where I t  can be seen that 
conjugate 4b (Fc available) I s  cleared from the bloodstream more 
slowly than 4a (Fc not available), and I s  localised  to a greater 
extent In the skin and urine than conjugate 4a. In contrast, there
Fig. 8.9a Congiarison of the body d istributions (t  adaiinistered dose) 
o f  HPMA copolyeer conjugate 4a (Fc not available) 5h after 
i .p .  administration to DBAg male mice aged either 3 «eeks 
( H )  or 16 veeks ( □ ) .  (All ligands were I-labe lled ).
r i l
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Fig. 8.10 Convarlson of the body d istribution  ( *  administered dose) 
of HPMA copolymer conjugates 4a (ED  ««d 4b O  5h after 
i.8. administration to 3-week old DBA2  male mice. {All 
ligands were “ l-labelled .)
1$ 2.4-tlmes as much thyius-associatad radioactivity aftar 
administration of conjugate 4a than 4b.
8.3 DISCUSSION
It  I s  hoped that antIbody-HPMA copolymer conjugates can be 
designed to achieve "targeted” drug-delivery, that Is,  to 
p referentia lly localise  in a target tissue and effect ce11 death.
Cartlldge, et a K  (1986) have shown that HPMA copolymer 
conjugates are able to cross compartmental barriers In vivo. Duncan, 
et a l¿  (1986), and Seymour,^ a K  (1986) have shown that the rapid 
clearance by the RE system, found after In vivo administration of 
co llo ida l carriers, was not typ ical of the HPMA copolymer carrier.
The experimental data presented In  th is  chapter show that conjugation 
of HPHA copolymer to antibody re su lt s  In an altered body distribution 
which I s  c loser to that of the unconjugated antl-Thy-1.2 antibody 
than that of the unmodified HPMA copolymer. Furthermore tissue/organ 
loca lisation  was dependent upon the route of administration, the 
orientation of the antibody w ithin  the conjugate, and the age of mice 
used. In particular an Increased liv e r  uptake of both unconJugateJ 
antl-Thy-1.2 and conjugate 4b, plus an Increased bone marrow 
loca lisation  of conjugate 4a were observed after l.v . administration 
to 16-week old mice.
As detailed In Chapter 3 there are s t i l l  many problems to be 
solved In the synthesis and characterisation o f these conjugates. 
Including a a precise d e fin it ion  of molecular weight, stoichiometry, 
and orientation of protein In the conjugates. Due to these problems 
of synthesis, repeated preparations of a proteln-HPMA 
copolymer-protein conjugate w ill  never be Identical. Bearing th is  
lim itation In mind. I t  has been shown by Rlhova & Kopecek (1985) and 
R1hova,et aK  (1986), using s im ila r  HPMA copolymer conjugates bound 
to both antl-Thy-1.2 and DNM, that after l.p. administration, a
phanMcologIctI effect I s  observed In tenis o f a reduction In  the 
nuaber of PFC In the spleen of Inaunised a ke . Data presented In 
th is  chapter show a 350% Increase In the aaount of HPKA copolyaer 
found In the thyaus after conjugation of HPHA copolyer to 
antl-Thy-1.2, than after conjugation to a non-specific antibody, an 
observation consistent with the therapeutic effect observed 
previously.
Rlhova & Kopecek (1985) have also used a skin transplantation 
aode1 to Investigate the effect of HPNA copolyaer, bound to both 
antl-Thy-1.2 and quaternary aamonlua groups, on the survival tiae of 
a skin a llograft In alee. Recipient alee were Injected with the 
conjugate 2, and 1 day before and 1, 2, 3, 5 and 7 days follow ing 
skin grafting. These workers found that the a b ility  of the 
antibody-conjugate to Increase survival tiae of the graft was 
s ign if ican tly  less than antibody alone. These published re su lt s  are 
consistent with the assuaptlon aade In Chapter 3, that the 
orientation of the antibody In the antIbody-HPMA copolyaer conjugates 
has not been optlalsed to effect aaxiaal antigen binding. A lso, the 
data presented In th is Chapter Indicate that an Fc Interaction aay be 
Important In determining the body distribution of antIbody-HPMA 
copolyaer conjugates containing whole antibody molecules, since there 
I s  a re lative ly  large localisation  In the skin of conjugates targeted 
by both antl-Thy-1.2 and non-specific IgG. This assumption I s  
further supported by greater sk in -loca lisation  of conjugate 4b (Fc 
presenting) than either 4a, or 4. Some form of Fc Interaction Is  
also Indicated In the thyaus and stomach, but su rp ris in g ly  not the 
live r.
Localisation of the antl-Thy-1.2 containing conjugates at the 
thymus, a major target organ, was re latively low (<1%). A possible 
explanation for th is re lative ly  poor localisation  was degeneration of
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thymus with age. The mice used In th is  study may have been too old to 
demonstrate optimal targeting to thymus (Rihova, 1987). For th is  reason the 
body d istribu tion  of anti-Thy-1.2 antibody-HPKA copolymer conjugates was 
determined in 3-week old OBA  ^ male mice. Unconjugated antibody did localise  
more e ffic ie n t ly  in the thymus of the younger mice. However, there was a 
dramatic decrease in the thymus localisation  of both conjugates 4a and 4b, 
together with an increased localisation  in the bone marrow. This difference 
in body d istribution  of unconjugated antibody and antibody-HPHA copolymer 
conjugate may be due to the size of the conjugate (Chapter 3, 3.2.3) 
becoming a lim iting factor in animals which are so small (6g), an effect 
which did not show it s e l f  in 30g mice.
Although the amount of anti-Thy-1.2 antibody-HPMA copolymer conjugate 
which reached the thymus was very low (<1%), Rihova, it a K  (1986) have 
reported a dramatic effect on the immune system of A/J mice (8-week old, 
female) using sim ilar conjugates. Obvious problems in d irectly  comparing 
the resu lts of th is  study with those o f Rihova, ^  a K  (1986) are the 
difference in stra in  of mice used and the fact that the two preparations of 
antibody-HPMA copolymer conjugates used cannot be guaranteed identical. 
Ideally, i t  is  necessary to look at both body d istribu tions and determine
preparation. As an in it ia l estimation of pharmacological potential, 
however, the resu lts seem promising, and are consistent with the work of 
others; Baldwin & Byers (1986) estimate that optimal localisation  of 79IT/36 
antibody, after administration to patients with colorectal cancer, is  only 
0.002% g '^  tissue; Hazra & Dass (1984) reports 0.1% (administered dose) 
tumour localisation  of ^^h-labelled anti-CEA antibody (whole, or 
fragments); Hunz,et a K  (1986) who achieved 0.45% (administered dose) tumour 
localisation  gm'* tissue 5 days after injection of antibody
fra9M n ts .  The raported resu lts o f Nunz,«t a K  (1986) Indicated 
that, In the fie ld  of radloimnunoliaglng, a mixture of HcAb gives 
optimal tumour localisation. Low percentage tumour localisation  I s  a 
common problem in the fie ld  of immunotargeting (Cobb I  Hu m , 1986). 
However, the published pharmacological effects achieved by such poor 
loca lisation  (Baldwin & Byers, 1986; Rihova,et a l^ 1986) suggest that 
more well-defined iimunoconjugates, in terms of molecular weight, 
stoichiometry, and orientation of the antibody within the conjugate, 
could Increase tumour localisation . This may consequently resu lt in 
the need to administer only minute quantities of the conjugates to 
patients, and so minimise the potential of an immune response towards 
the conjugates now seen by some workers (Duncan, 1987; Embleton, 
1987).
The low levels of target-cell localisation  of administered HPHA 
copolymer, and other solutes (after i.v . and i.p . administration) can 
be readily explained by reference to Fig. 8.11. After i.p. 
administration, a route which i s  becoming Increasingly important in 
chemotherapy (Flessner, et a K  1983; 198Sa,b), such large molecules 
as HPMA copolymer conjugates (Chapter 3) would not be expected to 
gain direct entry into cap illa r ie s (due to the properties of the 
cap illa ry  basement membrane and endothelial layer) but instead would 
be drained into the lymphatic c irculation. Once inside the lymphatic 
c ircu lation  conjugates would have access to extravascular target 
c e lls  such as the T -ce lls o f the lymphatic system (F re ita s ,^  a1. , 
1986) and possibly become Incorporated into the in te rs t it ia l f lu id s 
bathing organs. The thymus, spleen and live r  are a ll intimately 
involved in the lymphatic system (Andrews, 1979); in the data 
presented in th is  chapter the highest loca lisation  of anti-Thy-1.2 
antibody-HPMA copolymer conjugates in the thymus was found after I.p. 
administration.
Fig. 8.11 A sch«Mt1c dlagran to suawarlsa the fate of a HPMA
copolyier-antibody conjugates after either l.p . or l.v. 
adiln istratlon.
Urgit slU
Drainage Into the bloodstrean occurs via the thoracic duct and other 
lymphatic venous connections (Weinstein,et a L ,  1986). Once Inside the 
bloodstream, either after drainage from the lymphatics or after l.v. 
Injection, conjugate w ill have d ifferential access to organs depending upon 
the a b i l ity  o f the conjugate to cross endothelial barrier or penetrate 
cap illa ry  pores. The resu lts presented here show that d irect administration 
Into the bloodstream of 16-week old OBA  ^ mice (as compared to l.p. 
administration) resulted In a consistently higher percentage (administered 
dose) of the conjugate remaining within the c ircu lation. These results 
agree with those of Patel (1984) who found that after l.v . administration 
of liposomes (not engulfed by the RE system) they could not extravasate and 
remained In  the bloodstream (24h). An additional complication In the 
Interpretation of the data presented In th is Chapter I s  the presence of 
target T-ce11s In the bloodstream which may bind the antl-Thy-1.2 
antIbody-HPHA copolymer conjugates and subsequently migrate.
The most accessible organs to the HPHA copolymer-antibody conjugate are 
the liv e r,  spleen and bone marrow, where fenestrated endothella (30-80nm 
gaps) and sinusoidal endothella (ISOnm gaps) allow delivery to the 
parenchymal ce lls  of these organs (Wisse & de Leeuw, 1984). Data presented 
In th is  Chapter show an Increased localisation  of copolymer 4b (Fc 
available) In the live r  (together with a large Increase In faecal 
rad ioactiv ity  Indicative of degradation), spleen, and an Increased 
lo ca lisa t ion  of 4a (Fc not available) In the bone marrow after l.v .
Injection (than after i.p . administration). This difference In localisation 
of conjugates 4a and 4b Indicates that the antibody 1$ able to recognise Its 
target antigen, although data presented In Chapter 4 and 6 using conjugates 
Z (containing transferrin) and 3(conta1n1ng IgG) show that there will 
probably be Interference In antigen-antibody Interaction by bound
HPHA copolyvtr.
When the terget entigen 1s d ire ct ly  eccesslble to the 
vascuUture (Fig. 8.1l)effect1ve targeting should be a re latively 
easy task. Wolf & Gregorladls (1964) have used McAb ant1*Thy*l to 
target llposoM S to AKRA c e l ls  after l.v .  ad iln istratlon  of both 
ce lls and targeted llposoaes. The decreased aaount o f radioactivity 
present In the bloodstream after administration of conjugate 4a (when 
compared to conjugates 4 and 4b) paralleled by a dramatic Increase In 
rad ioactivity detected In the urine may be due to uptake and 
processing by target T-ce1ls In  the vasculature, with subsequent loss 
of degradation products In the urine.
It  w ill be more d if f ic u lt  to target effectively to extravascular 
target c e lls  (Fig. 6.11). Inevitably, only a small percentage of the 
administered dose Is  l ik e ly  to have the potential to reach a target 
cell-surface antigen and then maintain su ffic ien tly  high 
concentration of drug to effect cell death. For example after 
administration of antIbody-HPMA copolymer conjugate, there Is  
potential loss attributable to removal by the live r, uptake by the RE 
system, non-specific binding to serum proteins, or specific  binding 
to soluble antigen shed by the target ce ll.  Remaining conjugate must 
be able to extravásate (a problem seen here by the high percentage of 
blood-associated rad ioactivity remaining after 5h), find I t s  target 
ce lls, bind to the target cell-surface  antigen, undergo 
Internalisation and routing to the lysosomes where f in a lly  drug Is  
released to effect cell death. Duncan,et a1^ (1966) have achieved 
effective tumour cell death In OBA  ^ male mice Injected l.p. with 
L121Û leukaemia, using HPMA copolymer bound to ONM and using 
fucosylamlne as a targeting moiety. With the ever Increasing l i s t  of 
antibodies available for Immunotargeting and the technology to 
manipulate the antibody molecule structure, (Nishimura,et a l¿, 1967


9.1 IKTROOUCTIOW
Proteln-HPHA copolymer conjugates can only fu lf i l  th e ir  
potential as targeted drug>carr1ers i f  they have lie ite d ,  or ideally 
no, im n o ge n ic ity  in v ivo .
lamunogenicity i s  already regarded as a major problem when 
administering antibodies for diagnostic pvrposes (Courtenay-Luck, et 
a l. . 1986) or as antibody conjugates for chemotherapy (Duncan, 1987; 
Embleton, 1987). Certain experiments have shown that b inding protein 
to a soluble synthetic polymer (polyethylene glycol, PEG) can reduce 
it s  immunogenicity (Abuchowski, et a L ,  1977,a,b; Savoca, et a l.. 
1979; Davis, et aK , 1980). Likewise, i t  was considered possible 
that conjugation of HPHA copolymers to proteins, in particu lar 
antibodies, might produce conjugates with reduced Immunogenicity.
The immunogenicity of HPMA homopolymer and a number o f HPMA 
copolymers have previously been investigated (Rihova, et a K ,  1983; 
1984; 1985; Rihova & Riha, 1986) using a variety of techniques; (1) 
determination of the number of antibody-producing c e l ls  in  the 
spleens of immunised mice (2) demonstration of serum antibody using 
one of two methods (a) a passive haemagglutination assay or (b) an 
ELISA test.
Rihova, et aK  (1983;1985) have demonstrated several important 
characteristics of the immune response directed against HPMA 
homopolymer and HPHA copolymers;
1. There was no antibody response to HPHA homopolymer
2. Modification of the homopolymer to incorporate oligopeptide 
side-chains and model drugs (fluorescein isothiocyanate, FITC; 
2,4-dinitrophenol, DNP; a rsan ilic  acid, ARS) resulted in  an iMune 
response which was dependent upon the structure of the incorporated 
groups. Using side-chains composed of d ifferent amino acids, the 
relative order of immunogenicity was found to be qlycyl-glycl-OH>
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u1noc«proy1*1«ucy1-hexutthylene dlialn« > 
uilnocaproyl'PhcnyUUnyl'OH > g1ycy1-ph«ny1-1eucy1-g1ycy1-0H. 
Antibodifts war* raised mainly against the oligopeptide side-chains 
and model drugs.
3. The magnitude o f the antibody response was not affected by the 
number of side-chains per HPHA copolymer molecule.
4. The Imune response was dependent upon the mean molecular weight 
of the HPMA copolymer. After Injection of mice with HPHA copolymer of 
d ifferent mean molecular weight, the number of antibody-producing 
ce lls  detected in the spleens of-these mice was found to be 2-5 fold 
greater after Injection of HPMA copolymers with a mean molecular 
weight 150-200K Daltons, than after Injection of sim ila r HPHA 
copolymer conjugates of mean molecular weight 5K Daltons.
5. A lso, the Immune response was dependent upon the dose of antigen 
given to mice. Using a dose range 1-lOO^g Rlhova, ^  ^  (1985) 
found the optimal dose of polymer was lOpg. Higher doses were 
thought to be tolerogenic.
6. The genetic background of the mice was found to be very 
important In determining the Immune response. ft1hova,et ^  (1985) 
found, for example, that only one of five  stra in s of mice responded 
to HPMA copolymer-glycyl-ARS.
I t  was considered extremely Important to try to determine the 
Imunogenicity of the antIbody-HPHA copolymer conjugates described In 
th is  study. For th is  reason a short collaborative study was 
undertaken In the laboratory of Dr. B. Rlhova, Institute  of 
Microbiology, Prague. AO, or BIO, mice were Immunised with human 
serum albumin (HSA), Ig6, HPHA aalnolysed homopolymer (conjugate 1) 
or HPMA conjugated to either transferrin  (conjugate 2) or Igfi 
(conjugate 3). Substrate was administered e ither In complete 
Freund's adjuvant (to stimulate antibody production), or In solution
(•ore appropriate to the c lin ica l situation). Subsequently the serun 
antibody t it re  was detenalned using the ELISA technique.
9.1.1 Calculations
Calculations used In  th is  Chapter are as detailed In Chapter 2, 
Section 2,2.9.4.
9.2 RESULTS
Optlaal Interaction between antibody and antigen requires that 
each well of the ELISA plate 1$ coated with a monolayer of antigen.
In the short tiae available to perfone these experiments I t  was not 
possible to detenilne the concentration of each substrate necessary 
to achieve a monolayer. For th is reason wells were coated at one of 
two concentrations, SOO^igml'^  or 2ag«r^ irrespective of the 
molecular weight of the substrate (Or. Rlhova had found generally 
that S O O ^ r ^  was an Ideal concentration for other HPHA copolymer 
antigens).
A sumaary of the doses used for Imnunlsatlon is  given in Table 
9.1. A ll groups of mice (n-6 per group) were Injected with lOOtg of 
substrate in either CFA or In solution (for protocol see Chapter 2,
2 .2 .9.1).
When carrying out an ELISA assay serum samples are diluted 
se r ia lly  Into mlcrotltre plates. It  1s Important to understand the 
consequences of th is ongoing serial d ilution  of antibody. For 
example I t  can be seen (Table 9.2) that after d iluting  12-t1mes the 
reduction In antibody level would be approximately 4x10^ fold and 
likewise after a 24-t1mes d ilution the reduction would be 1.6x10^ 
fold. It  Is  usual In such experiments to Identify the highest 
d ilution  producing a definite  antibody-antigen reaction. The 
reciprocal of th is  antibody d ilution-factor I s  termed the antibody 
t itre.
A summary of the highest antibody d ilu tion  (HAD) at which an
Table 9.1
S u n ir y  of iM unlsatlon  Protocol
Substrate Dose
per
Imunisatlon
Method of 
Iflpunlsatlon
Strain of 
Mouse
Human Serum 100 ug CFA AJ; BIO
Albmin 100 SOL
Human Gamma 100 ug CFA AJ; BIO
Globulin (IgG) 100 ug SOL
Human Transferrin (TF) 100 ug SOL AJ; BIO
SOL
*HPMA-g1ygly-Tf 100 u9 CFA AJ; BIO
SOL
HPHA-g1yg1y-IqG 100 u9 CFA AJ; BIO
SOL
HPMA poly-N-(2-hydroxypropyl)-iiiethacrylaimde
CFA complete Freunds adjuvant
SOL In solution

antigen-antibody interaction could be detected, using the ELISA 
technique, i s  given in Table 9.3 and Figures 9.1 a-f. For ease of 
interpretation these graphs show the e ic ro tltre  we11 row number 
equivalent to HAD. This can be converted to an antibody t it re  by 
using Table 9.3.
Differences in antibody t it r e  obtained when coating the plates 
with SOOpgnr^ or Zmgnl*^ indicated that these resu lts would benefit 
from a calibration o f the number of molecules of substrate necessary 
to cover the well. With th is  lim itation in mind, it  can be seen from 
Fig. 9 a-f that the observed t it r e  was always higher after 
administration of substrate in  CFA.
Generally, there was a higher antibody response in AJ mice than 
was found in BIO mice, although th is  did not always hold true when 
using plates coated with 2ngmr^ substrate (possibly due to the 
formation of multilayers of substrate in the wells thus Interfering 
with the antibody-antigen interaction).
Under a ll conditions HPMA-gly-gly-aminopropanol was the least 
immunogenic substrate. The HAD corresponded to a 512-fold d ilution  
of serum. It  should be stressed that th is  response was very low 
indeed, but i t  was not possib le  to convert th is  to a concentration of 
antibody since no calibration  curves were constructed.
The most immunogenic substrate in AJ mice was IgG (HAD 1.6x10^; 
Fig. 9.1e, Tables 9.2 and 9.3) and in 610 mice was transferrin  (HAD 
2.4x10^: Fig. 9.1c; Table 9.2 and 9.3). It  i s  interesting to note 
that the highest antibody t it r e  detected in any experiment was 
against IgG after administration to AJ nice in CFA.
Conjugation of IgG to HPMA copolymer resulted in a much reduced 
antibody t it re  (Fig. 9.1e,f) when compared to unconjugated IgG in 
both AJ and BIO mice, p a rt icu la rly  after administration in CFA.
Ratios of antibody t it re s  measured against protein, and the
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corresponding prote1n*HPHA copolyaier conjugate, are given in Table 
9.4. A 250-fo1d decrease In antibody t it re  was found after 
conjugation of IgG to HPMA copolywer (independent of the 
concentration of antigen coating the a ic ro titre  plate wells) when 
administered in CFA to AJ mice. S im ilarly  a 63-125-fo1d decrease was 
found after administration in CFA to BIO mice. The reduction in 
antibody t it re  was much le ss pronounced after administration as 
solute (4-16-fo1d).
Conjugation of transferrin  to HPHA copolymer resulted in a 
s ligh t  reduction in antibody t it re  (approximately 2-4 fold) under a ll 
conditions,
9.3 DISCUSSION
In these experiments comparison of antibody t it re  against 
substrate given in solution or in CFA, showed that CFA, as expected, 
potentiates the iimune response. With the time scale of these 
experiments the stimulation of an antibody response by administration 
of conjugate in CFA was probably the most useful experimental model 
with which to make a comparison of proteins and protein polymer 
conjugates.
Conjugation of HPHA copolymer (low immunogenicity) to protein 
(highly iimunogenic) produced protein-polymer conjugate whose 
immunogenicity was up to 250-fold lower than that of the parent 
protein but higher than that of HPMA-gly-g1y*aminopropano1.
In accordance with the resu lts of Rihova, et aK  1983; 1985) 
HPHA-glycyl-glycyl-aminopropanol was found to e l ic i t  a very low 
immune response in both AJ and 610 mice. Also, in agreement with the 
earlier studies, an increase in molecular complexity, in th is case by 
incorporation of antibody or transferrin , resulted in a dramatic 
Increase in the Immunogenicity of the conjugate as a whole. It  was 
probable that antibodies against polymer conjugates were raised

against the protein coaponent of the conjugate, since I t  had 
previously been found that antibodies raised against nore simple HPMA 
copolymer conjugates were predominantly specific  for the oligopeptide 
s1de>cha1ns and certain Incorporated model drugs (Rlhova, et aK., 
1983; 1984).
The 250-fo ld  reduction of antibody t it re  against IgG after 
conjugation to HPHA Implies that HPHA has the potential to mask the 
Imeunogenicity of proteins, In  a sim ilar fashion to the a b ility  of 
PEG to reduce the Inmunogenicity of bovine serum albumin (Abuchowski, 
et al. 1977). This a b ility  o f PEG to a lter Immunological properties 
of a p rotein  has been attributed to PEG (and I t s  bound water) forming 
a shell around the protein, thus masking antigenic determinants. The 
possible stoichiometries of the conjugates 2 and 3 (Chapter 3, 3.2.3} 
would suggest that HPHA may be acting In a sim ila r manner, that Is, 
there could  be up to 20 HPHA copolymer molecules bound to each 
protein molecule. With the Increasing use o f antibodies 
(p a rticu la r ly  murine) In patients, th is a b ility  o f HPHA to reduce 
Imnunogenlclty of antibodies, or other proteins may have Important 
c lin ica l Implications. The problems of an anti-mouse Immunoglobulin 
response have already been reported (Courtenay-Luck, et a K ,  1966).
The Immunogenlcltles o f unconjugated transferrin  and IgG were 
found to be quite sim ilar. However, after conjugation of HPHA 
copolymer to transferrin, there was a much lower reduction In 
Immjnogenicity (2-4 fold) than that seen after conjugation of HPHA 
copolymer to IgG (250-fold).
In the complicated In v I m  milieu the reasons for these observed 
d ifferences In behaviour of the Immunocompetent c e lls  towards these 
two conjugates may be several-fo ld:-
1. The dose reglne of Im un ise tlon  wes based upon the weight (g) of 
protein irrespective of the molecular weight of the conjugate. The 
molecular weight of conjugate 3 (contains IgG) i s  approximately 
S-times higher than that of conjugate 2 (contains transferrin) 
(Chapter 3, 3.2.3). This would mean that approximately 5-times more 
molecules of conjugate 2 were administered to each mouse.
However, using the same lo g ic  in each dose the number of 
molecules of either conjugate 2 or 3 was much lower than the number 
of molecules of unconjugated protein. The observation that there was 
l i t t l e  difference in the antibody t it re  against transferrin  and 
conjugate 2 (contains transfe rrin ) implies that the number of 
molecules administered Is  not the only relevant factor.
2. The high molecular weight of conjugate 3 (>2x10^ Daltons) may 
promote phagocytosis by macrophages. This would be consistent with a 
molecular weight-dependent uptake of polymers described in v itro  
(Duncan,^ a h  1961) (see Chapter 1, 1.2).
In comparison the smaller conjugate 2 (280K Daltons) would not 
be expected to be removed as read ily by macrophages.
Phagocytosis by macrophages, the number o f molecules per dose, 
and relatively slow rates of extravasation of conjugates 2 and 3 
(Chapters 7, 8) may a ll contribute to prolonging contact of conjugate 
2 with the immunocompetent c e l ls  when compared with conjugate 3.
Interestingly, the extravasation of transferrin  (Chapter 7) was 
much greater than that of conjugate 2 (contains transferrin). 
Therefore, conjugate 2 would have greater exposure to immunocompetent 
c e lls  than transferrin. A ll o f these factors may explain why the 
observed 2-4-fold reduction in  antibody t it re  against transferrin  
after conjugation to HPHA copolymer is  not more pronounced, or 
equivalent, to that seen for IgG.
3. However, I f  conjúrete 3 Is  not readily removed by macrophages 
and I f ,  over the time scale of these experiments (6 weeks) there was 
lim ited a b i l ity  of these conjugates to extravásate (conjugate Z > 
conjugate 3) then It  Is  possible that conjugate 3 could induce 
imnunotolerance. Rlhova, et (1983, 196S) found that a lOOiig dose 
of high molecular weight HPMA copolymers (approximately 200K Daltons 
induced limnunotolerance.
A ll these points need c la rification  and the ir Interre lationsh ips 
determined. It  I s  possible that In vivo a ll of these factors play 
some ro le .  These observations, however, do suggest that conjugation 
of HPHA copolymer to protein may not necessarily reduce 
Im unogenicity of a ll proteins.
Further experiments are needed to determine (1) an appropriate dose 
regime o f  limwnlsatlon (2) relationship between molecular weight of 
antigen and the amount needed to coat an ELISA plate well with a 
monolayer (3) antibody t it re . In terms of moles of antibody produced 
(4) I f  the antibody produced Is  IgG or IgH. However, the limited 
control o f  molecular weight, stoichiometry and orientation  of 
protein, particularly antibody, In these conjugates (Chapter 3) means 
that no two preparations of a single conjugate w ill ever be 
Id en tica l. Necessarily, further experiments w ill therefore be able 
to characterise  only single  batches of antigen with Integral 
controls.

As a <jru9-carr1*r MPNA-copolynwr with It s  pendant, oligopeptide 
side*chains, specifica lly  designed for release of drug within the 
lysosomal compartment (Duncan, et aK , 1983), offers an Ideal means of 
delivering optimal concentration of drug to a target ce ll (see 
Chapter 1, 1.2). It  has already been shown that Incorporation of 
carbohydrate residues can effect selective uptake o f these conjugates 
(galactosamlne, specific  for hepatocytes, Duncan,^ ^  196S; 
fucosylamlne, specific  for L1210 ce lls, Duncan, et a l^ , 1987). This 
study has evaluated the potential use of HPMA copolymer conjugates 
containing protein. In particular antibody, for targeted 
drug-delivery.
The HPMA-copolymer conjugates used in th is study were among the 
f i r s t  to be prepared. As might be expected, b io log ica l evaluation 
has revealed a number of "teething* problems Inherent In their 
preparation.
1. High molecular weight (with particular reference to the 
conjugates containing IgG) was shown to decrease dramatically the 
a b i l ity  of conjugate to bind to cell surfaces, and subsequently gain 
access to the interior o f the cell (Chapters 4, S). The major 
contribution to the At of a protein (In  particular 
ant1body)-contain1ng conjugate Is  attributable to the protein 
component (150k Daltons, antibody: 80k Daltons, tran sfe rrin : 
approximately 15k Daltons HPMA copolymer). An Immediate reduction in 
the molecular weight of an antibody-containing conjugate can be 
achieved using F(ab) 2  fragments, rather than whole antibody molecules 
(see Chapter 1, Fig. 1.4). This would also have the added advantage 
of reducing the potential Immunogeniclty of these conjugates, since a 
large proportion of any Inmune response seen In patients is  thought 
to be raised against the Fc region of the antibody (Courtenay-Luck, 
et i l , ,  1986).
2. Th« sto ich loM try  of «11 conjugitcs was shown to be far 
fro« an Ideal ratio  of approaching 1:1, ant1body:copo1y«er. In 
Chapter 3 It  was proposed that up to 20 HPHA copolymer molecules nay 
be bound to the protein co«ponent. Such stoichiometries are In 
accordance with the resu lts presented In Chapter 4, where it  was 
shown that conjugation of HPHA copolymer to protein dramatically 
decreased cell-surface Interaction. However, it  was shown (Chapter 
6) that the conjugates did retain some specific ity  of binding. A 
high ratio of polymer to protein, In particular antibody, was also In 
accordance with the 2S0-fold reduction In  the inmunogenlcity of IgG 
seen after conjugation to HPHA copolymer (Chapter 9).
The problems of both stoichiometry and the orientation of a 
protein within HPHA copolymer-protein conjugates are a consequence of 
the simple nucleophilic substitution reaction used in their 
preparation (see Chapter 1, 1.2). When the targeting residue 
consisted of a sugar molecule, modified at carbon-2 to contain a 
primary amino-group the resulting conjugates were well defined, 
containing a known mol %, or weight %, of sugar (for example the 
fucosy1am1ne-HPHA copolymer conjugates used by Duncan,^ aK  1987 
contained 8-11 mol % of fucosylamine). This study has shown, 
however, that a simple nucleophilic substitution reaction is 
unsuitable for the conjugation of protein to HPHA copolymer. The 
reason for th is  is,  in comparison to a modified sugar which contains 
only one amino group, a protein contains many amino groups.
Inevitably there I s  limited control over the degree of substitution 
and no control over protein orientation In the conjugate. It  w ill be 
necessary to use alternative methods of conjugation i f  protein Is  
ever to act as targeting residue to I t s  fu ll potential.
There are a variety of methods available for conjugation of drug 
to antibody (reviewed Ghose A Bla ir, 1978). Hore recent examples
Include (1) fonutlon  of enide bonds between dru^ and antibody using 
water soluble carbodiiaides; for exaaple, Kulkarni, et ^  (1981) 
bound methotrexate to IgG via
l'ethy1-3,(3'-dimethy1aminopropy1)carbodiimide (2) modification of 
drug prior to conjugation; for example, Gallego, et aK  (1984) 
modified the sugar amino-group of daunoieycin (DNM) by reaction with 
c is  aconitic anhydride. The modified drug was subsequently coupled 
to IgG using a carbodiimide reaction (3) modification of both 
antibody and drug prior to conjugation; for example, Gallego, ^  ^  
(1984) have modifed IgG by Introduction of free th io l groups using 
N-succinimidyl-3(2-pyr1dyl-dithio)propionate. Hodified antibody was 
subsequently bound to 14-bromo-DNH. A ll these examples resulted in 
the formation of conjugates which retained some antibody specific ity. 
Nethods used for conjugation of drug to antibody may not, however, be 
appropriate for the conjugation of HPMA to antibody. With particular 
reference to the carbodiimide reaction, where coupling of antibody 
and drug occurs via activated carboxyl groups of the antibody 
molecule (of which the antibody molecule has many) there i s  s t i l l  the 
problem of reaction between two multifunctional groups. More 
appropriate methods of conjugation of HPHA copolymer to protein, in 
particular antibody, w ill involve immobilisation of the protein 
during synthesis, using for example an a ffin ity  column, or an antigen 
matrix (Pressman, 1980). Alternatively, conjugation of HPMA 
copolymer to antibody via the carbohydrate component of the antibody 
(see Chapter 1, Fig. 1.4; Rodwell, et a K ,  1986) may be a more 
suitable method of preparation.
Once the basic chemistry of conjugation of IgG to HPMA copolymer 
has been perfected the potential of these conjugates for use in 
targeted drug-delivery w ill be greatly increased. It  should then be 
possib le to bind IgG of any desired sp ec ific ity  to HPMA copolymer or.
a lternative ly, to use modified IgG. Although the structure of IgG Is  
Idea lly  suited for It s  ro le  In v ivo. I t  Is  not so Ideally suited for 
I t s  ro le  as a targeting residue for HPHA copolytner conjugates. There 
are a number of p o s s ib il it ie s  available now to modify IgG (1) 
Enzyme-cleavage to produce F(ab) 2  fragments (see Chapter 1, Fig.
1.5), these were mentioned above (2) Chimeric antibodies; gene 
sp lic in g  techniques allow human and mouse genes to be Joined, for 
example genes coding fo r the variable region of a mouse antibody can 
be Joined to genes coding for the constant region of a human antibody 
(Boullanne^et a K  1984; Golding,et ^  1985; Stevenson, et a K ,  1985; 
Nishimura, et 1987). These modified antibody molecules should 
be le s s Immunogenic In patients since they contain a human Fc region, 
and as stated earlier, a major component of the Immune response 
raised In patients against murine antibodies was thought to be raised 
against the Fc region (3) Hybrid antibodies; chemical reconstitution, 
or ce ll fusion techniques can produce antibodies with two different 
binding sp e c ific it ie s (reviewed M llste in & Cuello, 1984; Brennan, et 
a l . . 1985; Staerz, et ^  1985). These antibodies w ill retain the 
benefits of bivalent binding (higher a ffin ity  than univalent binding) 
and In addition be able to cro ss-link  two d ifferent antigens. Hybrid 
antibodies, and possib ly F(ab) 2  hybrid fragments may play an 
Important role In the future development of antIbody-HPMA copolymer 
conjugates. The reasons for this are several-fo ld;
(1) There may not ex ist a tumour-specific antigen, but Instead a 
tumour may express a characteristic set of antigens. Conjugation of 
possib ly  2 F(ab) 2  hybrid fragments to HPHA copolymer would 
effective ly give the conjugate the ab ility  to recognise a set, or 
combination, of up to four different antigens. For example, le t  us 
consider use of a hybrid specific for both the Thy-1 antigen and the 
transfe rrin  receptor; the data presented In Chapters 7 and 8
Indicated that these antigens were present on the same ce lls. Also, 
Sauvage, et a K , (1987) have shown an Increased survival tine of 
nice, previously Innoculated with SL-2 leukaemia, after 
administration of a combination of both anti-transferrin  receptor and 
antl-Thy-1.2 antibodies than after administration of either antibody 
alone. In order to minimise molecular weight I t  seems a logical step 
to have both these antigen-binding sites within the same antibody 
molecule.
(2) The consideration of avid ity (Interaction of antibody with 
antigen as a whole; multivalent antibodies w ill have a higher avid ity 
than monovalent antibodies. See Chapter 6, 6.3) versus a ffin ity  
(interaction between an antigen and the binding s ite  of one F(ab) arm 
o f an antibody) w ill always mean that HPHA copolymer conjugate bound 
to at least two antigen-binding site s w ill have an Increased 
sta b ility  (In  terms of Ka) at the cell surface than a sim ilar 
conjugate containing only one antigen-binding site . The data 
presented In Chapter 6 suggested that the high calculated "a ff in ity " 
o f the HPHA copolymer conjugate containing IgG was probably due to 
the presence of at least 10 antibody molecules In th is excessively 
large conjugate. The fact that such a large conjugate could bind to 
the cell surface, with such a high calculated a ffin ity  
(Ka,4.76xlO ^V *) indicates that conjugates approaching a more Ideal 
molecular weight (approximately 200k Daltons) and bound to at least 2 
F(ab) fragments o f different sp ec ific it ie s (possib ly  In the form of a 
hybrid F(ab)2 ) w ill have great potential In targeted drug-delivery.
There Is  obviously a great deal more work to be done before 
these conjugates are ready for use In patients. In particular the 
results obtained 1n Chapter 9, where up to a 250-fold reduction In 
Immune response towards conjugated protein was seen, are very 
encouraging but need to be expanded to determine the Itnmunogenicity
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Appendix 3.1
Data relating to the e lu tion  of HPMA copolymer conjugate 2 
through a Sephadex 4B/6B column (Fig. 3.10).
rad ioactiv ity  (cpw) detected
45 617
46 809
47 1011
48 1454
49 1873
so 2481
51 3329
52 4179
53 5204
54 6700
55 7956
56 9796
57 11206
58 12661
59 13693
60 13809
61 13661
62 12430
63 11008
64 9901
65 8391
66 7115
67 6285
68 5462
69 4797
70 4337
71 3920
72 3577
73 3197
74 3116
75 2826

151
DaU relating 
through a sephadex
Appendix 3.2
to the elution of HPflA copol.ymer conjugate 3 
AB/6B GPC colunm (Fig. 3.11).
Radioactivity (cpn)
corrected uncorrected
28 1326 1016
29 1460 2952
30 1595 4120
31 1730 3159
32 1865 2816
33 1999 2638
34 2134 2637
35 2269 2697
36 2403 2669
37 2538 2616
38 2673 2752
39 2807
40 2780
41 2960
42 3051
43 197
44 3337
45 3467
46 3639
47 3827
48 3823
49 4064
SO 4140
51 4265
52 4434
53 4576
54 4580
55 4495
56 4160
57 3824
58 3379
59 2973 2642
60 2611 2325
61 2216 2370
62 1821 2350

C ao u tT  prograi
Q f f w d  ftfl).
OOIOPRINT-PRAGUE PROGRWtC“ 
00200IMA(90,2)
0030PRINT"ENT£R CONSTANTS" 
0040PRINT"'a'*"
0050INPUTA
0060PRINT"b'«"
0070INPUTB
0080PRINT-ENTER FIRST PEAK COUNT-'Cl" 
0090INPUTC1
OlOOPRINT-ENTER NO. OF COUNTS"
oiioiNPirrc
0120HATA*ZER(C.2)
013OPRIKT"ENTER PEAK HEIGHTS"
0140X-CM
O150F0RI-1TOC
0160X-X+1
0170A{I,1)-X
0180PRINT"COUNT";X
0190INPUTA(I.2)
0200NEXTI
0210H1*0
022001-0
0230P-0
024OF0RI-1T0C
0250H1-HUA(I.2)
0260S1-A+{B*A(I.l))
0270S2-10 ST
0230D1-DU(A{I,2)/S2)
0290P1»P1+(S2*A(I,2))
0300NEXTI
0310H-P1/H1
0320N-H1/01
0330U-H/N
0340PRINT"PEAK PARAHETERS:"
0350PRINT"COUNT VALUES","HEIGHTS"
0360MATPRINTA
0370PRINT
03B0PRINT"'a'-";A
0390PRINT"‘b '-";B
0400PRINT"I«-";H
0410PRINT"NN-";N
0420PRINT"U-";U
0430EN0
Appendix 4
» used for the statistical detemlnatlo



APPENDIX 6
C*1cu1«t1ont ustd In Chapttr 7 to quantify tht body d istribu tion  of 
coftJMrtt 8 feon tilM  60K unconJugtttd HPHA copolwwrl.
As detailed In Chapter 3 (see Fig. 3.8} th is  preparation 
contains 60X non-conjugated HPHA copolymer.
The rad ioactivity administered that corresponds to conjugate 5 
I s  always 40X of the total counts administered.
To estimate the body d istribu tion  of conjugate 5 I t  was 
necessary to correct each organ/tlssue examined for the previously 
determined d istribu tion  of HPHA copolymer (Table 7.1).
The formula used for th is  calculation Is  given below, but f ir s t  
an example w ill be shown In detail.
Detailed Example
I f  4,550,077 cpm o f a preparation o f conjugate 5 were administered
1. That Is,  2,730,046 cpm correspond to the administered dose 
(A.O.) of KPHA copolymer
1,620,031 cpm correspond to the administered 
dose of conjugate 5.
2. Recovered rad ioactivity  In the live r after 5h was 
97,238 cpm.
It  was known from previous experiments that 0.5% (expressed 
as % administered dose) of HPHA copolymer would 
be found In the liv e r  after 5h (Table 7.1).
In th is case th is  would correspond to 2730046 x 0.005 cpm 
• 13,650 cpm.

3. The rad ioactivity In  an organ/tlssue due to the 
presence of HPMA -  [60% Total A.D.] x % A.D. localised
In the organ
-  Xciw
4. Radioactivity In the sane organ due to the presence 
of conjugate S
• Total rad ioactivity  Xcpn
detected In  the 
organ (cpn)
• Zcpw
5. Radioactivity In  t h is  organ expressed In terms of 
% administered dose
• Zcmp X 100 
40% Total A.D.
Chromatography (Pd-10) of urine, collected 5h after l.v. 
administration of HPMA-copolymer to OBA2 male mice (Table A.6), 
showed that 95% of urine-associated radioactivity eluted at the Vo. 
This Indicated that undegraded HPMA copolymer had passed readily 
through the kidney (consistent with the work of Seymour et 1986). 
Therefore, any rad ioactiv ity  detected In the urine after 
administration of conjugate 5 could be analysed as described above.
Table A:6
Percentage urine-associated radioactivity detected in Peak I (high 
molecular weight Ugand) and Peak I I  (low molecular weight degradation 
products) after elution through a Sephadex G-15 gel permiation column.
Ligand Urine-associated rad ioactivity
Peak I Peak 11
HPMA 95t 5*
HPKA copolymer 57* * 43%
conjugate 5
Corresponds to the calculated percentage o f counts attributable 
to unconjugated HPMA copolymer.
Appendix 7
Orqen weight as a percentegt of nouse body w igh t.
160
Organ mean percentage 
weight t  S.E. 
n • 24
Heart 0.55 i 0.1
Liver 5.08 ± 0.09
Lung 0.54 t  0.01
Kidney 1.87 t 0.2
Spleen 0.38 t  0.09
Thywjs 0.13 t 0.01
Submaxillary gland 0.86 ± 0.05
Skin 13.88 ± 0.2
Bone 61 taken from Kooistra (1979)
Stomach 2.77 t 0.19
Intestine 11.1 ± 0.2
